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ABSTRACT 
 
DUSTIN ELI BOSCH: Elucidating G protein signaling and ubiquitin conjugation in 
Entamoeba histolytica 
(Under the direction of Dr. David Peter Siderovski) 
 
 The intestinal parasite Entamoeba histolytica is responsible for an estimated 50 
million infections and 100,000 deaths per year worldwide. The causative agent of amoebic 
colitis and systemic amoebiasis is spread primarily through contaminated food and drinking 
water sources. Although reasonably effective treatments have long been available for 
invasive amoebiasis, imperfect patient response rates, drug side effects, and concern for 
emerging drug resistance all warrant exploration of new pharmacological targets in E. 
histolytica. This work describes structural, biochemical, and cell biological explorations of 
heterotrimeric G protein and Rho family GTPase signaling and ubiquitination in E. 
histolytica. 
 The heterotrimeric G protein subunits EhGα1, EhGβ1 and either EhGγ1/2 assembled 
a typical nucleotide-dependent heterotrimer. Overexpression of wildtype or dominant 
negative EhGα1 in E. histolytica altered chemotactic migration, Matrigel transmigration, 
host cell attachment, and cell killing. Transcriptomic studies linked EhGα1 expression and 
altered transcription and secretion of virulence factors. EhGα1 is distinct from the 
conventional mammalian Gα subfamilies, as revealed by sequence comparison and a crystal 
structure, but shares functionality with mammalian Gα12/13 in engaging an RGS-RhoGEF 
effector. EhRGS-RhoGEF is apparently autoinhibited, as indicated by structural obstruction 
 iv 
of its catalytic domain in the inactive state. However, co-expression with constitutively active 
EhGα1 and EhRacC lead to EhRGS-RhoGEF activation in cells. 
 The Rho family GTPase EhRho1 lacks a signature Rho insert helix and sensitivity to 
C3 exoenzyme. Crystal structures of EhRho1 indicate unique nucleotide-contacting residues 
that confer fast intrinsic nucleotide exchange activity. However, EhRho1 functions like its 
homologs in engaging a diaphanous-related formin effector to regulate actin polymerization. 
EhFormin1 is autoinhibited and is activated by Rho GTPase binding. A crystal structure of 
the EhRho1/EhFormin1 complex indicates similarity to human RhoC/mDia1, despite an 
absent secondary binding site at the Rho insert helix. 
 Multiple ubiquitin-proteasome pathway genes were differentially transcribed upon 
perturbed EhGα1 expression. EhUbiquitin was activated by the E1 enzyme EhUba1 and 
conjugated by the E2 enzyme EhUbc5, indicating a conserved ubiquitination cascade in E. 
histolytica. Crystal structures of EhUbiquitin and EhUbc5 suggested potentially unique 
polyubiquitin linkages, but a likely conserved mode of ubiquitin chain elongation. 
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CHAPTER 1 
 
GENERAL INTRODUCTION1 
 
1.1 OVERVIEW 
The parasite Entamoeba histolytica causes amoebic colitis and systemic amoebiasis. Among 
the known amoebic factors contributing to pathogenesis are signaling pathways involving 
heterotrimeric and Ras superfamily G proteins. Here, we review the current knowledge of the 
roles of heterotrimeric G protein subunits, Ras, Rho, and Rab GTPase families in E. 
histolytica pathogenesis, as well as of their downstream signaling effectors and nucleotide 
cycle regulators. Heterotrimeric G protein signaling likely modulates amoebic motility and 
attachment to and killing of host cells, in part through activation of an RGS-RhoGEF 
effector. Rho family GTPases, as well as RhoGEFs and Rho effectors (formins and PAKs) 
regulate the dynamic actin cytoskeleton of E. histolytica and associated pathogenesis-related 
cellular processes, such as migration, invasion, phagocytosis, and evasion of the host immune 
response by surface receptor capping. A remarkably large family of 91 Rab GTPases plays 
multiple roles in a complex amoebic vesicular trafficking system required for phagocytosis 
and pinocytosis and secretion of known virulence factors, such as amoebapores and cysteine 
proteases. Although much remains to be discovered, recent studies of G protein signaling in 
E. histolytica have enhanced our understanding of parasitic pathogenesis and suggested 
possible targets for pharmacological manipulation. 
1 Bosch, D.E. and Siderovski, D.P. (2013) G Protein Signaling in the Parasite Entamoeba histolytica. Exp. Mol. 
Med. (accepted review manuscript) 
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1.2 Entamoeba histolytica CAUSES AMOEBIC COLITIS AND SYSTEMIC 
AMOEBIASIS 
 
1.2.1 Epidemiology, disease sequelae, and current treatment options 
The parasite Entamoeba histolytica is the causative agent of infectious amoebic colitis and 
systemic amoebiasis [1]. The worldwide prevalence of E. histolytica infection is not precisely 
known, with the most recent published estimates (World Health Organization, 1997 [2]) 
being approximately 50 million infections and 100,000 deaths, annually. Epidemiological 
estimates have been historically complicated by limitations of diagnostic tests, as well as 
difficulty in differentiating E. histolytica from the morphologically similar, but typically 
nonpathogenic related Entamoeba species, E. dispar and E. moshkovskii [3]. However, more 
recently developed antigen detection and PCR-based modalities with improved sensitivity 
and specificity have allowed more accurate regional estimations of E. histolytica infections 
[4, 5]. The prevalence of E. histolytica infection is particularly high among susceptible 
populations with limited access to clean water. For instance, a study of preschool-aged 
children in Bangladesh revealed annual infections in 40-50% of subjects [6], a profile of 
Orang Asli ethnic groups in Malaysia found an overall prevalence of E. histolytica positive 
stool samples to be 15-20% [7], and E. histolytica was detected by PCR in 10-15% of a rural 
Mexican population [8]. The prevalence of antibodies specific for E. histolytica in sera of a 
Chinese population varied from 0.5 to 14%, depending on geographical location [9]. An 
interrelationship between host nutritional status and susceptibility to E. histolytica infection 
has also recently begun to emerge (reviewed in [10]). Although E. histolytica infection is 
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relatively rare in developed countries, such as the United States, it does occur among 
travelers, immigrants, and select susceptible subpopulations [11, 12]. Furthermore, outbreaks 
of E. histolytica have occurred due to contaminated municipal water supplies, for example 
[13]. 
 The life cycle of E. histolytica consists of an interchange between an encysted form 
and the motile, pathogenic trophozoite form. Entamoeba histolytica cysts, shed in the feces 
of infected human hosts, are transmitted primarily by ingestion of contaminated water or 
food [1]. Excystation occurs in the small intestine, and the resultant E. histolytica 
trophozoites may then colonize the large intestine while evading the host immune response 
[3]. Although the majority of E. histolytica infections are asymptomatic, trophozoites can 
penetrate the intestinal mucous barrier, resulting in colitis [1]. Amoebic colitis is 
characterized by trophzoite-mediated killing of intestinal epithelial cells and responding 
immune cells, as well as local tissue destruction [14]. In rare cases, E. histolytica 
trophozoites can enter the blood stream and spread systemically, giving rise to abscesses, 
primarily in the liver and less frequently in the lungs and brain [3]. Although systemic 
amoebiasis requires prior intestinal infection, amoebic liver abscesses can develop in the 
absence of symptomatic colitis [14, 15] and are known to appear months or years following 
exposure [16]. Thus, treatment is recommended for patients with E. histolytica infection, 
even in the absence of symptomatic disease [3]. 
 Nitroimidazoles, such as metronidazole, are the current best drugs for the treatment of 
invasive amoebiasis [3]. Approximately 90% of patients with mild or moderate amoebic 
colitis respond to nitroimidazole therapy, although persistent intestinal infection often 
requires additional treatment with paromomycin or diloxanide furoate for complete 
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eradication [3]. However, a significant fraction of patients with E. histolytica infection do not 
respond to nitroimidazoles, and relatively rare side effects such as allergic reactions, 
neuropathies, and additional gastrointestinal symptoms can also affect treatment tolerance 
[17]. Resistance of E. histolytica infection to nitroimidazoles and paromomycin has not yet 
emerged as a major limitation to treatment; however, numerous examples of antibiotic 
resistance in other microorganisms warrants further exploration of alternative 
pharmacological therapeutics [18]. A recent study identified auranofin, an FDA-approved 
rheumatoid arthritis drug, as a potent inhibitor of E. histolytica thioredoxin reductase and 
demonstrated its protective effects in a mouse model of amoebic colitis [19]. Other classes of 
compounds have also recently been pursued as nanomolar-potency inhibitors of E. histolytica 
growth in culture [20, 21]. Despite existing effective therapies, E. histolytica infection and 
associated disease remains endemic in many parts of the world, particularly in areas with 
contaminated drinking water and food sources [6, 8]. Problems with sanitation 
implementation and access to appropriate therapeutics could potentially be circumvented by 
the development of an E. histolytica vaccine, and efforts toward this goal are ongoing (e.g. 
[22]). 
 
1.2.2 Parasite factors in pathogenesis 
A number of E. histolytica molecular components have been thoroughly established as 
contributors to pathogenesis. During initial intestinal colonization, E. histolytica adheres to 
the colonic mucin layer primarily through a galactose-inhibitable lectin, known as the 
Gal/GalNAc lectin (reviewed in [23]). The trimeric surface protein is also a dominant factor 
in parasite attachment to host cells and subsequent tissue destruction, and functions 
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interdependently with the dynamic actin cytoskeleton of E. histolytica [23]. Trophozoites 
also secrete pore-forming peptides known as ‘amoebapores’ that assemble within host cell 
membranes to trigger cell death (reviewed in [24]). A relatively large family of E. histolytica-
encoded cysteine proteases also contributes to host cell killing, as well as degradation of the 
extracellular matrix during invasive amoebic infection and evasion of the host immune 
response through proteolysis of immunoglobulins and complement (reviewed in [25]). Many 
regulators of the actin-rich cytoskeleton within E. histolytica are also emerging as 
contributors to pathogenesis-related processes, such as phagocytosis of host cells, trophozoite 
motility and tissue invasion, and shedding of host antibodies by surface receptor capping 
(reviewed in [26-29]). 
 
1.3  HETEROTRIMERIC G PROTEINS AND RAS SUPERFAMILY GTPases  
Sequencing of the complete E. histolytica genome [30] and genome-wide expression studies 
(e.g. [31]) have revealed large numbers of putative cell signaling molecules expressed in the 
single-celled parasite, including a substantial family of >300 kinases [32]. Also prominent 
within the E. histolytica are genes encoding heterotrimeric G protein subunits (Gα, Gβ, and 
Gγ) and a large number of small, ~21 kDa G proteins belonging to the Ras superfamily [30]. 
Gα subunits and Ras GTPases are molecular switches and cellular signaling nodes that bind 
guanine nucleotides (GTP or GDP) through highly conserved, nucleotide-interacting 
sequencing motifs [33, 34]. As mammalian G proteins are known to be master regulators of 
cellular functions spanning cell division and proliferation, cytoskeletal dynamics, vesicular 
trafficking, and specific responses to extracellular cues [33, 35], it is likely that E. histolytica 
homologs are similarly important for trophozoite biology and pathogenicity. G protein 
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signaling pathways are also notable for amenability to pharmacological manipulation; 
particularly, heterotrimeric G protein signaling via G protein-coupled receptors (GPCRs) is 
the target of approximately one third of all currently FDA-approved drugs [36, 37]. 
 
1.4 REGULATION OF THE GUANINE NUCLEOTIDE CYCLE 
1.4.1 Heterotrimeric G proteins 
A Gα subunit in the inactive, GDP-bound state forms a heterotrimer with the obligate Gβγ 
dimer (Figure 1.1A). A seven-transmembrane G protein-coupled receptor, when activated by 
an extracellular ligand, engages the heterotrimer and catalyzes the release of GDP from the 
Gα subunit [38]. Thus the GPCR is a guanine nucleotide exchange factor (GEF) for the Gα 
subunit, promoting GDP release and subsequent binding of GTP, which is present in a higher 
concentration than GDP in the cytoplasm [34]. Nucleotide exchange is accompanied by 
structural rearrangement of three switch regions in the Ras-like domain of the Gα subunit, 
resulting primarily from nucleotide-binding pocket interactions with the γ-phosphoryl group 
of GTP [39]. The activated Gα·GTP separates from the Gβγ dimer, and both components are 
free to signal through downstream effectors [34]. Mammalian Gα subtypes engage different 
effectors: Gαs activates, while Gαi/o inhibits, cyclic AMP generation by adenylyl cyclase; 
Gαq stimulates phospholipase Cβ activity and subsequent release of intracellular calcium 
stores; and Gα12/13 signaling leads to Rho GTPase activation through RhoGEFs [34, 40]. 
Signaling is terminated by the intrinsic GTPase activity of the Gα subunit, leading to release 
of free phosphate and repeated formation of the Gαβγ heterotrimer (Figure 1.1A). Gα 
subunit-mediated GTP hydrolysis, and thus signal termination, is accelerated a by family of 
GTPase accelerating proteins (GAPs) known as ‘regulators of G protein signaling’ (RGS 
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proteins) [41]. RGS proteins do not directly contribute to the GTP hydrolysis reaction, but 
instead stabilize the Gα switch regions to allow for efficient hydrolysis [42]. Some Gα 
subunit effectors also enhance GTPase activity; particularly, phospholipase Cβ serves as a 
GAP for Gαq, and the Gα12/13 subfamily RGS-RhoGEF effectors possess a GTPase-
accelerating domain (the rgRGS domain) with distant homology to RGS proteins [40, 43]. 
An additional class of Gα regulators is the GoLoco motif protein family, members of which 
serve as guanine nucleotide dissociation inhibitors (GDIs) by binding directly to Gα·GDP 
and preventing nucleotide release [44]. 
 
1.4.2 Ras superfamily GTPases 
The nucleotide cycle of Ras superfamily G proteins and its regulators closely parallel that of 
heterotrimeric G proteins. Inactive, GDP-bound Ras GTPases are activated by guanine 
nucleotide exchange factors (GEFs) in a process that involves structural rearrangement of 
two switch regions within the G protein to promote release of GDP and the Mg2+ cofactor 
(Figure 1.1B) [33, 45]. Following binding of GTP, activated Ras superfamily GTPases 
engage a host of downstream effectors. In contrast to heterotrimeric G proteins, the intrinsic 
GTPase activity of Ras superfamily members is typically very slow. Thus, Ras superfamily-
specific GAPs truly ‘activate’ GTP hydrolysis (rather than merely accelerate hydrolysis as is 
the case with Gα GAPs) by contributing directly to the reaction, as typified by the “arginine 
finger” of p120GAP [46, 47]. In another distinct difference with Gα subunits, Ras 
superfamily GTPases typically possess a C-terminal cysteine residue that is isoprenylated in 
cells by specific lipid moiety transferases, a posttranslational modification that promotes 
membrane association [33]. GDIs associated with Ras superfamily GTPases slow nucleotide 
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exchange and utilize an isoprenyl group binding site to extract GTPases from, and shuttle 
them between, cellular membranes [48, 49].  
 
1.5 HETEROTRIMERIC G PROTEIN SIGNALING IN E. histolytica 
Prior to completion of the E. histolytica genome-sequencing project [30], indirect evidence 
for heterotrimeric G protein signaling components existing within E. histolytica accumulated 
in the literature, but specific genes and associated protein products had not been identified. 
Studies on the effects of histamine and serotonin, typical G protein coupled receptor agonists, 
on E. histolytica trophozoites revealed alterations in pathogenicity and phagocytic activity, as 
well as enhancement of virulence in a mouse model [50-53], suggesting the possible presence 
of a hormone-sensing G protein signaling pathway within E. histolytica. Exposure of E. 
histolytica to fibronectin fragments resulted in actin cytoskeleton rearrangements, as well as 
changes in intracellular calcium and cAMP levels [54-56], raising the possibility of 
fibronectin-responsive Gαq, Gαs, and/or Gαi/o signaling in trophozoites. Additional indirect 
evidence arose from studies utilizing cholera toxin (CTX) and pertussis toxin (PTX), factors 
know to ADP-ribosylate and activate Gαs or inhibit Gαi/o signaling, respectively. Both CTX 
and PTX were seen to ADP-ribosylate multiple proteins of diverse molecular weights in 
trophozoite lysates, and cholera toxin treatment lead to increased cAMP formation in both 
cytoplasmic and cell membrane preparations, as well as increased adhesion to a fibronectin-
coated surface [57]. Studies in the related species Entamoeba invadens further suggested the 
possibility of heterotrimeric G protein signaling in Entamoeba. The catecholamines 
epinephrine and norepinephrine, classic GPCR agonists in mammals, were found to promote 
E. invadens encystation at high nanomolar or low micromolar concentrations, although a 
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traditional concentration-response pattern was not observed [58]. The authors hypothesized 
the presence of a β1 adrenergic receptor-like entity on trophozoite cell surfaces, as further 
supported by radioligand binding with a specific antagonist. Furthermore, chromatography 
techniques identified catecholamines within E. histolytica extracts, suggesting a potential 
autocrine G protein signaling loop [58]. Additional studies implied that CTX or PTX 
treatment, as well as the adenylyl cyclase-stimulating compound forskolin could also 
promote cAMP accumulation in and encystation of E. invadens, while application of an 
adenylyl cyclase inhibitor was reported to have opposite effects [59]. Together with 
epinephrine-induced binding of GTPγS on trophozoite membranes, these findings were 
suggestive of an adrenergic signal transduction cascade involving Gαs- and/or Gαi/o-like 
proteins with opposing regulatory effects on an adenylyl cyclase. 
 However, the sequenced E. histolytica genome [30], as well as those of E. dispar and 
E. invadens, have revealed the presence of two putative Gα subunits, a single Gβ subunit, 
and at least two Gγ subunits [60, 61]. Absent from the genome are clear homologs to 
mammalian phospholipase Cβ, as well as G protein-regulated adenylyl cyclases or cyclic 
nucleotide phosphodiesterase [30]. Thus, although exposure of E. histolytica to stimuli such 
as fibronectin and catecholamines may lead to cAMP accumulation or increased intracellular 
calcium levels, it is unlikely that these effects are mediated by traditional Gαs/adenylyl 
cyclase, Gαi/o/adenylyl cyclase, or Gαq/phospholipase Cβ signaling pathways. Also, we have 
been unable to identify within the E. histolytica genome clear homologs of adrenergic, 
histamine, and serotonin receptors (unpublished data and [60]), suggesting that the functional 
effects of these biogenic amines on trophozoites may not be mediated by traditional 
GPCR/heterotrimeric G protein signaling.  
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 Analysis of both the sequence and structure of the Gα subunit EhGα1 revealed a lack 
of homology to mammalian Gα subfamilies, including Gαs and Gαi/o [60]. This finding, 
together with a lack of the C-terminal cysteine required for ADP ribosylation by PTX, 
suggests that EhGα1 is unlikely to be specifically be modified by bacterial toxins [60]. The 
observed effects of CTX and PTX treatment on Entamoeba trophozoites might instead result 
from off-target effects, a hypothesis supported by CTX- and PTX-mediated ADP ribosylation 
of multiple proteins of diverse molecular weights in E. histolytica trophozoite lysates [57]. 
Despite its lack of phylogenetic relationship to any particular mammalian Gα subfamily [60], 
EhGα1 shares functional similarity with Gα12/13 subunits in engaging and contributing to the 
activation of an RGS-RhoGEF effector (Figure 1.2) [62]. An evolutionary origin of E. 
histolytica heterotrimeric G protein signaling independent from but functionally convergent 
with that of mammalian Gα12/13/RGS-RhoGEF pathways is suggested by multiple factors, 
including sequence divergence of EhGα1, the canonical nature of its interaction with the 
EhRGS-RhoGEF RGS domain (i.e. as opposed to the rgRGS domain found in mammalian 
RhoGEFs), and the structural features of the autoinhibited EhRGS-RhoGEF [60, 62]. 
Expression of constitutively active EhGα1 and EhRacC mutants, together with the effector 
EhRGS-RhoGEF, leads to Rho family GTPase activation in Drosophila S2 cells [62], 
suggesting that heterotrimeric G protein and Rho family GTPase signaling pathways 
communicate in E. histolytica (Figure 1.2). However, no specific Rho family GTPase has yet 
been identified as an EhRGS-RhoGEF substrate. Overexpression of either wild type EhGα1 
or a dominant negative, constitutively EhGβγ-bound mutant has opposing effects on 
trophozoite migration, invasion, and host cell attachment and killing, suggesting that 
heterotrimeric G protein signaling modulates multiple pathogenesis-related behaviors [60]. 
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Perturbation of EhGα1 expression also leads to significant changes in the E. histolytica 
transcriptome and altered the secretion of cytotoxic cysteine proteases [60], suggesting a 
possible functional overlap with Rab family GTPases (see below). Overexpression of 
EhRGS-RhoGEF has similar effects on trophozoite function when compared to the dominant 
negative EhGα1, consistent with its function as an EhGα1 GAP (also demonstrated in vitro) 
and, thus, a negative regulator of heterotrimeric G protein signaling in the context of its 
overexpression [60, 62]. Nucleotide exchange is rate-limiting in the EhGα1 nucleotide cycle 
[60], as seen in mammalian Gα subunits, suggesting that GEF activity is needed for signal 
activation. Yet the E. histolytica genome lacks homologs of non-receptor GEFs for 
heterotrimeric G proteins such as Ric-8 and GIV [30, 63], leading to the hypothesis that E. 
histolytica may express one or more GPCRs (i.e. a putative cell surface-spanning, EhGα1-
directed GEF; Figure 1.2). Although a bona fide heterotrimeric G protein couple receptor has 
not yet been identified in this organism, one or more receptor/ligand pairs would provide 
valuable tools for manipulating G protein signaling in E. histolytica and also potentially serve 
as a candidate drug discovery target [36, 60]. 
 A second, putative Gα subunit (AmoebaDB acc. no. EHI_186910) exhibits a unique 
domain structure, with an N-terminal Gα-like fold easily identifiable despite substantial 
sequence divergence from mammalian Gα subunits, and a C-terminal PP2C-related 
phosphatase domain [61]. The Gα-like region lacks determinants for CTX- or PTX-mediated 
ribosylation (as does EhGα1); furthermore, this putative Gα subunit lacks the otherwise very 
well-conserved nucleotide binding motifs shared among all G proteins, suggesting a lack of 
nucleotide binding (unpublished data and [64]). This apparently expressed protein awaits 
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functional assessment of its Gα-like domain and its unique relationship to the adjacent 
phosphatase domain. 
 EhGβ1 dimerized with one of two E. histolytica Gγ subunits when expressed in 
mammalian cells, and the EhGβγ dimer in turn bound EhGα1 in a nucleotide state-selective 
fashion [60]. Gβγ subunits also frequently engage downstream effectors, even when the 
associated Gα subunits lack a major known effector, as seen in the case of Arabidopsis 
thaliana sugar sensing and yeast phermone signaling [65, 66]. Signaling downstream of 
EhGβγ is a distinct possibility for E. histolytica and may contribute to the phenotypic effects 
of perturbed EhGα1 expression [60]; however, no EhGβγ effectors have yet been identified. 
 
1.6 RAS SUPERFAMILY GTPases IN E. histolytica 
The E. histolytica genome encodes a remarkably large number of small GTPases for a single-
celled parasite (>170 annotated in AmoebaDB, [67]), suggesting a prominent role for Ras 
superfamily G protein signaling. The Ras superfamily can be divided into the Ras subfamily, 
typically regulating cell proliferation and survival; the Rho family that regulates actin 
organization, the cell cycle, and gene expression; the Ran family, implicated primarily in 
nucleocytoplasmic transport; and the Rab and Arf families, known as regulators of vesicular 
transport and trafficking (reviewed in [33]). Ten Ras proteins and two related Rap homologs 
have been described in E. histolytica [68, 69], although the complete set of Ras homolog 
genes has not been described since completion of the E. histolytica genome sequencing 
project. At least 20 Rho family GTPases, including Rho, Rac, and Cdc42 homologs are 
transcribed by E. histolytica trophozoites [70-72]. The Rab family is the most numerous 
small G protein group described in E. histolytica, with 91 annotated genes [73]. Although not 
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yet described in the literature, putative Ran and Arf family GTPases also exist in the E. 
histolytica genome [67]. While a small fraction of E. histolytica Ras superfamily GTPases 
has been investigated, the extent of functional redundancy, signaling specificity, and 
nucleotide cycle regulation among small G proteins remain largely unknown. Given the poor 
genetic tractability of E. histolytica trophozoites, investigations of G protein signaling in this 
organism have largely been limited to overexpression studies. While overexpression is 
certainly an informative genetic perturbation, it should be noted that overexpressed G 
proteins, or nucleotide cycle-impaired mutants thereof, are subject to potential 
mislocalization and non-physiological functions.  
 
1.6.1 Ras family GTPases 
An initial study in E. histolytica trophozoites identified two Ras genes and two related Rap 
genes, as well as a single protein that apparently cross-reacted with a mammalian anti-Ras 
antibody [68]. Ras family GTPases in mammals and yeast are isoprenylated with either a 
geranylgeranyl or a farnesyl group at the characteristic C-terminal CaaX motif, where “a” is 
an aliphatic amino acid and the final residue is predictive of either geranylgeranylation or 
farnesylation [33]. Expression of EhRap2, EhRas1, and CaaX motif mutants thereof, in 
mammalian reticulocytes revealed that E. histolytica Ras GTPases can be isoprenylated, but 
that their CaaX motif sequences are less predictive of the specific isoprenyl group added than 
mammalian counterparts [74]. An E. histolytica farnesyltransferase (EhFT), consisting of two 
subunits, was later cloned and shown to farnesylate human H-Ras and EhRas4, to the 
exclusion of three other E. histolytica Ras isoforms, indicating a distinct CaaX motif 
selectivity for isoprenylation [69]. Recombinant EhFT is resistant to mammalian farnesyl 
 14 
transferase inhibitors, precluding their use as tools in studying Ras GTPase function in E. 
histolytica trophozoites. Ras GTPases and related signaling machinery have been the targets 
of much pharmaceutical development effort, given the centrality of oncogenic Ras signaling 
to cellular proliferation and survival in many human malignancies [75]. However, no studies 
of perturbed Ras signaling in E. histolytica have yet emerged. Similarly, putative regulators 
of Ras nucleotide cycling (e.g. GEFs and GAPs) and candidate Ras effectors are currently 
understudied in E. histolytica.  
 
1.6.2 Rho family GTPases 
Entamoeba histolytica possesses a highly dynamic, actin-rich cytoskeleton that participates 
in many pathogenesis-related processes (reviewed in [28]) as well as two major actin-
associated myosins (reviewed in [29, 76]). Remarkably rapid actin remodeling is apparent in 
trophozoite motility [77], a process regulated by extracellular matrix interactions [78] as well 
as self-generated chemokines [79]. Cytoskeletal remodeling is also intimately associated with 
E. histolytica phagocytosis [26] and surface receptor capping [27]. As master regulators of 
the actin cytoskeleton, as well as cell division and transcription in mammals, Rho GTPases 
and their associated proteins have been a focus of intense investigation in E. histolytica. 
 The first identified Rho family GTPase in E. histolytica was EhRho1, also later 
referred to as EhRhoA1 (Figure 1.3) [70]. As a homolog of human RhoA, EhRho1 was a 
natural candidate substrate for the Rho-inhibiting C3 exoenzyme from Clostridum botulinum, 
a protein whose ectopic expression in E. histolytica trophozoites leads to ribosylation of an 
~25 kDa protein and reduces both proliferation and host cell killing [80]. However, 
recombinant EhRho1 was later found not to be a substrate for C3 exoenzyme [81], but 
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instead glucosylated in vitro by both C. difficile toxin B and C. novyi α-toxin [82]. However, 
use of these two Clostridium toxins to study EhRho1 function in vivo is impaired by a lack of 
trophozoite membrane permeability [82]. A structural study of EhRho1 has more recently 
highlighted its conserved conformational difference between the GDP- and GTP-bound 
states, as well as its distinct lack of a “Rho insert helix” -- a structural feature that 
differentiates all other Rho family GTPases from the greater Ras superfamily [72]. EhRho1 
also differs from its homologs at a key nucleotide-binding residue, a feature found to confer 
rapid intrinsic nucleotide exchange, but not constitutive activity [72, 81]. However, EhRho1 
does exhibit a signature activity of other Rho family GTPases; expression of a constitutively 
active mutant in human cells promotes actin stress fiber formation [72]. Activated 
EhRho1·GTP binds a Diaphanous-related formin effector protein, EhFormin1, in contrast to 
multiple other E. histolytica Rho family GTPases (Figure 1.3) [72, 83]. EhFormin1 is known 
to modulate actin polymerization, to be autoinhibited by an N- to C-terminal intramolecular 
interaction like its well-studied mammalian homologs [84], and to be specifically activated 
by EhRho1·GTP [83]. A recent crystal structure of the EhRho1·GTPγS/EhFormin1 complex 
revealed a similar mode of interaction compared to mammalian RhoC/mDia1. However, the 
E. histolytica complex lacks a secondary binding site involving the Rho insert helix. 
Structure-based mutagenesis also yielded insights into specificity requirements for Rho 
GTPase/effector pairings [83]. EhFormin1 (also called EhDia) belongs to a family of eight E. 
histolytica formin proteins, three of which were Diaphanous-related (i.e. containing tandem 
Rho GTPase binding domains (GBDs) and formin homology three domains (FH3s)) [85, 86]. 
Overexpressed EhFormin1 in trophozoites localizes to pseudopodia, the microtubular 
assembly in the nucleus, and cytoplasmic F-actin structures in response to serum [86]. 
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Furthermore, EhFormin1- and EhFormin2-overexpressing amoebae exhibit cell division 
defects, with an increased number of nuclei per cell and increased average DNA content per 
nucleus [86], suggesting that EhRho1/EhFormin1 signaling may be involved in actin 
polymerization in pseudopodia and/or trophozoite cell division (Figure 1.3). 
 EhRho1 has also been implicated in signaling downstream of lysophosphatidic acid 
(LPA), an agent that promotes actin polymerization and associated F-actin structures, alters 
concanavalin A (ConA)-induced surface receptor capping, increases migration and invasion, 
and modulates erythrophagocytosis in E. histolytica trophozoites [54, 87]. LPA treatment (on 
the order of 10 µM concentration) has been reported to promote EhRho1 activation in E. 
histolytica, as measured by a GST-Rhotekin Rho binding domain (RBD) pull-down assay 
[54, 87]. However, we and others have been unable to observe nucleotide-specific interaction 
between GST-Rhotekin RBD and either epitope-tagged EhRho1 expressed in cells or 
purified recombinant EhRho1 (unpublished data), suggesting that EhRho1 binding observed 
in other studies [54, 87] may be the result of non-specific interactions, or that the employed 
anti-EhRho1 antibody may cross-react with one or more other E. histolytica Rho family 
GTPases. LPA-induced EhRho1 activation has also been assessed by co-
immunoprecipitation with a human antigen-derived anti-Rho kinase 2 (ROCK-2) antibody 
[54]; however no ROCK homologs in E. histolytica have yet been described or are apparent 
in the genome [67]. 
 A number of Rac homologs are also expressed in E. histolytica [71], including 
EhRacA. Overexpression of a constitutively active EhRacA(G12V) in trophozoites leads to 
delayed cell division, as well as defects in phagocytosis of bacteria, human erythrocytes, and 
mucin-coated beads, and alterations in ConA-stimulated receptor capping [88]. Furthermore, 
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EhRacA was seen to specifically engage the p21-binding domain (PBD) of the p21-activated 
kinase EhPAK2, both in amoebic lysates and in the context of purified recombinant proteins 
(Figure 1.3) [89]. PAKs are effectors for canonical Rho family GTPases, and their 
serine/threonine kinase activities and/or localizations are modulated by binding of activated 
G proteins (reviewed in [90]). Trophozoites engineered to overexpress the kinase domain of 
EhPAK2, but not the full-length protein or the N-terminal regulatory region, exhibit defects 
in collagen matrix invasion, surface receptor capping, and cytokinesis [89]. Phenotypic 
overlap between EhRacA(G12V) and EhPAK2 kinase domain strains suggests a role for 
EhRacA/EhPAK2 signaling in surface receptor capping and regulation of cell division. 
 EhRacG has also been identified as a contributor to pathogenesis-related functions in 
E. histolytica. Overexpression of constitutively active EhRacG(G12V) in trophozoites leads 
to formation of a minor population of giant multinucleated cells, indicating a likely 
cytokinesis defect [91]. Filamentous actin arrangements and surface receptor capping are also 
altered with EhRacG(G12V) expression, and electron microscopy observations suggest 
increased budding of membrane vesicles [91]. Endogenously expressed EhRacG is enriched 
in ConA-induced uroids, together with filamentous actin and myosin II, consistent with its 
regulatory role in surface receptor capping via modulation of the actin cytoskeleton [91]. 
 Activated EhRacC was recently shown to directly engage the heterotrimeric G protein 
effector EhRGS-RhoGEF [62]. Expression of constitutively active EhRacC, together with 
constitutively active EhGα1 is required to achieve EhRGS-RhoGEF activation in Drosophila 
S2 cells [62], suggesting a convergence with heterotrimeric G protein signaling. However, 
the contributions of EhRacC to cellular processes in E. histolytica remain to be directly 
assessed. 
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 A number of other putative Rho family GTPase effectors have been described in E. 
histolytica, although without unequivocally associated G proteins. For instance, two other 
diaphanous-related formins with GBD-FH3 domain tandems are encoded by the E. 
histolytica genome, in addition to the EhRho1 effector EhFormin1 [86]. Overexpressed 
EhFormin2 in trophozoites, like EhFormin1, is localized in pseudopodia and pinocytic and 
phagocytic vesicles, and results in mitosis and cytokinesis defects [86], suggesting some 
functional redundancy among diaphanous-related formins despite differences in their Rho-
GTPase binding sites and, thus, likely differences in Rho activator specificity ([83] and 
unpublished data). A fourth GBD-FH3 tandem protein, the actin-binding EhNCABP166, has 
also been implicated as a modulator of phagocytosis, chemotactic migration, and possibly 
proliferation in trophozoites [92]. The small G protein specificity of the EhNACAP166 
GBD-FH3 domain tandem has been investigated; however, these binding experiments were 
conducted with denatured Rho GTPases [92], and intact Rho tertiary structure is required for 
the typical Rho/GBD-FH3 association (e.g. [83]). Some of the seven identified PAK family 
members, in addition to the EhRacA effector EhPAK2, have also been studied in E. 
histolytica. EhPAK (also called EhPAK1) localizes to pseudopods during amoebic migration 
and to the uroid upon ConA-induced capping [93]. The N-terminus of EhPAK1 was found to 
bind human Rac1 with typical nucleotide specificity (i.e. dependent on the GTP-bound state) 
despite the lack of an identifiable PBD; trophozoites overexpressing the EhPAK1 kinase 
domain exhibit reduced migration, an increased number of membrane extensions, and an 
increased rate of erythrocyte phagocytosis [94]. EhPAK3 is also expressed in trophozoites, 
and both recombinant protein purified under denaturing conditions and protein 
immunoprecipitated from amoebic lysates exhibit apparent kinase activity [95]. 
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 Putative regulators of Rho family GTPase nucleotide cycling are also prominent in 
the E. histolytica genome [30], including ~70 Dbl homology (DH) domain-containing 
candidate RhoGEFs, ~70 encoded RhoGAP domain-containing proteins, and a single 
RhoGDI. Although no studies of RhoGAP proteins have yet emerged, they are likely to 
regulate pathogenesis-related functions like their associated GTPases. Recombinant purified 
EhRhoGDI binds EhRho1 in a nucleotide state- and isoprenylation-dependent fashion [72]. 
As the only apparent RhoGDI, it is likely that this protein also engages other inactive Rho 
GTPases in E. histolytica to impair nucleotide exchange and regulate their subcellular 
localization.  
 Better studied are a number of Dbl family RhoGEFs. For example, overexpression of 
EhGEF1 in trophozoites decreases total cellular filamentous actin, reduces amoebic 
migration, and alters killing of mammalian cells [96, 97]. In vitro nucleotide exchange assays 
indicate that EhGEF1 likely catalyzes exchange on EhRacG and EhRho1 (the latter 
illustrated in Figure 1.3A), although concentrations of GEF protein employed in these assays 
as well as a concentration-response analysis were not included in this report [97]. Later 
studies utilized structural homology models to predict EhGEF1 Dbl homology domain (DH) 
point mutations that impaired GEF activity toward EhRho1 and EhRacG, as indicated by 
maximal nucleotide analog fluorescence at a single time point [98]. However, kinetic 
analysis is a preferable measure of GEF activity, as maximal fluorescence readings are 
subject to artifacts due to differing specific activities of recombinant proteins, non-specific 
binding, fluctuations in instrumentation settings, and/or “buffer shifts” in fluorescence that 
vary among protein preparations. EhGEF1 small-molecule inhibitors have also been pursued, 
based on a docking analysis using a homology model to existing mammalian RhoGEF 
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structures (~50% or less sequence similarity) [99]. Five compounds were assessed for 
EhGEF1 inhibition by in vitro nucleotide exchange assays and found to be active at ~50-100 
µM concentrations [99]. However, exchange kinetics were not assessed, a typical 
concentration-response pattern was not obtained, and direct binding of compounds to 
EhGEF1 (or potentially Rho GTPases) has not yet been demonstrated in these studies. 
Furthermore, the specificity of these potential pharmacological tools, for instance across 
other E. histolytica RhoGEFs, remains to be determined. 
 The armadillo-repeat containing EhGEF2 has been implicated in erythrocyte 
phagocytosis, trophozoite proliferation, and chemotaxis, based upon an E. histolytica strain 
engineered to overexpress a dominant negative point mutant [100]. Both the N-terminal and 
DH domain regions were seen to contribute to EhGEF2 membrane localization. EhGEF2 was 
also suggested to activate EhRacA-D, EhRacG-H, and EhCdc42 in vitro [100], although no 
kinetic analysis was provided in this report and the fluorescence time courses shown appear 
to be caused by buffer shifts upon GEF addition rather than a single exponential binding 
event per se. Which Rho substrates and dominant negative mutant-impaired signals are 
relevant for the observed in vivo effects are currently unknown. 
 The DH-PH domain tandem of a third Dbl family RhoGEF, EhGEF3, stimulates 
nucleotide exchange on EhRacA and EhRho1 in vitro [101]. Simultaneous EhGEF3 and 
EhRacA overexpression in E. histolytica leads to increased migration toward fibronectin, 
while a dominant negative EhGEF3 mutant has the opposite effect. Overexpressed EhGEF3, 
but not the dominant negative point mutant, also promotes EhRacA activation in 
trophozoites, as assessed by a GST-EhPAK2 PBD pulldown assay, suggesting a role for 
EhGEF3/EhRacA signaling in chemotactic migration (Figure 1.3) [101]. EhGEF3 and 
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EhRacA co-localize in caps induced by ConA treatment, suggesting a possible additional role 
in surface receptor capping [101]. 
 Members of a family of eleven RhoGEFs in E. histolytica each contain a FYVE 
domain, known to associate with inositol phospholipids and to decorate early phagosomes in 
trophozoites [102]. A GFP-tagged mammalian FYVE domain overexpressed in trophozoites 
was observed to translocate to phagocytic cups and phagosomes during host cell 
phagocytosis [103]. One overexpressed FYVE domain-containing RhoGEF, EhFP4, is also 
recruited to phagocytosis-related structures [103], and overexpression of the isolated FYVE 
domain from EhP4 impairs trophozoite phagocytosis. Interaction of EhFP4 or its DH-PH 
domains with recombinant E. histolytica Rho family GTPases has been assessed with pull-
down assays. EhFP4 was seen to interact with EhRacC, EhRacD, and two unnamed G 
proteins, although nucleotide state selectivity was not assessed, and the authors reported 
inability to detect nucleotide exchange activity [103]. Thus, it remains to be established 
whether these FYVE domain-containing RhoGEFs exhibit GEF activity and whether there is 
any functional interplay between their FYVE and DH-PH domains. 
 
1.6.3 Rab family GTPases 
The E. histolytica genome encodes a remarkable 91 Rab family G proteins, many of which 
are not clear homologs of mammalian Rabs, suggesting an unusually high degree of 
complexity underlying vesicular trafficking regulation in trophozoites [73, 104, 105]. 
Endosomes isolated from E. histolytica by magnetic fractionation are associated with 
virulence-associated cysteine protease activity, as well as enrichment of Rab GTPases, such 
as EhRab11 and potentially a Rab7 homolog [106]. The importance of phagocytosis and 
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pinocytosis in nutrient uptake by trophozoites, the secretion of virulence factors like 
amoebapores and cysteine proteases, as well as the critical role of membrane-associated 
proteins like the Gal/GalNAc lectin, all support the hypothesis that Rab-regulated vesicular 
trafficking is important for E. histolytica biology and pathogenesis [14, 23, 24].  
 EhRabA is localized to vesicles at steady state, but moves to the leading edge in 
motile cells and the membrane opposite ConA-induced caps, as well as to membrane 
extensions upon N-formyl peptide-induced polarization [107]. Expression of a dominant 
negative EhRabA mutant in trophozoites produces changes in cell morphology and 
polarization, impairs motility, and reduces host cell attachment and killing, but has no 
observable effect on pinocytosis or erythrophagocytosis [108]. Conversely, overexpression of 
constitutively active EhRabA perturbs erythrophagocytosis and leads to formation of large 
tubular organelles apparently derived from the endoplasmic reticulum (ER) [109]. Two 
subunits of the Gal/Gal-NAc lectin and a cysteine protease are mislocalized to the EhRabA-
induced organelles, and similar effects are seen with brefeldin A treatment, suggesting that 
EhRabA regulates trafficking between the ER and Golgi apparatus [109]. 
 EhRabB is one of the first identified and the most frequently studied Rab family 
GTPases in E. histolytica. Initial immunofluorescence studies localized endogenous EhRabB 
to cytoplasmic vesicles and noted its translocation to the plasma membrane and phagocytic 
cups during erythrophagocytosis [110, 111]. Poor phagocytosis in a mutant E. histolytica 
strain correlated with increased expression of EhRabB, as well as substantial sequence 
differences between this mutant EhRabB and wild-type EhRabB, providing further evidence 
for its involvement in phagocytosis [112], although a causal association was not established. 
EhRabB was also observed to be enriched at phagosomes in a proteomics study [113]. 
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Overexpression of EhRabB in trophozoites leads to a small diminution of phagocytosis, 
while expression of a dominant negative mutant (N118I) leads to decreases in both 
phagocytosis and cell monolayer destruction [114]. Of particular interest, EhRabB(N118I)-
expressing trophozoites do not form liver abscesses in a hamster model, while vector-
transfected and wild type EhRabB-expressing amoebae do form such abscesses, establishing 
EhRabB signaling as likely important for pathogenesis [114]. EhRabB was reported to 
interact with the transmembrane protein EhGPCR-1 by yeast two-hybrid, although binding 
data were not shown in this study [115]. Despite its initial naming as a G protein coupled 
receptor, further sequence analysis has indicated that EhGPCR-1 is more likely a Wnt-
binding factor, rather than a heterotrimeric G protein GEF per se [60]. 
 Entamoeba histolytica also expresses Rab5- and Rab7-related G proteins [116, 117]. 
Overexpressed EhRab5 and EhRab7A localize to independent vesicular structures at steady 
state, but exposure of these overexpression-modified trophozoites to erythrocytes is seen to 
cause convergence of the two Rabs at a large “pre-phagosomal vacuole” (PPV), distinct from 
actual phagosomes [118]. Electron microscopy studies have identified small amoebapore-
containing vesicles in the PPV, suggesting a role for EhRab5 and/or EhRab7A in delivering 
cytotoxic amoebapores to phagosomes [118]. Consistent with this hypothesis, overexpression 
of wild type EhRab5 enhances phagocytosis kinetics and amoebapore transport, while 
expression of either constitutively active or dominant negative EhRab5 mutants impairs PPV 
formation and phagocytosis [118]. EhRab7 also co-localizes with early endosomes [116], and 
overexpression of EhRab7A in trophozoites reveals its subcellular localization to lysosomes 
and an increased acidic cellular compartment, as well as decreased cellular cysteine protease 
activity [119]. A retromer-like complex of E. histolytica proteins is seen to engage 
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recombinant EhRab7A in a nucleotide-dependent fashion, primarily through the C-terminus 
of EhVps26, leading to the hypothesis that EhRab7A may contribute to retrograde transport 
from vacuoles and phagosomes to the Golgi apparatus [119]. An E. histolytica homolog of 
Rab8 has also been cloned, but no cellular functions have yet been established for this G 
protein other than its vesicular localization [120, 121]. 
 EhRab11 exhibits a punctate distribution in trophozoites and moves to the cell 
periphery upon iron and serum starvation of trophozoites [122], in contrast to EhRab7 and 
EhRabA. Iron and serum starvation is associated with altered cytokinesis and increased 
detergent-resistant cells, but whether EhRab11 contributes to these phenotypes is unknown 
[122]. A related isoform, EhRab11B, also exhibits a vesicular distribution, and 
overexpression of EhRab11B in trophozoites leads to an increase in both intracellular and 
secreted cysteine proteases [123]. Amoeba overexpressing EhRab11B exhibit slightly 
increased exocytosis of a fluid-phase marker and more efficiently kill mammalian cells, an 
effect reversed by treatment with the cysteine protease inhibitor E64 [123]. These findings 
suggest that the E. histolytica Rab11 isoforms have non-redundant functions. 
 No studies of Rab GTPase nucleotide cycle regulators in E. histolytica have yet 
emerged. The E. histolytica genome encodes for ~20 proteins with DENN domains [67], 
known in mammals to serve as Rab GEFs, along with other structurally unrelated proteins 
[124]. Also present are ~50 Rab-GAP/TBC domain containing proteins and two putative Rab 
GDIs [67]. Examination of these likely Rab regulators may shed further light on signaling 
mechanisms contributing to E. histolytica pathogenicity, especially in the context of vesicular 
trafficking mechanics. 
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1.7 THE UBIQUITIN-PROTEASOME SYSTEM IN E. histolytica 
Among a number of genes with altered transcription upon perturbed EhGα1 expression are 
components of the ubiquitin-proteasome system, including a ubiquitin gene itself [60]. 
EhUbiquitin was previously shown to differ substantially in sequence from the otherwise 
highly conserved homologs in other species, although EhUbiquitin expression complements 
ubiquitin gene deletion in yeast [125, 126]. The likely importance of the ubiquitin-
proteasome pathway in Entamoeba is evidenced by the impairment of trophozoite growth 
and encystation upon treatment with three proteasome inhibitors, lactacystin, clasto-
lactacystin beta-lactone, and MG-132 [127]. Following completion of the E. histolytica 
genome sequencing [30], a complete bioinformatic analysis identified activating enzymes 
(E1), conjugating enzymes (E2), and ligases (E3) for ubiquitin as well as most other 
ubiquitin-like modifiers (ULMs) [128]. A recent study described functional ubiquitin 
conjugation machinery, including E1, E2, and E3 enzymes. EhUba1 (E1) catalyzes ATP-
dependent activation of EhUbiquitin, transfer to the conjugating enzyme (E2) EhUbc5, and 
selective interaction between EhUbc5 and the E3 ligase EhRING1 [129]. Crystal structures 
of EhUbiquitin reveal clustering of the non-conserved residues, including an extra surface 
lysine, on a single surface that is not utilized in most structurally characterized ubiquitin 
interactions [129]. Thus, E. histolytica has been shown to express a functional ubiquitination 
enzyme cascade that likely regulates protein stability and proteasomal degradation, among 
other functions [130]. 
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1.8 CONCLUSION AND PERSPECTIVE 
A number of G proteins have been implicated in the pathogenic processes of E. histolytica, 
particularly heterotrimeric G proteins, a number of cytoskeleton-associated Rho GTPases, 
and also Rab GTPases primarily involved in vesicular trafficking. Exploitation of known 
signaling pathways for pharmacological manipulation is attractive, both in the development 
of tools for interrogating the specific functions of G protein signaling in E. histolytica, and as 
a potential approach to the development of anti-amoebiasis therapeutics. A first step has been 
taken in developing small molecule inhibitors for EhGEF1 [99], and other E. histolytica 
RhoGEFs may be targetable given some prior success in inhibiting mammalian Rho GTPase 
activation (e.g. [131, 132]). Some Ras and Rho GTPase effectors, particularly kinases like 
the PAKs and members of the mitogen-activated protein kinase (MAPK) cascade members, 
have also proven tractable as pharmacological targets in humans (e.g. [133, 134]). However, 
the importance of Ras effectors and downstream kinases in E. histolytica pathogenesis has 
not yet been explored. Particularly promising for pharmacological development is the 
recently described heterotrimeric G protein signaling within E. histolytica [36, 60], although 
identification of a bona fide GPCR and ligand pair in E. histolytica remains a barrier at this 
time. 
 Aside from pharmacological goals, much remains to be discovered regarding 
modulation of the Ras superfamily GTPase functions in E. histolytica, particularly regarding 
nucleotide cycle regulators (GAPs, GEFs, and GDIs). Also unclear is the interplay among the 
well-populated small G protein families in E. histolytica, such as the >20 member Rho 
family and the 91 member Rab family. Are many of these GTPases redundant in function and 
regulation? How is GTPase specificity for effectors and nucleotide cycle regulators achieved, 
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given such large numbers of simultaneously expressed G proteins in a single cell? Further 
study of both heterotrimeric and small G proteins in E. histolytica will likely add to our 
understanding of parasite biology and pathogenicity, as well as signaling in other organisms.  
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Figure 1.1. Nucleotide cycle regulation of heterotrimeric and Ras superfamily G 
proteins. (A) Gα subunits cycle between GDP- and GTP-bound states. GPCRs serve as 
GEFs for G protein heterotrimers, stimulating their release of GDP. Conversely, GoLoco 
motifs are GDIs that slow nucleotide exchange by Gα subunits. RGS proteins are GAPs for 
Gα subunits, promoting signal termination by both activated Gα subunits and free Gβγ. (B) 
The small G protein nucleotide cycle parallels that of heterotrimeric G proteins, with GEF-
stimulated and GDI-inhibited nucleotide exchange as well as GAP-mediated activation of 
GTP hydrolysis. 
 29 
 
 
Figure 1.2. Model of heterotrimeric G protein signaling in E. histolytica. Activated 
EhGα1, together with GTP-bound EhRacC, engages the autoinhibited EhRGS-RhoGEF, 
leading to Rac GTPase signaling in Drosophila S2 cells [62], although no specific E. 
histolytica Rho family substrate for EhRGS-RhoGEF has yet been identified. Both EhGα1 
and EhRGS-RhoGEF alter trophozoite migration, host cell attachment, and cell killing by 
altered cysteine protease secretion [60, 62]. An associated GPCR is postulated, but not yet 
established within this signaling pathway. Despite its name, the protein EhGPCR-1 is more 
likely a Wnt-binding factor than a ligand-activated heterotrimeric G protein GEF [60]. 
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Figure 1.3. EhRho1 and EhRacA signaling modulate pathogenic behaviors in E. 
histolytica. (A) Nucleotide exchange on EhRho1 is known to be catalyzed by EhGEF1 in 
vitro [97]. EhRho1 engages the GBD-FH3 domain tandem of the diaphanous-related and 
autoinhibited EhFormin1 to modulate actin polymerization [83]. EhFormin1 has also been 
implicated in trophozoite proliferation and cytokinesis [86]. (B) EhRacA nucleotide 
exchange is known to be accelerated by EhGEF3 in vitro [101]. Constitutively active 
EhRacA perturbs phagocytosis and chemotaxis, as well as surface receptor capping in 
trophozoites [88]. EhRacA·GTP was also shown to bind EhPAK2, a likely effector whose 
kinase domain is implicated in collagen matrix invasion, cytokinesis and surface receptor 
capping [89]. Stimulation of EhPAK2 kinase activity by EhRacA is postulated, but has not 
yet been established. 
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CHAPTER 2 
 
HETEROTRIMERIC G-PROTEIN SIGNALING IS CRITICAL TO PATHOGENIC 
PROCESSES IN Entamoeba histolytica1 
 
2.1  OVERVIEW 
 
Heterotrimeric G-protein signaling pathways are vital components of physiology, and many 
are amenable to pharmacologic manipulation. Here, we identify functional heterotrimeric G 
protein subunits in Entamoeba histolytica, the causative agent of amoebic colitis. The E. 
histolytica Gα subunit EhGα1 exhibits conventional nucleotide cycling properties and is 
seen to interact with EhGβγ dimers and a candidate effector, EhRGS-RhoGEF, in typical, 
nucleotide-state-selective fashions. In contrast, a crystal structure of EhGα1 highlights 
unique features and classification outside of conventional mammalian Gα subfamilies. E. 
histolytica trophozoites overexpressing wildtype EhGα1 in an inducible manner exhibit an 
enhanced ability to kill host cells that may be wholly or partially due to enhanced host cell 
attachment. EhGα1-overexpressing trophozoites also display enhanced transmigration across 
a Matrigel barrier, an effect that may result from altered baseline migration. Inducible 
expression of a dominant negative EhGα1 variant engenders the converse phenotypes. 
Transcriptomic studies reveal that modulation of pathogenesis-related trophozoite behaviors 
by perturbed heterotrimeric G-protein expression includes transcriptional regulation of  
1 Bosch, D.E., Kimple, A.J., Muller, R.E., Giguere, P.M., Machius, M., Willard, F.S., Temple, B.R., and 
Siderovski, D.P. (2012) Heterotrimeric G-protein Signaling Is Critical to Pathogenic Processes in Entamoeba 
histolytica. PLoS Pathogens. 8(11): e1003040. 
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virulence factors and altered trafficking of cysteine proteases. Collectively, our studies 
suggest that E. histolytica possesses a divergent heterotrimeric G-protein signaling axis that 
modulates key aspects of cellular processes related to the pathogenesis of this infectious 
organism. 
 
2.2  INTRODUCTION 
GTP-binding proteins (G-proteins) are important transducers of cellular signaling [1]. 
Heterotrimeric G-proteins are composed of three distinct subunits (Gα, Gβ, and Gγ) and 
typically coupled to seven-transmembrane domain, G-protein coupled receptors (GPCRs). 
Gα binds guanine nucleotide while Gβ and Gγ form an obligate heterodimer [1]. 
Conventionally, Gα forms a high-affinity binding site for Gβγ when Gα is in its inactive 
GDP-bound state. Activated receptor acts as a guanine nucleotide exchange factor (GEF) for 
Gα, releasing GDP and allowing subsequent GTP binding. The binding of GTP causes a 
conformational change in three flexible “switch” regions within Gα, resulting in Gβγ 
dissociation. Gα·GTP and freed Gβγ independently activate downstream effectors, such as 
adenylyl cyclases, phospholipase C isoforms, and Rho-family guanine nucleotide exchange 
factors (RhoGEFs) to modulate levels of intracellular second messengers [1, 2]. ‘Regulator of 
G-protein signaling’ (RGS) proteins generally serve as inhibitors of Gα-mediated signaling 
[3]; however, one class of RGS protein, the RGS-RhoGEFs, serve as positive “effectors” for 
activated Gα signal transduction [2, 4].  
 Heterotrimeric G-protein signaling has provided a wealth of targets amenable to 
pharmacologic manipulation, most prevalent being the GPCR itself [5]. Heterotrimeric G-
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proteins in mammals regulate processes as diverse as vision, neurotransmission, and vascular 
contractility [1, 5]. Heterotrimeric G-proteins in non-mammalian organisms also exhibit a 
wide range of functions; for example, pheromone and nutrient sensing in yeast [6], 
hydrophobic surface recognition in the rice blast fungus [7], and cellular proliferation and 
chemical gradient sensing in the slime mold Dictyostelium discoideum [8, 9]. 
 Entamoeba histolytica causes an estimated 50 million infections and 100,000 deaths 
per year worldwide [10]. E. histolytica infection is endemic in countries with poor barriers 
between drinking water and sewage; however, outbreaks also occur among travelers and 
susceptible subpopulations in developed countries [11]. Upon cyst ingestion, the amoeba 
may colonize the human colon. Although the majority of infections are asymptomatic (e.g. 
ref [12]), a fraction results in symptomatic amoebic colitis. Migratory E. histolytica 
trophozoites attach to intestinal epithelial cells through a Gal/Gal-NAc lectin [13]. Amoebae 
subsequently kill host cells through a number of mechanisms, including secretion of cell-
perforating amoebapores [14, 15] and release of cytotoxic cysteine proteases [16].  
 E. histolytica has been studied for more than 50 years, and some of the signaling 
pathways important for pathogenesis have been identified. Several transmembrane kinases 
have been implicated cellular proliferation, phagocytosis, and the establishment of intestinal 
infection [17-19]. Calcium signaling is also involved in phagocytosis; for instance, calcium 
binding protein 1 (EhCaBP1) modulates the actin cytoskeleton at phagocytic cups and, 
together with the EhC2PK kinase, is involved in phagosome maturation [20-23]. Rho family 
GTPases and their activating exchange factors are also involved in a variety of pathogenic 
processes, including migration, phagocytosis, and surface receptor capping [24-27]. The 
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related Rab family small GTPases control trafficking and maturation of cellular vesicles, and 
are implicated in processes such as phagocytosis and cysteine protease secretion [28-31]. 
 However, many E. histolytica signaling components, and thus potential targets for 
therapeutic intervention, remain under-studied. For example, recent sequencing of the E. 
histolytica genome identified multiple potential cell signal transduction components; e.g., 
307 putative protein kinases representing all seven eukaryotic kinase families have been 
identified, including receptor tyrosine kinases [19, 32]. In this paper, we describe genetic, 
structural, and biochemical data establishing the identity of E. histolytica heterotrimeric G-
protein signal transduction components as well as their regulatory roles in pathogenesis-
related behaviors of E. histolytica.  
 
 
2.3.  EXPERIMENTAL PROCEDURES 
 
2.3.1 Cloning of E. histolytica G-protein subunits 
The open reading frame (ORF) of EhGα1 was amplified from E. histolytica genomic DNA 
(Dr. M. Vargas, Center of Investigation and Advanced Studies, Mexico City) by polymerase 
chain-reaction (PCR) using Phusion polymerase (New England BioLabs) and Invitrogen 
primers. Amplicons were subcloned using ligation-independent cloning [33] into a Novagen 
pET vector-based prokaryotic expression construct (“pET-His-LIC-C”) to form N-terminal 
tobacco etch virus (TEV) protease-cleavable, hexahistidine-tagged fusions. Mutations were 
made using QuikChange site-directed mutagenesis (Stratagene). ORFs of EhGα1, EhGβ1, 
EhGγ1, and EhGγ2, codon-optimized for mammalian cells, were obtained from Geneart 
(Regensburg, Germany); EhGα1 with an internal FLAG epitope, DYKDDDK inserted after 
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His-83, was also obtained for co-immunoprecipitations. Sequences for EhGγ1 and EhGγ2, 
identified in genomic shotgun sequences were MSQQQLTRLLQEKERLMKNFERSKNLM 
KVSEACSDLVNFTKSKVDPFSPEFKDSNPWDKNNEGGCCALV and MSQQQLIRLLQ 
EKERLMKNFERSKNLMKVSEACSELVNFTKNKIDPFSPEFKDTNPWDKSSNAGCCSL
M, respectively.  
 
2.3.2 Protein purification  
Human Gαi1 was purified as described [34]. For hexahistidine-tagged EhGα1 and EhRGS-
RhoGEF, B834 E. coli were grown to an OD600nm of 0.7−0.8 at 37°C before induction with 
700 µM or 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG), respectively, for 14-16 hours 
at 20°C. Cell pellets were resuspended in N1 buffer (for EhGα1: 50 mM Tris-HCl, pH 8.0, 
300 mM NaCl, 10 mM MgCl2, 10 mM NaF, 30 µM AlCl3, 50 µM GDP, 30 mM imidazole, 
5% (w/v) glycerol; for EhRGS-RhoGEF: 50 mM HEPES pH 8.0, 150 mM NaCl, 30 mM 
imidazole, 5% (w/v) glycerol) and lysed at 10,000 kPa using an Avestin Emulsiflex. Cleared 
lysates were applied to nickel-nitrilotriacetic acid resin (GE Healthcare), washed, and eluted 
with N1 buffer containing 300 mM imidazole. Eluted protein was resolved using a calibrated 
size exclusion column (GE Healthcare) with S200 buffer for EhGα1 (50 mM Tris-HCl pH 
8.0, 250 mM NaCl, 5 mM DTT, 5% (w/v) glycerol, and 50 mM GDP) or EhRGS-RhoGEF 
(50 mM Tris-HCl pH 8.0, 250 mM NaCl, 5 mM DTT, 5% (w/v) glycerol). Comparison of 
global fold between wild type and E39K mutant EhRGS-RhoGEF was performed using 
circular dichroism as previously described [35]. 
 For crystallization, the flexible N-terminal helix (22 residues) was removed from 
EhGα1; similar alterations in human Gα aided crystallization while not perturbing the 
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resulting structure [34].  For anomalous dispersion, a selenomethionine derivative was 
produced using selenomethionine-containing minimal media (Molecular Dimensions). 
Selenomethionine EhGα1ΔN was purified by nickel-NTA chromatography as above, TEV 
protease cleavage and anion exchange chromatography, as described for Gαi1 [34].  Prior to 
gel filtration, EhGα1ΔN was subjected to reductive alkylation with a dimethylamine-borane 
complex, exactly as described [36]. Selenomethionine EhRGS-RhoGEF lacking the first two 
and last two residues (a.a. 3-517) was purified by nickel-NTA chromatography as above, 
with TEV protease cleavage of the affinity tag and a second nickel-NTA chromatography 
step prior to gel filtration. 
 
2.3.3 Crystallization and structure determination 
Crystals of lysine-methylated selenomethionine EhGα1ΔN (lacking 22 N-terminal residues) 
were obtained by vapor diffusion from hanging drops at 18°C.  EhGα1ΔN at 15 mg/mL in 
crystallization buffer (50 mM HEPES pH 6.5, 150 mM NaCl, 10 mM MgCl2, 10 mM NaF, 
30 µM AlCl3, and 50 µM GDP) was mixed 1:1 and equilibrated against crystallization 
solution containing 1.5 M ammonium sulfate, 175 mM K/Na tartrate, and 100 mM sodium 
citrate pH 5.6.   Hexagonal rod crystals grew to 300 x 40 x 20 µm over 21 days. EhGα1ΔN 
crystals displayed the symmetry of space group P212121 (a = 56.3 Å, b = 56.9 Å, c = 229.8 Å, 
α = β = γ = 90°), with two monomers in the asymmetric unit.  Prior to data collection, 
crystals were serially transferred for ~30 seconds to well solution supplemented with 25% 
(v/v) glycerol at 5% increments and plunged into liquid nitrogen. 
 Anomalous diffraction data were obtained at 0.97954 Å wavelength (selenium 
absorption peak) and 100K temperature at the GM/CA-CAT ID-D beamline (APS, Argonne 
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National Labs) and processed using HKL2000 [37]. Since the EhGα1 crystals were sensitive 
to radiation, a highly redundant dataset was assembled by combining partial datasets 
collected at seven points along a single rod-shaped crystal.  Heavy atom searching, 
experimental phasing, and automated model building used Phenix AutoSol [38].  Heavy atom 
searching identified 26 of 26 possible sites, and refinement yielded an estimated Bayes 
correlation coefficient of 59.7 to 2.8 Å resolution.  After density modification, the estimated 
Bayes correlation coefficient increased to 59.8.  ~80% of the model was constructed 
automatically, and the remaining portion was built manually. The current model (Table 2.1) 
contains two EhGα1 monomers bound to GDP; AlF4- could not be located in the electron 
density map and thus does not seem to be incorporated, despite the presence of AlCl3, MgCl2, 
and NaF (AMF) in the crystallization buffer. 
 Refinement was carried out against peak anomalous data with Bijvoet pairs kept 
separate using phenix.refine [38] interspersed with manual model revisions using the 
program Coot [39] and consisted of conjugate-gradient minimization and calculation of 
individual atomic displacement and translation/libration/screw (TLS) parameters [40]. 
Residues that could not be identified in the electron density were: chain A, 19-21, 221-222, 
304-317, 356-358; chain B, 19-22, 188-196, 219-224, 302-313, 354-358.  The model exhibits 
excellent geometry as determined by MolProbity [41].  A Ramachandran analysis identified 
95.2% favored, 4.8% allowed, and 0% disallowed residues.  A refined molecular replacement 
solution of diffraction data to 3.3 Å from native, methionine-containing EhGα1 crystals 
showed no noticeable differences at this resolution.  The selenomethionine EhGα1 data, of 
higher quality and resolution, were used for refinement of the current model. Coordinates and 
structure factors are deposited in the RCSB Protein Data Bank (id 3RKA).  
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 Crystals of EhGα1 were obtained only in the presence of GDP·AMF, but no electron 
density was observed for the AlF4-, and thus and thus our structure is representative of the 
inactive, GDP-bound state.  Part of switch 3 in both monomers of the asymmetric unit and 
most of switch 2 in chain B are disordered, which is characteristic of the Gα inactive state in 
the absence of Gβγ binding [42, 43].  Switch 2 forms a well-ordered helix in chain A (Fig. 
2.9) with Trp-196 in a solvent-exposed position, also indicative of the inactive state.  This 
conserved tryptophan rotates into a hydrophobic pocket upon activation by either GTP or 
AMF (Fig. 2.4, 2.8; [34]).  Interestingly, the switch 2 region of EhGα1 occupies a position 
intermediate between that seen for human transducin in either the GDP- or AMF-bound 
forms (Fig. 2.8C,D; PDB 1TAG and 1TAD).  The unique conformation of switch 2 in 
EhGα1 is likely a result of crystal contacts; Trp-196 and the N-dimethylated Lys-195 interact 
with a hydrophobic patch on the neighboring molecule (Fig. 2.8B).  These crystal contacts 
may pull switch 2 away from the nucleotide pocket, potentially allowing AlF4- to dissociate 
from EhGα1 and thus accounting for its absence in the electron density map.  Another 
example of a GDP-only bound Gα structure despite crystallization in the presence of 
GDP·AMF is human Gα13 [42].  The authors hypothesize that low-pH crystallization 
conditions are unfavorable for AlF4- binding, which is corroborated by the study presented 
here as our EhGα1 crystals were grown at low pH (~4.5) as well. 
 
2.3.4 qRT-PCR of E. histolytica gene transcription  
RNA from ~1 x 106 E. histolytica HM1:IMSS trophozoites (Dr. William Petri Jr., UVa) was 
isolated by TRIzol Reagent (Invitrogen) and phenol extraction as per manufacturer’s 
instruction.  RT-PCR was conducted exactly as in [44], with and without added reverse 
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transcriptase (RT) to control for genomic DNA contamination, since the target E. histolytica 
transcripts lacked suitable intron/exon boundaries.  The number of cycles until threshold (Ct) 
was determined using an ABI Prism 7700.  The threshold cycle number of each gene in RT-
negative control reactions was subtracted from the Ct value for each transcript in RT-
containing reactions, yielding ΔCt.  
 For timecourse validation of RNA-seq results, RNA was isolated (RNeasy, Qiagen) 
from uninduced trophozoites (time zero) or trophozoites exposed to 5 µg/mL of tetracycline 
for 6, 12, or 24 hours. RT-PCR was conducted and threshold cycles determined exactly as for 
detection of signaling component transcripts, above. Changes in transcript levels were 
determined by the 2-ΔΔCt method as described previously [44], with the time zero average 
being assigned a 100% value. Each time point represents duplicate RT-PCR reactions 
conducted on duplicate biological samples, and statistically significant difference from time 
zero determined by an unpaired, two-tailed Student’s t-test. 
 qRT-PCR primers (5’->3’ direction) for quantitation of E. histolytica gene expression 
were as follows:  GAPDH, forward CATATTAAGGGAGGAGCTAAGA, reverse 
ATGCCTCAGTGTTAACTCCA, probe F-TCAGCCCCATCTGCTGATGCACCA-Q; 
EhGβ1, forward TTCGTATTAGAAGTTCATGGGT, reverse 
GGACACAATATTATCAAGACCAC, probe F-TGACATGTGCCTATGCCCCTTCTATG-
Q; EhGα1, forward CCTAAAAGTAAAGAATTTACTACAG, reverse 
CATCTGCCCAAAGTGCTTCA, probe F-ACCCTGTTACTCTTCCATTTTCACCAG-Q; 
EhGγ1, forward AACTTCGAGAGATCAAAGAACT, reverse 
CAGGACTGAAAGGGTCTACT, probe F-
TGAAAGTAAGTGGAGCATGTTCTGAATTAG-Q; amoebapore A, forward 
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GGAGCAGTTGATAAAGTAACTGA, reverse CCATATGAAACAATCTTTGTGCA, 
probe F-CACTCTGTGCTAAAGCAGATGGTCTTG-Q; cysteine protease (EHI_006920), 
forward AGAAGCACTAACTCCAGTAAAG, reverse 
CTTTCAAGAAATCCAATAGCAGC, probe F-
AGCCCAACATGTCCCTCTTGAAAATTG-Q.  “F” represents fluorescein, or 5’-
tetrachloro-fluorescein (TET) in 18S, and “Q” represents the quencher, TAMRA. 
 
2.3.5 Western blotting 
Trophozoites in the logarithmic growth phase were harvested and washed three times in PBS. 
For assessment of amoebapore A expression, trophozoites were grown in the presence or 
absence of 5 µg/mL tetracycline for 24 hours prior to harvesting. Trophozoites were lysed in 
buffer containing 20 mM Tris pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 1% (v/v) 
NP-40 alternative (Calbiochem), 0.25% deoxycholate, and protease inhibitors (Complete 
Mini, Roche), and insoluble fractions were removed by centrifugation. For assessment of 
FLAG-EhGα1 overexpression, soluble lysates were incubated overnight with anti-FLAG 
affinity gel (Sigma) prior to elution in SDS buffer and protein separation by SDS-PAGE. 
Proteins were transferred to nitrocellulose membranes and immunoblotted with an anti-
FLAG HRP conjugate (M2 monoclonal antibody, Sigma), a polyclonal anti-amoebapore A 
(kind gift of Dr. M. Leippe, Kiel, Germany), or an HRP-conjugated anti-β actin (cat. # sc-
47778, Santa Cruz). 
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2.3.6 Fluorescence complementation and co-immunoprecipitation 
Yellow fluorescent protein (YFP) bimolecular fluorescence complementation was performed 
as described [45] with modifications below. Codon-optimized ORFs of EhGγ isoforms were 
subcloned as HA-tagged fusions to the N-terminal 159 amino acids of YFP-venus 
(pcDNA3.1-YFPN; Dr. Nevin Lambert, MCG). The EhGβ1 ORF was subcloned as an HA-
tagged fusion with a C-terminal fragment (residues 159-239) of YFP-venus (pcDNA3.1-
YFPC; also obtained from Dr. Lambert, along with control YFPN-human Gγ2 and YFPC-
human Gβ1 fusions). 200,000 COS-7 cells per well in 6-well dishes were transfected with 1 
µg DNA using FuGENE-6 as per manufacturer’s directions. Empty pcDNA3.1 DNA was 
used to maintain a constant amount of total DNA per well. Forty-eight hours post-
transfection, epifluorescence was observed using an Olympus IX70 microscope with 
Hamamatsu monochrome CCD camera. Digital images were imported into MATLAB 2007a 
and quantified as previously described [45]. Pixels with greater than 40 units of intensity 
were considered to be fluorescent, and the percentage of positive pixels was quantified. All 
experiments were repeated three times. Co-immunoprecipitation was performed using the 
YFP-fusion proteins as previously described [45]. 
 
2.3.7 Nucleotide binding, hydrolysis, and EhGα1 activation 
Spontaneous GDP release, measured by [35S]GTPγS incorporation, and [γ-32P]GTP 
hydrolysis by single turnover assays were both quantified as previously described [34]. For 
GTPase acceleration assays, increasing concentrations of purified EhRGS-RhoGEF were 
added along with the hydrolysis-initiating magnesium. Real-time monitoring of EhGα1 
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tryptophan fluorescence (excitation 280 nm; emission 350 nm) was conducted as described 
for Gαi1 [34].  
 
2.3.8 Evolutionary analysis 
The protein sequences of Gα subunits from humans, S. cerevisiae, A. thaliana, D. 
melanogaster, and D. discoideum were aligned and an unrooted phylogram derived using T-
coffee [46]. Percent amino acid sequence similarities of EhGα1 and S. cerevisiae GPA1 were 
calculated relative to each human Gα subunit, using a multiple sequence alignment, as 
described previously [47].  The Gα family of Drosophila melanogaster served as a positive 
control for subfamily classification.   
 
2.3.9 Surface plasmon resonance 
Optical detection of protein binding was conducted as described previously [48]. Briefly, 
His6-tagged EhRGS-RhoGEF was immobilized on an NTA chip surface and increasing 
concentrations of wildtype EhGα1 and mutants were flowed over at 10 µL/s in various 
nucleotide states.  
 
2.3.10 Trophozoite stable transfection 
EhGα1 and EhGα1S37C were subcloned with internal FLAG epitope tags into a tetracycline-
inducible expression vector, described previously [49]. Axenic cultures were transfected by 
lipofection as previously described [50]. Briefly, amoebae at ~5 x 106/mL were suspended in 
medium 199 (Sigma) supplemented with 5.7 mM cysteine, 1 mM ascorbic acid, 25 mM 
HEPES (pH 6.9), 15 µg of DNA, and 30 µL of Superfect (Qiagen). After 3 hours at 37 °C, 
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trophozoites were transferred to TYI-S-33 medium overnight and selected for stable 
transfection with 10 µg/mL hygromycin over 3 weeks. 
 
2.3.11 Trophozoite migration and Matrigel transmigration 
Trophozoite migration assays were performed essentially as described previously [51].  
Briefly, amoebae were grown in the presence or absence of 5 µg/mL tetracycline for 24 
hours, harvested in log growth phase, suspended in serum free TYI growth medium, and 
50,000 cells loaded in the upper chamber of a Transwell migration chamber (Costar, 8 µm 
pore size). The lower chamber contained growth medium with or without 15% adult bovine 
serum. Transwell plates were incubated at 37°C for 2 hr under anaerobic conditions (GasPak 
EZ, BD Biosciences). Matrigel transmigration assays were performed in similar fashion, 
except that Matrigel was first diluted to 5 mg/mL in serum free TYI growth medium, layered 
on the Transwell porous filter, and allowed to gel for 6 hr prior to assay initiation. Incubation 
time was also extended to 16 hr to allow penetration. Migrated trophozoites attached to the 
lower chamber wall were detached on ice, fixed, and counted. Each experiment was 
performed in triplicate and statistical significance among four independent experiments was 
determined by an unpaired, two-tailed Student’s t-test. 
 
2.3.12 Host cell attachment 
Attachment of E. histolytica trophozoites to epithelial monolayers was assessed as previously 
described [18]. Chinese hamster ovary (CHO) cells were grown to confluency in 24-well 
plates, washed, and fixed in 4% paraformaldehyde for 30 minutes. Trophozoites (3 x 105) 
grown in the presence or absence of 5 µg/mL tetracycline for 24 hours were added to the 
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fixed monolayers in medium 199 supplemented with 5.7 mM cysteine, 1 mM ascorbic acid, 
and 25 mM HEPES (pH 6.9). After incubation at 37°C for 30 minutes, each well was washed 
gently two times with warm PBS to remove unattached trophozoites. Monolayer-attached 
trophozoites were detached on ice and quantified by counting with an inverted microscope. 
In similar experiments, trophozoites were labeled with carboxyfluorescein diacetate 
succinimidyl ester (CFDA-SE). Attached fluorescent trophozoites were counted in three 
microscopic fields at 10X magnification. Each experiment was performed in quadruplicate 
and statistical significance determined by an unpaired two-tailed Student’s t-test. 
 
2.3.13 Cell killing 
Killing of mammalian cells (Jurkat) was assessed using the CytoTox-ONE membrane 
integrity assay (Promega). In 96-well plates, 5 x 105 Jurkat cells and/or 2.5 x 104 
trophozoites, grown with or without 5 µg/mL tetracycline for 24 hours, were incubated at 
37°C in 200 µL of medium 199 (Sigma) supplemented with 5.7 mM cysteine, 0.5% BSA, 
and 25 mM HEPES pH 6.8. After 2.5 hr, 50 µL of medium from each well was incubated 
with Cytotox reagent and a colorimetric measure of extracellular lactate dehydrogenase 
activity was obtained after 10 min.  0.5% Triton X-100 was used to define 100% host cell 
death. Each experiment was performed with five replicates and statistical significance among 
three independent experiments was determined by an unpaired two-tailed Student’s t-test. 
 
2.3.14 Whole transcriptome shotgun sequencing 
Total RNA from 106 trophozoites each of the tetracycline-induced (5 µg/mL tetracycline for 
24 hours) EhGα1wt and EhGα1S37C strains, as well as a tetracycline-free control, was isolated 
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using an RNeasy Mini Kit (Qiagen) per manufacturer’s instructions. Duplicate RNA 
purifications and sequencing were obtained for each condition. 
 Quality of total RNA from each sample was estimated by automated electrophoresis 
(Bioanalyzer, Agilent). Libraries were constructed using TruSeq RNA library preparation 
kits (Illumina) according to manufacturer’s recommendations; molarity was estimated by 
analysis of DNA concentration from fluorometer detection and DNA fragment size. Prepared 
libraries with equal molarity were pooled and used for multiplex sequencing reactions. 
Libraries were sequenced using 57 cycles in a single end Illumina flowcell v.3 on a 
HiSeq2000 instrument (Illumina) at the UNC High Throughput Sequencing Facility. Primary 
data analysis and demultiplexing was performed using a standard Illumina pipeline 1.8.2. 
 Resulting mRNA sequence reads were mapped to the annotated Entamoeba 
histolytica genome (AmoebaDB.org) using Bowtie v0.12.7 [52]. Between 12 x 106 and 32 x 
106 reads were aligned for each sample. Aligned reads were further analyzed with Cufflinks 
v1.3.0 [53] and visualized using the Integrative Genomics Viewer 
(www.broadinstitute.org/igv/). Cuffdiff was used to determine differential expression by 
comparing relative transcript abundances between pairs of duplicate experiments: EhGα1wt 
expression vs. tetracycline-free control, EhGα1S37C expression vs. tetracycline-free control, 
and EhGα1wt vs. EhGα1S37C expression. Genes exhibiting statistically significant differential 
transcription were compiled and corresponding annotations retrieved using software from Dr. 
Chung-Chau Hon (Institut Pasteur) [54]. Transcripts that were either up- or down-regulated 
in both the induced EhGα1wt and EhGα1S37C strains were excluded from further analysis, 
because of potential transcriptional modulation due to tetracycline treatment. Functions of the 
associated proteins were inferred from prior E. histolytica studies, by similarity to 
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mammalian protein families, or from conserved domains of known function. All encoded 
proteins without annotated conservation and those with domains of unknown function were 
classified as “unknown”. 
 
2.3.15 Cysteine protease activity 
Intracellular cysteine protease activity in amoebic lysates was assayed essentially as 
described previously [55]. Crude extracts of 106 trophozoites, grown with or without 5 
µg/mL tetracycline for 24 hours, were obtained by lysing with 5 cycles of freeze-thaw. Total 
protein concentration was quantified by Bradford’s method. 2 mg of azo dye-impregnated 
collagen (Sigma) with 100 µg of crude extract in 500 µL of protease activation buffer (100 
mM Tris pH 7.0 and 10 mM CaCl2) were incubated at 37°C for 18 hr, then terminated with 
500 µL of 10% TCA. Samples were centrifuged to exclude intact collagen fibers, and 
supernatants collected for absorbance reading at 540 nm. In parallel experiments, the 
inhibitor p-hydroxy-mercuribenzoic acid (PHMB) was included at 1 mM to assess the 
fraction of specific cysteine protease activity. Residual protease activity (after PHMB 
treatment) was subtracted to determine total cysteine protease activity.  
 Extracellular cysteine protease activity was also assayed with azo-collagen as 
described above. However, 106 trophzoites were incubated at 37 °C for 3 hr in 500 µL PBS 
supplemented with 20 mM cysteine, 0.15 mM CaCl2, and 0.5 mM MgCl2, conditions known 
to sustain E. histolytica growth and allow cysteine protease secretion [56].  Following 
centrifugation, the cell-free conditioned medium was assayed for cysteine protease activity as 
above. Statistical significance was determined by an unpaired, two-tailed Student’s t-test. 
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2.4.  RESULTS 
 
2.4.1 Identification of E. histolytica heterotrimeric G-protein subunits 
By a BLAST sequence similarity search with human Gαi1 (E-value cutoff of 10-30), we 
identified a single gene in E. histolytica encoding a putative Gα subunit (EhGα1; 
AmoebaDB EHI_140350) also present in the related E. dispar, E. invadens, E. moshkovskii, 
and E. terrapinae. One Gβ subunit was also identified (AmoebaDB EHI_000240) by 
sequence similarity to human Gβ1 (E-value cutoff of 10-30), termed EhGβ1 (Fig. 2.1B). As 
Gβ subunits form obligate heterodimers with short Gγ polypeptides or Gγ-like (GGL) 
domains [3], we also searched for putative Gγ-encoding genes. Based on sequence similarity 
with S. cerevisiae Ste18 and D. discoideum gpgA, together with alignment of candidate 
protein sequences and identification of key functional residues, we identified two putative 
Gγ-encoding genes named EhGγ1 and EhGγ2; these two open-reading frames (in the NCBI 
E. histolytica genomic contigs AAFB02000029.1 and AAFB02000157.1, respectively) each 
possess a C terminal CAAX-box that specifies isoprenylation in conventional Gγ subunits 
[57].  
 To determine whether these G-protein subunits are expressed in E. histolytica, we 
amplified trophozoite mRNA using quantitative RT-PCR. Transcripts of EhGα1, EhGβ1, 
and EhGγ1 were all detected, along with the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH; AmoebaDB EHI_167320) (Fig. 2.2). 
  
2.4.2 Functional assessments of E. histolytica G-protein subunits 
To determine whether the identified EhGα1, EhGβ1, EhGγ1, and EhGγ2 subunits form 
conventional heterodimeric (Gβγ) and heterotrimeric (Gα·GDP/Gβγ) complexes, 
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bimolecular fluorescence complementation and co-immunoprecipitation assays were 
performed (Fig. 2.3A, B).  The N-terminal half of yellow fluorescent protein (YFPN) was 
fused to EhGγ1 and EhGγ2 open reading frames while the C-terminus of YFP (YFPC) was 
fused to EhGβ1.  Only when YFPC and YFPN are fused to interacting proteins will the 
fluorescent protein fold and function correctly [58], as shown with the human G-protein 
subunits Gβ1 and Gγ2 (Fig. 2.3A). Significant cellular fluorescence was observed only when 
EhGα1 was co-transfected with YFPC-EhGβ1 and either YFPN-EhGγ1 or YFPN-EhGγ2 (Fig. 
2.3B). As expected, co-expression of YFPC alone with any of the YFPN-fusions did not yield 
measurable cellular fluorescence. EhGβ1/γ1 and EhGβ1/γ2 dimers were found to interact 
with EhGα1 only in the presence of GDP (and not GTPγS) (Fig. 2.3C), consistent with 
canonical Gα·GDP/Gβγ interaction selectivity.   
 To determine if E. histolytica Gα binds and hydrolyzes GTP, EhGα1 was purified 
from E. coli. Spontaneous nucleotide exchange (as measured by [35S]GTPγS binding) was 
determined to be 0.27 min-1 and 0.064 min-1 at 30 °C for EhGα1 and human Gαi1 
respectively (Fig. 2.4A). The observed EhGα1 exchange rate is comparable to that of Gαo 
[59], one of the faster spontaneous exchangers among mammalian Gα subunits. EhGα1 
exhibited an intrinsic GTP hydrolysis rate of 0.21 min-1 at 20 °C (Fig. 2.4B), comparable to 
rates previously observed for human Gαi1 and Gαi3 under the same conditions (e.g., ref. 
[60]).   
 Trp-196 in switch 2 of EhGα1 is universally conserved among Gα subunits (e.g., Fig. 
2.1A) and translocates to a hydrophobic pocket upon Gα activation – an event which is 
easily measured as a dramatic change of intrinsic tryptophan fluorescence in select Gα 
subunits that lack multiple additional tryptophan residues (e.g., ref. [34]). Exposure to the 
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activating reagent AlF4- and magnesium (AMF) increases tryptophan fluorescence (Fig. 
2.4C), and thus EhGα1 appears to assume a similar, activated switch conformation as 
conventional Gα subunits. Since the measured rates of EhGα1 nucleotide exchange (0.27 
min-1 at 30°C) and hydrolysis (0.21 min-1 at 20°C) were on the same order of magnitude, we 
tested whether hydrolysis was rate-limiting, as seen for the A. thaliana Gα protein, AtGPA1 
[61].  While EhGα1 assumes an activated conformation upon exposure to the non-
hydrolyzable GTP analog, GppNHp, as indicated by intrinsic tryptophan fluorescence, 
addition of hydrolyzable GTP was insufficient to activate EhGα1 (Fig. 2.4D).  Thus, 
nucleotide exchange is the rate-limiting step in the steady-state nucleotide cycling of EhGα1, 
as for mammalian Gα subunits, indicating that activation likely relies on GEF-stimulated 
exchange. 
 
2.4.3 EhGα1 functional mutants  
To further characterize EhGα1 activation properties and provide tools for probing G-protein 
function in E. histolytica trophozoites, we mutated presumed key residues of the nucleotide-
cycling function of EhGα1. Gln-189 in switch 2 (Fig. 2.1A) is predicted to coordinate the 
critical nucleophilic water responsible for γ-phosphoryl group hydrolysis [62]. Mutation of 
this residue to leucine in mammalian Gα subunits results in inability to hydrolyze GTP even 
in the presence of GTPase-accelerating proteins [59]. The corresponding EhGα1(Q189L) 
mutation abolished the ability of EhGα1 to hydrolyze GTP (Fig. 2.4E), suggesting a 
conserved role for the switch 2 Gln-189 residue in orienting the nucleophilic water. The 
Q189L mutant also exhibited a slower rate of 0.026 min-1 (95% C.I., 0.021-0.031 min-1) for 
GTPγS binding compared to wildtype (Fig. 2.4F), likely due to the slow rate of GTP 
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dissociation in the absence of hydrolysis. Co-immunoprecipitation experiments demonstrated 
that EhGα1(Q189L) did not interact with EhGβ1/γ2 dimers when cell lysates were incubated 
with either GDP or GTPγS (Fig. 2.5), consistent with a state of constitutive activation. 
 In a mutagenesis screen [63], the mammalian Gα residue corresponding to Ser-37 of 
EhGα1, when mutated to cysteine, was identified as constitutively binding Gβγ irrespective 
of whether presented with GDP or GTP analogs. We hypothesized that we could create an 
EhGα1 variant that constitutively binds GDP by mutating Ser-37 to cysteine. The 
EhGα1(S37C) mutant showed no appreciable GTPγS binding (Fig. 2.4F), consistent with 
dominant negative behavior due to disrupted GTP/Mg2+ binding. Given that the 
EhGα1(S37C) mutant did not bind GTP, single turnover assays were not possible with this 
mutant. However, EhGα1(S37C) was observed to form a heterotrimer with EhGβ1/γ2 in the 
presence of either GDP or GTPγS (Fig. 2.5), consistent with dominant negative character.  
 
2.4.4 Evolutionary analysis of EhGα1 and identification of a putative effector 
In an attempt to identify the Gα subunit family that EhGα1 most closely resembles, we 
generated a phylogenetic tree comparing Gα subunits from multiple species (Fig. 2.6A) 
using MEGA5 [64]. EhGα1 is only distantly related to the metazoan Gα subunits, including 
the Gα12/13 subfamily that couples to RGS-RhoGEFs. EhGα1 is most similar to D. 
discoideum Gα9, a Gα subunit involved in cellular proliferation [9], although low bootstrap 
values in the phylogram region surrounding EhGα1 indicate uncertain topology. EhGα1 also 
has similarity to A. thaliana GPA1 and the yeast Gα subunits, GPA1 and GPA2, the latter 
with roles in pheromone response and nutrient sensing, respectively [6]. The A. thaliana 
GPA1 regulates diverse processes, such as transpiration and cellular proliferation in response 
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to glucose [65, 66]. We also calculated sequence similarity between EhGα1 and an array of 
human Gα subunits based upon multiple sequence alignments.  In calibrating this method, 
the five known Gα subunits of Drosophila melanogaster showed sequence similarity patterns 
allowing facile classification into each of the Gα subfamilies (Gαs, Gαi/o, Gαq, Gα12/13) (Fig. 
2.7A); however, both EhGα1 and GPA1 from Saccharomyces cerevisiae exhibited low 
sequence similarities to each of the human Gα subfamilies (Fig. 2.7B).  EhGα1 exhibits the 
lowest similarity to each mammalian Gα tested, implying a likely early evolutionary 
departure from an ancestral Gα.   
 The E. histolytica genome was found to encode an RGS domain-containing RhoGEF 
(AmoebaDB EHI_010670; named EhRGS-RhoGEF) with distant homology to the RGS-
RhoGEF effectors of mammalian Gα12/13 subunits; no other canonical Gα effector proteins, 
such as adenylyl cyclases or phospholipase Cβ isoforms, were identified. The transcript 
encoding EhRGS-RhoGEF was detected within trophozoite mRNA using quantitative RT-
PCR (Fig. 2.2). Recombinant EhRGS-RhoGEF was therefore expressed and purified from E. 
coli; as measured by surface plasmon resonance, immobilized EhRGS-RhoGEF protein was 
found to bind EhGα1 selectively in its GDP·AlF4- (AMF) nucleotide state (Fig. 2.6B). This 
selective binding is consistent with a putative EhGα1 effector function for EhRGS-RhoGEF, 
yet occurs in the absence of significant homology of EhGα1 to the mammalian Gα12/13 
subunits that interact with mammalian RGS RhoGEFs [2, 4]. 
 
2.4.5 A crystal structure of EhGα1 
 To gain better insight into the distant homology of EhGα1 versus other Gα subunits, 
we determined a crystal structure of EhGα1 bound to GDP by single-wavelength anomalous 
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dispersion (SAD) using data to 2.6 Å resolution (Table 2.1; Fig. 2.8).  To obtain high-quality 
diffracting crystals, we modified EhGα1 by removing its extended N-terminal helix (a.a. 1-
22) and subjecting it to reductive lysine methylation. Neither alteration perturbed the 
nucleotide cycle or activation kinetics of EhGα1 (Fig. 2.4B,C). EhGα1 features the highly 
conserved Ras-like and all-helical domain structure and nucleotide-binding pocket 
characteristic of Gα subunits (Fig. 2.9A). The three switch regions are ordered in one of the 
two monomers in the asymmetric unit, likely due to crystal contacts (Fig. 2.8B). EhGα1 
exhibits a highly conserved mode of nucleotide interaction, including the dispositions of 
residues Ser-37 and Gln-189 (Fig. 2.9B). The guanine ring is embraced by the conserved 
NKxD motif (residues 254-257; Fig. 2.10), with the hydrophobic portion of Lys-255 packing 
against the planar guanine ring. The phosphate-binding loop (P-loop) forms numerous polar 
contacts with the α- and β-phosphoryl groups of GDP [62]. 
 Unique to EhGα1 is the absence of an αB helix in the all-helical domain (Fig. 2.9A).  
Although the segment between αA and αC (αA-αC loop) could be affected by crystal 
packing, five prolines scattered throughout this loop (positions 84, 89, 99, 103, and 106; Fig. 
2.1A) suggest this region likely also lacks helical structure in solution. GoLoco motif-
containing proteins are one of the few molecules that interact with the αB helix (e.g., ref. 
[34]); not surprisingly, given the lack of a structurally-conserved binding site on EhGα1, the 
E. histolytica genome does not seem to encode any GoLoco motifs. EhGα1 also harbors a 
unique 16-residue insert in the Ras-like domain following the α4 helix (Figs. 2.9A, 2.1A).  A 
portion of this insert forms a short β-strand (here termed β7) that extends the six-stranded β-
sheet common to all heterotrimeric and Ras-family GTPases [67, 68], followed by a 15-
residue loop that is disordered in our crystal structure.  This region of Gα is critical for 
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interaction with GPCRs as seen, e.g., in the crystal structure of the β2 adrenergic receptor/Gs 
complex [69]. Because this region is important for receptor coupling and/or specificity, the 
existence of this insert in EhGα1 suggests a potentially unique GPCR-coupling mechanism 
in E. histolytica, but no receptor has yet been identified (see Discussion). 
 
2.4.6 G-protein signaling perturbation modulates trophozoite migration, Matrigel 
transmigration, and host cell attachment and killing 
 To determine roles of heterotrimeric G-protein signaling in pathogenesis-related 
behaviors of E. histolytica, HM-1:IMSS trophozoites were stably transfected with 
tetracycline-inducible expression plasmids [49] encoding either wildtype EhGα1 or the 
dominant negative EhGα1S37C (Fig. 2.11A). A strain expressing the constitutively active 
EhGα1Q189L could not be established, potentially due to cellular toxicity; however, 
overexpression of wildtype EhGα1 is expected to result in a moderately higher basal level of 
signaling to downstream components. Overexpression of signaling components is subject to 
limitations, including the possibility that supra-physiological expression levels and/or protein 
mislocalization result in toxicity or other cellular effects not typically mediated by 
endogenous signaling. However, this approach is useful to suggest cellular processes that 
may be regulated by heterotrimeric G-protein signaling and to mimic the gross perturbation 
that may be achieved with pharmacological agents acting on this pathway. 
Immunofluorescence of overexpressed EhGα1 revealed a diffuse, cytoplasmic cellular 
distribution that did not differ significantly between the wild type and S37C mutant strains 
(Fig. 2.12A). Endogenous EhGα1 was not assessed due to a current lack of specific 
antibodies. To assess potential effects of Gα subunit overexpression on trophzoite growth 
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and viability, growth curves were assessed for the parent HM-1:IMSS, EhGα1wt, and 
EhGα1S37C strains in the presence and absence of tetracycline. No significant differences in 
growth or viability (>90% at all time points) were observed over three days, although 
trophozoites expressing EhGα1S37C displayed a trend toward slower growth at day 3 (Fig. 
2.12B). All subsequent cellular experiments were conducted following growth with or 
without tetracycline for 24 hours. 
 Trophozoite motility is related to the pathogenesis of amoebic colitis, likely 
contributing to tissue invasion [70, 71]. Tetracycline-induced EhGα1wt overexpression 
increased migration in the absence of a serum stimulus while EhGα1S37C expression reduced 
migration in the presence or absence of serum in Transwell migration assays (Fig. 2.11B), 
suggesting that perturbation of heterotrimeric G-protein signaling may regulate motility at 
baseline and potentially in response to serum factor stimuli. However, the reduced migration 
of the EhGα1S37C strain in the presence of serum may be due to the lower baseline 
trophozoite motility, as observed in the absence of a serum stimulus, rather than due to 
specific heterotrimeric G-protein involvement in a signaling response to serum factors. 
Tetracycline treatment had no measurable effect on the migration of the HM-1:IMSS parent 
strain or trophozoites transfected with an empty expression vector (Fig. 2.13A). 
 E. histolytica invades the intestinal mucosa, giving rise to ulcers and, in rare cases, 
systemic amoebiasis [72, 73].  To assess migration across a barrier, transfected trophozoite 
strains were profiled by a Transwell assay, with upper and lower chambers separated by 
Matrigel. Induced expression of EhGα1wt enhanced, but EhGα1S37C reduced, Matrigel 
transmigration relative to uninduced controls (Fig. 2.11C), revealing a potential regulatory 
role for heterotrimeric G-protein signaling. Tetracycline treatment had no effect on the 
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transmigration of HM-1:IMSS or empty vector-transfected trophozoites (Fig. 2.13B). The 
effects of EhGα1wt and EhGα1S37C overexpression on Matrigel transmigration displayed the 
same trends seen for migration in the absence of serum (Fig. 2.11B). Thus, differential 
baseline migration rates may account for part or all of the observed differences in Matrigel 
transmigration. 
 E. histolytica trophozoites also attach to and kill host cells, including intestinal 
epithelium and responding immune cells. Host cell attachment, achieved primarily through a 
galactose-inhibitable lectin [13, 74], is required for subsequent cell killing. Trophozoites 
expressing EhGα1wt displayed greater attachment to CHO cell monolayers than uninduced 
controls, and the opposite effect was seen in the EhGα1S37C strain (Fig. 2.14A, 2.15). 
EhGα1wt overexpression enhanced Jurkat cell killing, as assessed with a membrane integrity 
assay, while trophozoites expressing the dominant negative EhGα1S37C were less cytotoxic 
(Fig. 2.14B). Tetracycline treatment had no effect on host cell attachment or killing by HM-
1:IMSS or empty vector-transfected trophozoites (Fig. 2.13C, D). Thus, perturbation of 
heterotrimeric G-protein signaling also regulates host cell killing by E. histolytica. Similar 
patterns were observed in host cell attachment and cell killing assays; different degrees of 
attachment upon expression of EhGα1wt or EhGα1S37C may be partially or wholly 
responsible for the observed changes in contact-dependent cell killing. 
 
2.4.7 Regulation of transcription by perturbed heterotrimeric G-protein signaling  
 To gain insight into potential mechanisms by which perturbation of EhGα1 
expression controls pathogenesis-related behaviors in E. histolytica, RNA-seq was performed 
on mRNA isolated from trophozoites expressing EhGα1wt, EhGα1S37C, and uninduced 
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controls. To emphasize highly transcribed genes and eliminate potential transcriptional 
effects of tetracycline treatment, transcripts with a Fragments Per Kilobase of exon per 
Million fragments mapped (FPKM) value less than 10 and transcripts that were up- or down-
regulated (in the same direction) in both EhGα1wt and EhGα1S37C samples (24 hour 
tetracycline treatment at 5 µg/mL) relative to uninduced  (tetracycline-free) trophozoites 
were excluded. Twenty-one genes were differentially transcribed in opposite directions upon 
expression of either EhGα1wt or EhGα1S37C (Fig. 2.16A). Transcriptional changes of 
multiple genes were verified over a 24-hour time course by RT-PCR (Fig. 2.17). For 
instance, EhGβ1 was found to be more highly expressed in trophozoites expressing 
EhGα1S37C.  Analysis of putative functions for the differentially transcribed genes revealed a 
diversity of responses to altered heterotrimeric G-protein signaling (Fig. 2.16). Stress 
response-related transcripts, such as those encoding heat shock proteins, were exclusively 
down-regulated upon EhGα1wt expression and up-regulated in the dominant negative 
EhGα1S37C strain; conversely, numerous metabolic enzymes were selectively up-regulated 
following expression of EhGα1S37C, suggesting that heterotrimeric G protein signaling may 
be involved in sensing and responding to vital extracellular nutrients. 
 Genes with known effects on E. histolytica pathogenesis were also differentially 
transcribed, as measured by RNA-seq. (Table 2.2). For example, the host cell lytic factor 
amoebapore C was up-regulated upon EhGα1wt expression, while the amoebapore A 
precursor was down-regulated by EhGα1S37C (Table 2.2), consistent with the higher or lower 
cell killing efficiencies, respectively, of each strain (Fig. 2.14B) [14, 15, 70]. Down-
regulation of amoebapore A upon expression of EhGα1S37C was confirmed by RT-PCR at the 
transcriptional level, and by western blot at the protein level (Fig. 2.17; anti-amoebapore A 
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was a gift from Dr. M. Leippe, U. of Kiel, Germany). A number of cysteine proteases, known 
factors in both host cell killing and Matrigel transmigration [56], were differentially 
transcribed following expression of EhGα1S37C (Table 2.1). The down-regulation of one 
cysteine protease (EHI_006920) was confirmed by RT-PCR (Fig. 2.17). Ten Rab family 
GTPases, known to regulate vesicular trafficking and cysteine protease secretion [31], as well 
as other putative secretion/trafficking proteins, were also differentially transcribed. 
Specifically, four cysteine protease binding factors (CBPFs), recently shown to modulate 
cysteine protease secretion [75], were down-regulated in trophozoites expressing EhGα1S37C 
(Table 2.1). These transcriptional effects suggested that altered cysteine protease activity 
and/or secretion may be a mechanism by which perturbation of heterotrimeric G-protein 
signaling modulates Matrigel transmigration and host cell killing (Figs. 2.11C & 2.14B). To 
test this hypothesis, intracellular and secreted cysteine protease activities were each measured 
in the EhGα1wt and EhGα1S37C strains. EhGα1wt expression increased extracellular and 
decreased intracellular cysteine protease activity, likely reflecting more efficient vesicular 
trafficking and secretion (Fig. 2.16C). In contrast, EhGα1S37C expression resulted in a trend 
toward more intracellular protease activity, although not statistically significant (p = 0.07), 
and significantly less extracellular protease activity relative to uninduced control 
trophozoites, correlating with reduced Matrigel transmigration and cell killing by this strain 
(Figs. 2.11C & 2.14B). 
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2.5. DISCUSSION 
 
Here we demonstrate that functional heterotrimeric G-protein subunits are encoded by the 
pathogen Entamoeba histolytica, including single Gα and Gβ subunits, and two Gγ subunits. 
Like their mammalian counterparts, EhGα1, EhGβ1, and EhGγ1/2 form a nucleotide state-
dependent heterotrimer. EhGα1 binds and hydrolyzes GTP and its switch regions undergo a 
conserved conformational change. When in an activated state, EhGα1 is seen to engage a 
putative effector protein, namely an RGS domain-containing RhoGEF (EhRGS-RhoGEF). 
EhRGS-RhoGEF likely represents a functional signaling link between heterotrimeric G-
proteins and Rho family GTPases in E. histolytica. Indeed, Rho GTPases and other Dbl 
family RhoGEFs in E. histolytica have been implicated in multiple processes important for 
pathogenesis-related processes such as actin reorganization during chemotaxis, surface 
receptor capping, cell killing, phagocytosis, and tissue destruction [24-27, 76].  
 The sequence of EhGα1 diverges from each of the mammalian Gα subunit 
subfamilies, including the Gα12/13 subfamily that couples to RGS-RhoGEFs. Thus EhGα1 
likely represents an early evolutionary departure from the metazoan Gα/RGS-RhoGEF 
signaling axis, or possibly a signaling pathway of similar function with an independent 
evolutionary origin. A search of publicly available genome sequences using SMART [77] 
identified the RGS and DH-PH domain combinations exclusively in metazoan species, with 
the only exception being the amoebazoans. This lack of RGS-RhoGEF related proteins in 
non-metazoan species suggests an independent origin of the E. histolytica Gα/RGS-RhoGEF 
interaction; however, we cannot rule out the possibility that a Gα/RGS-RhoGEF interaction 
arose early in evolutionary history, such as an ancestral Unikonta supergroup member (e.g. 
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[78]), and was later lost in fungal species, but retained in metazoans and amoebae. Among 
the species compared in this study, EhGα1 was found to be most similar in sequence to the 
D. discoideum Gα9, followed more distantly by S. cerevisiae GPA1 and GPA2, as well as A. 
thaliana GPA1. This set of Gα subunits is only loosely related by function, with D. 
discoideum Gα9 regulating cellular proliferation [9], while yeast GPA1 and GPA2 transduce 
signals in response to pheromones and nutrients, respectively [6]. A variety of downstream 
signaling machinery is utilized as well, with S. cerevisiae pheromone signaling occurring 
predominantly through Gβγ subunit effectors, while S.c. GPA2 engages an adenylyl cylase 
effector [6]. The current study clearly differentiates EhGα1 from these relatively similar Gα 
subunits on the sequence level, demonstrating interaction with an RGS-RhoGEF effector and 
no significant effect on cellular proliferation, but apparent roles in multiple pathogenesis-
related processes of E. histolytica. 
 Perturbation of heterotrimeric G-protein signaling in E. histolytica trophozoites was 
observed to modulate migration, Matrigel transmigration, and host cell attachment and 
killing. Notably, trophozoite Matrigel transmigration is dependent on general migration to 
some degree, and host cell killing is dependent on attachment. Thus, the effects of 
heterotrimeric G-protein perturbation on Matrigel transmigration and host cell killing may be 
partially or wholly due to the alterations in migration and attachment, respectively. Induced 
expression of the dominant negative EhGα1S37C impaired these pathogenic processes, 
suggesting that antagonizing G-protein signaling may reduce E. histolytica virulence. The 
complete mechanisms by which heterotrimeric G-proteins are linked to specific trophozoite 
behaviors remain to be elucidated. For instance, it is presently unclear which signaling 
cascades are utilized to effect transcriptional changes in response to perturbed EhGα1 
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expression. EhGα1 likely engages its RGS-RhoGEF effector, leading to activation of specific 
Rho GTPases, some of which are known to regulate cytoskeletal dynamics required for such 
processes as migration and Matrigel transmigration [24, 27, 76, 79]. EhGβγ may also engage 
as yet unidentified effectors, like its homologs in other species, leading to changes in 
pathogenic processes [1]. 
 It is presently unclear how heterotrimeric G-protein signaling is activated in E. 
histolytica. Since nucleotide exchange is the rate-limiting step in the nucleotide cycle of 
EhGα1, an exchange factor, such as a GPCR, is likely required for high levels of EhGα1 
activation. At this time, the only putative GPCR described is the Rab GTPase-binding protein 
EhGPCR-1 [80].  While it would be compelling to demonstrate receptor-mediated nucleotide 
exchange on EhGα1, our own bioinformatic analysis revealed that EhGPCR-1, while 
containing seven-transmembrane spanning regions, is more likely a conserved Wnt-binding 
factor required for Wnt secretion (as seen in C. elegans) [81]. Identification of a bona fide 
GPCR/ligand pair or other heterotrimeric G-protein activation mechanism in E. histolytica 
will provide powerful tools for further probing of the roles of heterotrimeric G-protein 
signaling in trophozoites. 
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Figure 2.1. The genome of Entamoeba histolytica encodes heterotrimeric  
G-protein subunits.  (A) A multiple sequence alignment of EhGα1 with selected Gα 
subunits from other species (Dd = Dictyostelium discoideum, Sc = Saccharomyces 
cerevisiae, Hs = Homo sapiens).  The secondary structure information above the aligned 
sequences reflects the crystal structure of EhGα1 (this study), with naming adapted from 
human transducin (PDB 1TND).  Residues mutated in this study are marked with black 
arrowheads, and gray bars indicate relative sequence identity. A 110-residue insert within Sc 
GPA1 (gray box) was omitted for clarity. Although a number of E. histolytica proteins are 
reportedly ADP-ribosylated by pertussis toxin [82], EhGα1 is not likely to be a substrate as it 
lacks the C-terminal cysteine ADP-ribosylation site shared among conventional Gαi/o 
subunits (e.g., Cys-351 in human Gαo). Based on the sequence of the amino terminus of 
EhGα1, it is likely that this protein is myristoylated on its second residue (glycine) and 
palmitoylated on its third residue (cysteine) [57].  (B) EhGα1 is aligned with selected Gβ 
subunits in a fashion identical to panel A with secondary structure elements as found in 
transducin Gβγ (PDB 1TBG).	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Figure 2.2. Heterotrimeric G-protein signaling components are expressed in  
E. histolytica. qRT-PCR amplification of RNA isolated from HM1 E. histolytica 
trophozoites (a kind gift of Dr. William Petri, Jr.) confirmed transcription of EhGα1, EhGβ1, 
EhGγ1, and EhRGS-RhoGEF genes.  The basally expressed housekeeping gene GAPDH was 
included as a control. ΔCt reflects the difference in threshold cycle relative to reactions 
lacking reverse transcriptase, used as a control for DNA contamination. Error bars represent 
standard error of the mean. 
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Figure 2.3. E. histolytica G-protein subunits form a heterotrimer in a nucleotide-
dependent manner.  Interactions between Gβ and Gγ subunits were detected with split-YFP 
protein complementation in COS-7 cells.  (A) Human Gβ1 heterodimerized with human Gγ2, 
but not with E. histolytica Gγ subunits.  (B) EhGβ1 interacts with EhGγ1 or EhGγ2 when co-
expressed with EhGα1.  (C) G-protein heterotrimer formation in the presence of excess GDP 
(“D”) or the non-hydrolyzable GTP analog, GTPγS (“T”), was examined with co-
immunoprecipitation.  EhGβ1 and EhGγ1 or EhGγ2 interacted selectively with EhGα1 in its 
GDP-bound, inactive state. Error bars represent standard error of the mean for three 
experiments. * represents statistically significant difference from zero, as determined by 95% 
confidence intervals excluding zero. 
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Figure 2.4. EhGα1 cycles between an active, GTP-bound state and an inactive, GDP-
bound state.  (A) EhGα1 bound non-hydrolyzable GTPγS as determined by radionucleotide 
binding.  The observed exchange rate, kobs = 0.27 min-1 ± 0.06, indicates faster spontaneous 
GDP release than human Gαi1 (kobs = 0.06 min-1 ± 0.01).  (B) EhGα1 hydrolyzed GTP[γ-32P] 
at 0.21 min-1 ± 0.02, as determined by single turnover hydrolysis assays. No difference was 
observed for selenomethionine, lysine-methylated EhGα1 used for crystallization. (C) 
EhGα1 changes conformation upon binding the transition state mimetic aluminum 
tetrafluoride.  Intrinsic EhGα1 fluorescence following excitation at 285 nm increases upon 
activation, reflecting burial of a conserved tryptophan on switch 2 (Trp-196). (D) EhGα1 
adopts an active switch conformation upon addition of the non-hydrolyzable GTP analog 
GppNHp, as reflected by increased intrinsic tryptophan fluorescence.  The kinetics of 
GppNHp-mediated activation are consistent with the kinetics of radiolabeled GTP analog 
binding (Fig. 2.4A).  In contrast, addition of hydrolyzable GTP does not result in EhGα1 
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activation, indicating that nucleotide exchange, rather than GTP hydrolysis, is the rate-
limiting step in the nucleotide cycle of EhGα1. (E, F) Two EhGα1 point mutants were 
profiled for effects on nucleotide cycle.  The dominant negative S37C possessed negligible 
GTP binding.  The constitutively active Q189L bound but did not hydrolyze GTP. Error bars 
in all panels represent standard error of the mean. 
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Figure 2.5. The inactive EhGα1(S37C) constitutively binds to EhGβ1γ2, while the 
constitutively active EhGα1(Q189L) mutant does not. Co-immunoprecipitations of 
EhGα1 and mutants with EhGβ1 and EhGγ2 were conducted as in Figure 2.3.  As predicted, 
the dominant negative S37C mutant remains bound to EhGβ1γ2, even in excess GTPγS.  The 
constitutively active, GTPase-deficient Q189L mutant does not bind EhGβ1γ2 in either 
nucleotide state. 
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Figure 2.6. Evolutionary relationship of Gα  subunits and identification of EhRGS-
RhoGEF as a putative effector for activated EhGα1. (A) Gα subunit protein sequences 
from E. histolytica, D. discoideum (D.d.), A. thaliana (A.t.), S. cerevisiae (S.c.), D. 
melanogaster (D.m), and H. sapiens (H.s.) were aligned and a bootstrapping consensus 
phylogram created using MEGA5 [42]. Bootstrap values are indicated at each branch point. 
EhGα1 is distantly related to metazoan Gα subunits, specifically the adenylyl cyclase 
stimulatory Gαs, adenylyl cyclase inhibitory Gαi/o, phospholipase Cβ coupled Gαq, and 
RGS-RhoGEF activating Gα12/13 subfamilies. (B) Recombinant EhRGS-RhoGEF protein 
was immobilized on a surface plasmon resonance chip and EhGα1 protein flowed over in 
one of two nucleotide states. The EhRGS-RhoGEF biosensor bound EhGα1 selectively in the 
activated, GDP·AlF4--bound state (AMF). 
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Figure 2.7. Mammalian Gα subfamily homology analyses. Sequence similarity to human 
Gα subunits was plotted for the Gα subunits from Drosophila melanogaster (A), 
Saccharomyces cerevisiae GPA1, and EhGα1 (B).  In contrast with D. melanogaster 
subunits, EhGα1 cannot be classified as a member of any particular Gα subfamily. 
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Figure 2.8. Structural comparison of EhGα1 with Hs transducin and switch 2 
crystal contacts.  (A) The two EhGα1 molecules in the asymmetric unit are highly 
similar, although switch 2 of chain B (wheat) is partially disordered.  (B) Crystal contacts 
between the ordered switch 2 of chain A (blue) and a neighboring molecule (orange) 
likely account for the structural differences between the two molecules in the asymmetric 
unit.  The non-polar Trp-196 and N-dimethyl lysine-195 (MLY-195) interface with a 
hydrophobic patch on a neighboring molecule.  Switch 2 may be drawn away from the 
nucleotide pocket, accounting for the absence of bound AlF4- (see discussion below).  (C, 
D) The model of EhGα1 is superposed with human transducin in two nucleotide states 
(slate blue, AMF, PDB 1TAD; teal, GDP, PDB 1TAG).  EhGα1 lacks an αB helix seen 
in transducin and all other Gα subunits and contains a unique α4-β6 insert (orange).  
Switch 2 of EhGα1 (chain A) adopts a distinct conformation from both the active and 
inactive forms of transducin, likely due to crystal contacts with a neighboring molecule. 
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Figure 2.9. Structure of EhGα1 reveals a conserved fold with unique features.  The 
crystal structure of EhGα1 was determined by single anomalous dispersion (SAD) using 2.6 
Å resolution data (Table 2.1).  (A) The EhGα1 Cα backbone is shown in green, bound to 
GDP in purple sticks. Conserved switch regions (SW 1-3) are dark blue.  Trp-196 is solvent-
exposed in the inactive state and buried when switch 2 adopts its activated conformation.  
Unique among Gα subunits, EhGα1 lacks an αB helix in the all-helical domain (red; labeled 
‘αA-αC loop’) but possesses a unique short β-strand insert (β7) and a loop (orange) between 
the conserved α4 helix and β6 strand.  Disordered regions in switch 3 (residues 222 and 223) 
and the β7-β6 loop (residues 302-310) are indicated by dashed lines. (B) Ser-37, conserved 
among Gα subunits, is an important ligand for Mg2+, a cofactor for GTP binding and 
hydrolysis.  Mutation of Ser-37 to Cys is predicted to produce a dominant negative EhGα1 
[41]. Gln-189 is required for orienting the nucleophilic water during GTP hydrolysis; its 
mutation to Leu is predicted to cripple GTPase activity, yielding a constitutively active 
EhGα1. 
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Figure 2.10. Electron density map of the guanine nucleotide binding pocket of EhGα1.  
A region of the 2Fo-Fc electron density map is shown in stereo view from the structure of 
EhGα1 (yellow sticks) bound to GDP (purple sticks). The nucleotide binding pocket is highly 
similar to mammalian Gα subunits, featuring a conserved phosphate binding loop (P-loop; 
Glu-33 shown) and an NKxD motif (residues 254-257). Switch one also directly contacts the 
nucleotide, and Arg-163 forms polar contacts with the P-loop Glu-33. 
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Figure 2.11. Heterotrimeric G-protein signaling increases trophozoite migration across 
porous membranes and Matrigel layers. (A) Trophozoites were stably transfected to 
express wildtype EhGα1 or dominant negative EhGα1S37C under tetracycline control. (B) 
EhGα1wt-expressing trophozoites showed greater migration across a porous membrane in the 
absence of stimuli (serum-free) while amoebae expressing EhGα1S37C showed lower 
migration toward both serum-free and serum-containing nutritive media. Migration of HM-
1:IMSS trophozoites was not significantly different from the non-induced EhGα1wt and 
EhGα1S37C strains. Tetracycline treatment was 5 µg/mL over 24 hours. (C) Trophozoites 
expressing EhGα1wt were better able to migrate through a Matrigel layer than uninduced 
controls. Conversely, EhGα1S37C expression greatly reduced Matrigel transmigration. Parent 
strain HM-1:IMSS trophozoites were unaffected by tetracycline treatment and were 
indistinguishable from non-induced EhGα1wt and EhGα1S37C. Error bars represent standard 
error of the mean. * represents statistical significance by an unpaired, two-tailed Student’s t-
test (p < 0.05) for four independent experiments. 
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Figure 2.12. Expression of EhGα1wt or EhGα1S37C does not significantly alter 
trophozoite proliferation. (A) The cellular distribution of overexpressed FLAG-EhGα1wt 
and FLAG-EhGα1S37C were assessed by immunofluorescence with a Cy3 anti-FLAG 
conjugate. Both wild type and mutant EhGα1 exhibited similar diffusely cytoplasmic 
localizations following induced expression by treatment with 5 µg/mL tetracycline for 24 hr. 
Nuclei were stained with DAPI. (B) Trophozoites of the parent HM-1:IMSS, EhGα1wt, and 
EhGα1S37C strains were seeded in TYI medium with or without 5 µg/mL tetracycline and cell 
numbers assessed over 3 days. Cell viability was >90% at each measurement, as determined 
by trypan blue dye exclusion. No significant differences in growth were identified among the 
strains, although trophozoites induced to express EhGα1S37C trended toward slower growth at 
day 3. Error bars represent standard error of the mean for three independent experiments. 
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Figure 2.13. E. histolytica transfected with empty vector is not affected by tetracycline 
treatment. HM-1:IMSS trophozoites were stably transfected with empty tetracycline-
inducible expression vector. (A) Transwell migration and (B) Matrigel transmigration of 
parent strain and vector-transfected trophozoites did not differ significantly upon tetracycline 
treatment of 24 hours prior to the assay. Similarly, transfection with empty vector and 
tetracycline treatment had no significant effect on host cell attachment (C) or host cell killing 
(D). Error bars represent standard error of the mean for four independent experiments in 
panels A-C and three independent experiments in panel D. Statistical significance was tested 
using an unpaired, two-tailed Student’s t-test. 
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Figure 2.14. Heterotrimeric G-protein signaling positively regulates E. histolytica 
attachment to host cells as well as host cell killing. (A) Trophozoites attach to CHO cell 
monolayers, primarily through a galactose-inhibitable lectin. Overexpression of EhGα1wt 
enhanced monolayer attachment, while expression of EhGα1S37C reduced attachment. Parent 
strain HM-1:IMSS trophozoites were unaffected by tetracycline treatment and were 
indistinguishable from non-induced EhGα1wt and EhGα1S37C. Attached trophozoites 
quantities were obtained by multiplying detached cell concentrations by a dilution factor.  
* indicates a statistically significant difference (p < 0.05) between quadruplicate experiments. 
Error bars represent standard error of the mean. * indicates statistical significance by an 
unpaired, two-tailed Student’s t-test (p < 0.05) for four independent experiments. (B) 
Amoebae overexpressing EhGα1wt or EhGα1S37C displayed enhanced or reduced abilities to 
kill Jurkat (human T-lymphocyte) cells, respectively, as measured by LDH release in a 
membrane integrity assay. Cell killing by HM-1:IMSS trophozoites was not altered by 
tetracycline treatment. 0.5% Triton X-100 was added to Jurkat cells to define 100% host cell 
lysis. Tetracycline treatment was 5 µg/mL over 24 hours.  Error bars represent standard error 
of the mean. * indicates statistical significance by an unpaired, two-tailed Student’s t-test (p 
< 0.05) for three independent experiments, with four technical replicates each. 
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Figure 2.15. Microscopic analysis of perturbed E. histolytica attachment to host cells 
upon overexpression of EhGα1wt or EhGα1S37C. (A) Trophozoites grown in the presence 
or absence of 5 µg/mL tetracycline were fluorescently labeled with CFDA and allowed to 
attach to fixed, confluent layers of CHO cells. Phase contrast (upper panels) and 
epifluorescence (lower panels) images were obtained of attached trophozoites. (B) 
Attachment was quantified by counting trophozoites in three microscopic fields (10X). 
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Overexpression of EhGα1wt enhanced monolayer attachment, while expression of EhGα1S37C 
reduced attachment. Parent strain HM-1:IMSS trophozoites were unaffected by tetracycline 
treatment and were indistinguishable from non-induced EhGα1wt and EhGα1S37C. Error bars 
represent standard error of the mean. * represents statistical significance by an unpaired, two-
tailed Student’s t-test (p < 0.05) for three independent experiments. 
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Figure 2.16. Heterotrimeric G-protein signaling alters E. histolytica transcription to 
modulate cysteine protease secretion. (A) 96 genes or 394 genes were differentially 
transcribed upon overexpression of EhGα1wt or EhGα1S37C, respectively, when compared to 
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uninduced controls as determined by RNA-seq. 21 transcripts were oppositely regulated in 
trophozoites expressing EhGα1wt vs EhGα1S37C. (B) Differentially transcribed genes were 
categorized by putative function based on prior studies, homology to genes of known 
function, or predicted protein domains of known function. “Virulence/encystation” category 
includes genes known to modulate E. histolytica pathogenesis, such as cysteine proteases [1]. 
(C) Both intracellular and secreted cysteine protease activities were assessed with an azo-
collagen assay. EhGα1wt overexpression enhanced cysteine protease secretion, while 
EhGα1S37C expression resulted in less extracellular (E), despite higher intracellular (I), 
cysteine protease activity, suggesting that transcriptional responses downstream of 
heterotrimeric G-protein signaling modulate E. histolytica pathogenic processes in part by 
regulating cysteine protease secretion. Tetracycline treatment in all experiments was 5 
µg/mL over 24 hours.  * = statistical significance by an unpaired, two-tailed Student’s t-test 
(p < 0.05) for four independent experiments. 
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Figure 2.17. RT-PCR analysis of differentially transcribed genes and altered expression 
of amoebapore A protein. (A) qRT-PCR amplification of RNA isolated from HM1 E. 
histolytica trophozoites confirmed differential transcription of EhGα1, EhGβ1, amoebapore 
A, and a cysteine protease (EHI_006920) upon tetracycline treatment of the parent HM-
1:IMSS, EhGα1wt, or EhGα1S37C strains over 24 hours. * indicates statistically significant 
difference from time zero (no tetracycline exposure), using an unpaired, two-tailed Student’s 
t-test for two technical duplicates of two independent experiments. EhGα1 expression was 
significantly up-regulated in the EhGα1wt and EhGα1S37C strains, while EhGβ1 was up-
regulated and amoebpore A and cysteine protease (EHI_006920) were down-regulated upon 
expression of EhGα1S37C. (B) Trophozoite lysates were subjected to western blotting with 
anti-amoebapore A (kind gift of M. Leippe, U. of Kiel, Germany), with actin serving as a 
loading control. Amoebapore A protein expression is reduced in parallel with its 
transcriptional downregulation upon overexpression of EhGα1S37C. 
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Table 2.1.  Data collection and refinement statistics  
for lysine-methylated selenomethionine EhGα1. 
 
 EhGα1·GDP 
PDB accession code 4FID 
  
Data collection  
Space group P212121 
Cell dimensions    
    a, b, c (Å) 56.3, 56.9, 229.8 
    α, β, γ  (°) 90, 90, 90 
 Peak 
Wavelength (Å) 0.97954 
Resolution (Å) 45.9 - 2.60 (2.62 – 
2.60)* 
No. unique reflections 43,503 
Rmerge (%) 7.7 (98.2)** 
I / σI 30.7 (2.6) 
Completeness (%) 99.3 (94.0) 
Redundancy 13.3 (13.3) 
  
Refinement  
Resolution (Å) 45.9 – 2.6 (2.7 – 2.6) 
No. reflections 43503 (4336) 
Rwork / Rfree (%) 18.9 / 25.8 (25.8 / 36.4) 
No. atoms 5013 
    Protein 4905 
    Ligand/ion 56 
    Water 39 
B-factors (Å2)  
    Protein 58.1 
    Ligand/ion 57.4 
    Water 44.8 
R.m.s deviations  
    Bond lengths (Å) 0.008 
    Bond angles (°) 1.205 
*Values in parentheses are for highest-resolution shell.  
**All data were collected from a single crystal. 
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Table 2.2. Genes differentially transcribed in E. histolytica trophozoites expressing EhGα1 or 
EhGα1S37C with known roles in pathogenesis or putative vesicular trafficking functions. 
Gene name AmoebaDB accession no. 
fold change upon 
EhGα1 expression  
(p value) 
fold change upon 
EhGα1S37C expression  
(p value) 
Virulence genes    
amoebapore C EHI_118270 2.6 (0.002)  
myosin II heavy chain EHI_014010 2.4 (< 0.001)  
vacuolar ATP synthase EHI_029370 1.7 (0.001)  
EhRGS-RhoGEF EHI_010670 2.2 (0.001)  
amoebapore A precursor EHI_159480  -1.6 (0.004) 
cysteine protease EHI_062480  -2.2 (< 0.001) 
cysteine protease EHI_126170  -1.5 (0.021) 
cysteine protease EHI_138460  -1.5 (0.007) 
cysteine protease EHI_006920  -2.5 (< 0.001) 
cysteine protease EHI_045290  1.5 (0.010 
cysteine protease EHI_064430  2.3 (< 0.001) 
Gal/GalNac lectin light subunit EHI_049690  1.6 (0.005) 
Gal/GalNac lectin intermediate subunit EHI_183000  2.6 (< 0.001) 
EhGβ EHI_000240  1.6 (0.004) 
Rab family GTPases    
Rab GTPase EHI_168450 1.9 (0.002) -1.9 (0.001) 
Rab GTPase (RabK5) EHI_012380 1.5 (0.011)  
Rab GTPase (RabX22B) EHI_014060 1.6 (0.004)  
hypothetical protein (Rab domain) EHI_014210 1.8 (< 0.001)  
Rab GTPase (Rabl1) EHI_177550 2.3 (< 0.001)  
Rab GTPase (Rab7C) EHI_189990  -161.1 (< 0.001) 
Rab GTPase (Rab11A) EHI_005460  2.3 (< 0.001) 
Rab GTPase (Rab11D) EHI_056100  2.4 (< 0.001) 
Rab GTPase (Rab2C) EHI_067850  2.0 (< 0.001) 
Rab11B EHI_107170  10.3 (< 0.001) 
Other secretion/trafficking proteins    
VHS domain containing protein EHI_087590 2.1 (< 0.001) -1.7 (0.002) 
hypothetical protein (DENN domain) EHI_014090 1.8 (< 0.001) -1.6 (< 0.001) 
hypothetical protein (DENN domain) EHI_010320 1.8 (0.006)  
Rab GTPase activating protein EHI_060420 2.6 (< 0.001)  
ankyrin EHI_004990 2.1 (< 0.001)  
hypothetical protein (SFT2-like) EHI_200980 1.9 (0.006)  
MIT domain protein EHI_093860 1.8 (0.007)  
Rab GTPase activating protein EHI_170310  -1.5 (0.018) 
TBC1 domain family RabGAP 5 EHI_058320  -2.0 (< 0.001) 
ankyrin repeat protein EHI_134800  -1.7 (0.019) 
hypothetical protein (M6PR binding) EHI_161980  -2.1 (< 0.001) 
kinesin motor protein EHI_196390  -1.8 (< 0.001) 
cysteine protease binding factor 2 EHI_087660  -2.0 (< 0.001) 
cysteine protease binding factor 3 EHI_161650  -1.7 (0.001) 
cysteine protease binding factor 4 EHI_012340  -1.6 (0.005) 
cysteine protease binding factor 5 EHI_137940  -2.3 (< 0.001) 
hypothetical protein (DENN domain) EHI_135120  2.9  (0.002) 
hypothetical protein (TBC/RabGAP) EHI_189120  2.0 (0.005) 
vesicle-fusing ATPase EHI_004640  2.4 (< 0.001) 
adaptor protein (AP) family protein EHI_023600  1.9 (0.001) 
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Gene name AmoebaDB accession no. 
fold change upon 
EhGα1 expression  
(p value) 
fold change upon 
EhGα1S37C expression  
(p value) 
AP-3 complex subunit delta 1 EHI_158840  2.2 (< 0.001) 
AP-3 complex subunit EHI_164810  2.1 (< 0.001) 
dynamin-like protein EHI_052740  2.6 (< 0.001) 
clathrin-adaptor medium chain EHI_099240  2.5 (< 0.001) 
coatamer beta subunit EHI_088220  2.2 (0.002) 
coatamer beta subunit EHI_173180  2.4 (0.018) 
coatamer beta subunit EHI_173390  2.6 (< 0.001) 
Sec1 family protein EHI_093130  2.2 (< 0.001) 
hypothetical protein (VHS domain) EHI_152920  1.8 (0.003) 
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CHAPTER 3 
STRUCTURAL DETERMINANTS OF RGS-RhoGEF SIGNALING CRITICAL  
TO Entamoeba histolytica PATHOGENESIS1 
 
3.1 OVERVIEW 
G-protein signaling pathways, as key components of physiologic responsiveness and timing, 
are frequent targets for pharmacologic intervention. Here, we identify an effector for 
heterotrimeric G-protein α subunit (EhGα1) signaling from Entamoeba histolytica, the 
causative agent of amoebic colitis. EhGα1 interacts with this effector and GTPase-
accelerating protein (GAP), EhRGS-RhoGEF, in a nucleotide state-selective fashion. Co-
expression of EhRGS-RhoGEF with constitutively active EhGα1 and EhRacC leads to Rac-
dependent spreading in Drosophila S2 cells. EhRGS-RhoGEF overexpression in E. 
histolytica trophozoites leads to reduced migration toward serum and lower cysteine protease 
activity, as well as reduced attachment to, and killing of, host cells. A 2.3 Å crystal structure 
of the full-length EhRGS-RhoGEF reveals a putative inhibitory helix engaging the DH 
domain Rho-binding surface and the PH domain. Mutational analysis of the EhGα1/EhRGS-
RhoGEF interface confirms a canonical RGS domain rather than a RhoGEF-RGS (“rgRGS”) 
domain, suggesting a convergent evolution toward heterotrimeric and small G-protein cross-
talk.  
1 Bosch, D.E., Kimple, A.J., Manning, A.J., Muller, R.E., Willard, F.S., Machius, M., Rogers, S.L., and 
Siderovski, D.P. (2012) Structural Determinants of RGS-RhoGEF Signaling Critical to Entamoeba histolytica 
Pathogenesis. Structure. 21(1):65-75. 
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3.2 INTRODUCTION 
Heterotrimeric G-protein signaling pathways are frequent targets for pharmacologic 
manipulation [1]. The Gα subunit in its inactive, GDP-bound conformation engages the 
obligate Gβγ dimer [2]. A ligand-activated seven-transmembrane G-protein coupled receptor 
(GPCR) promotes nucleotide exchange on the Gα subunit. Upon binding of GTP by the Gα 
subunit, three switch regions undergo a conformational change, leading to separation from 
Gβγ and subsequent activation of downstream effectors such as adenylyl cyclases, 
phospholipase C, and Rho-family guanine nucleotide exchange factors (RhoGEFs) [2, 3]. 
Signaling is terminated by the GTPase activity of the Gα subunit and reassembly of the 
Gα·GDP/Gβγ heterotrimer. 
 ‘Regulator of G-protein signaling’ (RGS) proteins accelerate the intrinsic GTP 
hydrolysis activity of Gα subunits and thereby serve as negative regulators of signaling [4]. 
Canonical nine-helix RGS domains exhibit highest affinity for Gα in its transition-state 
mimetic form, stabilizing the switch regions for efficient hydrolysis [5]. Members of the 
RGS-RhoGEF family of Gα effectors contain N-termini with similarity to RGS domains 
(called ‘RhoGEF-RGS’ or ‘rgRGS’ domains), in combination with Dbl homology (DH) and 
pleckstrin homology (PH) domains that together mediate activation of Rho family GTPases 
[3]. The DH domain engages substrate Rho GTPases, promoting nucleotide release, while the 
PH domain frequently modulates exchange in various Dbl-family RhoGEF members [6]. In 
contrast to 9-helix RGS domains, rgRGS domains have a distinct 12-helix fold and engage 
Gα12/13 subunits through an effector-like interface involving primarily switch 2 and the α3 
helix [3]. An N-terminal extension of the rgRGS domain containing an “IIG” sequence motif 
contacts the Gα12/13 switch regions and all-helical domain and, in the case of p115 RhoGEF, 
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is required for GTPase accelerating protein (GAP) activity toward Gα12/13 subunits. Although 
structures of RGS-RhoGEFs with both the rgRGS and DH-PH domain tandems have not yet 
been elucidated, p115 RhoGEF is thought to be activated by an allosteric “GEF switch” 
mechanism that involves a conformational change of an N-terminal extension of the DH 
domain [7]. Recent low-resolution structural studies of full-length p115 RhoGEF suggest an 
elongated domain architecture and a potential bimodal interaction with Gα13, namely the 
effector interface with the rgRGS domain and a potential additional interface with the DH 
domain [8]. The activation mechanism of another mammalian RGS-RhoGEF, PDZ-RhoGEF, 
is thought to be complex, involving disruption of an electrostatic RGS-DH linker and DH 
domain interaction, perturbation of a putative RGS-DH linker “molten globule”, and 
membrane recruitment, as well as a “GEF switch” [9, 10]. Low-resolution SAXS studies of 
PDZ-RhoGEF also suggested an ensemble of elongated domain architectures [10]. 
 Entamoeba histolytica causes an estimated 50 million infections and 100,000 deaths 
per year worldwide, with highest incidence in countries with poor barriers between drinking 
water and sewage [11]. Following ingestion of encysted E. histolytica, the trophozoite, or 
amoeboid form of the parasite attaches to and destroys intestinal epithelial cells, giving rise 
to amoebic colitis [12]. Although the molecular details of signaling pathways in E. histolytica 
remain understudied, a relatively large family of Rho GTPases and Dbl family RhoGEFs are 
known to modulate cytoskeletal dynamics, as well as key pathogenic processes such as 
trophozoite migration, extracellular matrix invasion, and killing and phagocytosis of host 
cells [13-15].  
 Recently, we identified a functional heterotrimeric G-protein signaling pathway in E. 
histolytica; perturbation of the Gα subunit, EhGα1, elucidated positive regulatory roles for 
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G-protein signaling in pathogenic processes such as trophozoite migration and invasion, host 
cell attachment, and cell killing [16]. Overexpression of either wild type EhGα1 or a 
dominant negative mutant in E. histolytica trophozoites resulted in altered transcription of 
numerous genes that have implicated multiple potential mechanisms by which G-protein 
signaling modulates pathogenesis. From this study, a set of Rho GTPase signaling proteins, 
including an RGS-RhoGEF, and actin-associated proteins was observed to be differentially 
transcribed downstream of heterotrimeric G-proteins (Table 3.1). We hypothesized that 
EhRGS-RhoGEF, like its mammalian homologs, serves as an EhGα1 effector and signals 
through Rho family GTPases, with important roles in Entamoeba histolytica pathogenesis. 
Here, our results describe EhRGS-RhoGEF as an effector and GTPase accelerating protein 
(GAP) of EhGα1, with importance for E. histolytica motility, host cell attachment, cell 
killing, and cysteine protease secretion. Activation of EhRGS-RhoGEF by co-expression of 
constitutively active EhGα1 and EhRacC leads to Rac family GTPase-dependent cell 
spreading in Drosophila S2 cells. Furthermore, we provide a crystal structure of the full-
length RGS-RhoGEF in the inactive state, elucidating its molecular architecture and likely 
distinct evolutionary origin relative to the mammalian RGS-RhoGEFs. 
 
3.3 EXPERIMENTAL PROCEDURES 
3.3.1 Cloning and protein purification 
The open reading frames (ORFs) of EhGα1, EhRGS-RhoGEF, and EhRacC were amplified 
from E. histolytica genomic DNA (a gift from Dr. W.A. Petri, U. of Virginia) by polymerase 
chain-reaction (PCR) using Phusion polymerase (New England BioLabs) and Invitrogen 
primers. Amplicons were subcloned using ligation-independent cloning [17] into a Novagen 
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pET vector-based prokaryotic expression construct (“pET-His-LIC-C”) to form N-terminal 
tobacco etch virus (TEV) protease-cleavable, hexahistidine-tagged fusions. Mutations were 
made using QuikChange site-directed mutagenesis (Stratagene). For hexahistidine-tagged 
EhGα1, EhRGS-RhoGEF, and EhRacC, B834 E. coli were grown to an OD600nm of 0.7−0.8 
at 37°C before induction with 700 µM, 1 mM, or 500 µM isopropyl-β-D-
thiogalactopyranoside (IPTG), respectively, for 14-16 hours at 20°C. Cell pellets were 
resuspended in N1 buffer (for EhGα1: 50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 10 mM 
MgCl2, 10 mM NaF, 30 µM AlCl3, 50 µM GDP, 30 mM imidazole, 5% (w/v) glycerol; for 
EhRGS-RhoGEF: 50 mM HEPES pH 8.0, 150 mM NaCl, 30 mM imidazole, 5% (w/v) 
glycerol; for EhRacC: 50 mM HEPES pH 7.5, 250 mM NaCl, 5 mM MgCl2, 50 µM GDP or 
GTP, 30 mM imidazole, and 5% (w/v) glycerol) and lysed at 10,000 kPa using an Emulsiflex 
(Avestin, Ottowa, Canada). Cleared lysates were applied to nickel-nitrilotriacetic acid resin 
(GE Healthcare), washed, and eluted with N1 buffer containing 300 mM imidazole. Eluted 
protein was resolved using a calibrated size exclusion column (GE Healthcare) with S200 
buffer for EhGα1 (50 mM Tris-HCl pH 8.0, 250 mM NaCl, 5 mM DTT, 5% (w/v) glycerol, 
and 50 µM GDP), EhRGS-RhoGEF (50 mM Tris-HCl pH 8.0, 250 mM NaCl, 5 mM DTT, 
5% (w/v) glycerol), or EhRacC (50 mM Tris pH 8.0, 200 mM NaCl, 5 mM MgCl2, and 5% 
(w/v) glycerol). Comparison of global fold between wild type and E39K mutant EhRGS-
RhoGEF was performed using circular dichroism as previously described [18]. For 
crystallization, two residues were removed from both the N- and C-terminus of EhRGS-
RhoGEF, and the hexahistidine tag cleaved with TEV protease prior to size exclusion 
chromatography. 
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 For mammalian HEK293T and Drosophila S2 cellular experiments, open reading 
frames of EhRGS-RhoGEF, EhGα1, and EhRacC were synthesized with codon optimization 
for mammalian cell expression and subcloned into pcDNA3.1 or pMT/V5-His vectors (Life 
Technologies). EhRGS-RhoGEF and EhRacC were tagged with N-terminal HA and FLAG 
epitopes, respectively, and an internal FLAG tag was inserted after His-83 in EhGα1. D.m. 
Rac1(G14V) with an N-terminal myc epitope tag was also subcloned into the pMT/V5-His 
vector. 
 
3.3.2 Crystallization and structure determination 
Crystals of the full-length EhRGS-RhoGEF (a.a. 1-519) yielded diffraction data not suitable 
for either molecular replacement or anomalous dispersion. However, by removing two 
residues on both the N- and C-termini of EhRGS-RhoGEF we obtained another crystal form 
with improved diffraction quality, ultimately allowing structure determination by SAD. 
Crystallization was achieved by hanging drop vapor diffusion at 18°C.  EhRGS-RhoGEF at 
15 mg/mL in crystallization buffer (50 mM HEPES pH 7.5, 100 mM NaCl, and 1 mM DTT) 
was mixed 1:1 and equilibrated against crystallization solution containing 16% (w/v) PEG 
3350 and 100 mM sodium malonate pH 5.0.  Hexagonal plate crystals grew to 400 x 150 x 
20 µm over 5 days. EhRGS-RhoGEF crystals displayed the symmetry of space group C2 (a = 
86.1 Å, b = 46.3 Å, c = 142.6 Å, α = γ = 90°, β = 104.2°), with one monomer in the 
asymmetric unit.  Prior to data collection, crystals were cryoprotected in crystallization 
solution supplemented with 25% (v/v) glycerol. 
 Anomalous diffraction data were obtained at 0.97954 Å wavelength (selenium 
absorption peak) and 100K temperature at the GM/CA-CAT ID-D beamline (APS, Argonne 
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National Labs) and processed using HKL2000 [19]. A highly redundant data set was 
obtained combining partial data sets from five points along the EhRGS-RhoGEF plate 
crystal. Heavy atom searching identified 8 of 8 possible sites, and refinement yielded an 
estimated Bayes correlation coefficient of 48.2 to 2.5 Å resolution.  After density 
modification, the estimated Bayes correlation coefficient increased to 66.0.  ~75% of the 
model was constructed automatically, and the remaining portion was built manually. The 
current model (Table 3.2) contains one EhRGS-RhoGEF monomer.  
 Refinement was carried out against peak anomalous data with Bijvoet pairs kept 
separate using phenix.refine [20] interspersed with manual model revisions using the 
program Coot [21] and consisted of conjugate-gradient minimization and calculation of 
individual atomic displacement and translation/libration/screw (TLS) parameters [22]. 
Residues that could not be identified in the electron density were: 1, 139-140, 153-156, and 
452-454.  The model exhibits excellent geometry as determined by MolProbity [23].  A 
Ramachandran analysis identified 97.6% favored, 2.4% allowed, and 0% disallowed 
residues. Coordinates and structure factors are deposited in the RCSB Protein Data Bank (id 
4GOU). 
 
3.3.3 Single turnover nucleotide hydrolysis 
GTP hydrolysis by single turnover assays was quantified as previously described [24]. For 
GTPase acceleration assays, increasing concentrations of purified EhRGS-RhoGEF were 
added along with the hydrolysis-initiating magnesium.  
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3.3.4 Surface plasmon resonance 
Optical detection of protein binding was conducted as described previously [25]. Briefly, 
His6-tagged wild type or mutant EhRGS-RhoGEF was immobilized on an NTA chip surface 
by capture coupling and increasing concentrations of wildtype EhGα1 and mutants were 
flowed over at 10 µL/s in various nucleotide states. In complementary experiments, GST-
EhGα1 was immobilized on an anti-GST chip surface, as described [26], and increasing 
concentrations of EhRGS-RhoGEF and mutants flowed over. 
 
3.3.5 NTA affinity co-preciptiation 
HEK293T cells were transfected with DNA encoding an HA epitope-tagged EhRGS-
RhoGEF RGS domain (a.a. 1-152), codon optimized for mammalian cell expression. Cells 
were plated in 6-well dishes and transfected with 1.5 µg of DNA and Lipofectamine 2000 
(Invitrogen). Cells were lysed in buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 5 
mM MgCl2, 1 mM EDTA, 1% NP-40 alternative (Calbiochem), 10% deoxycholate, and 5 
mM imidazole. The lysis buffer was supplemented with 10 µM GTP; 10 µM GDP; or 10 µM 
GDP, 10 mM NaF, and 30 µM AlCl3. Cellular lysates were cleared by high-speed 
centrifugation at 4°C for 20 minutes. Purified His6-EhGα1 (50 µg) was added to the cleared 
cell lysate and rocked at 4°C for 30 minutes prior to addition of NTA-agarose and continued 
rocking for 4 hours. NTA-agarose was pelleted and washed three times with lysis buffer, and 
bound proteins resolved by SDS-PAGE, transferred to nitrocellulose, and detected by α-HA 
immuno-blotting or Ponceau S staining. 
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3.3.6 Trophozoite stable transfection 
EhRGS-RhoGEF was subcloned with an N-terminal FLAG epitope tag into an E. histolytica 
expression vector, described previously [27]. Axenic cultures were transfected by lipofection 
as previously described [28]. Briefly, amoebae at ~5 x 106/mL were suspended in medium 
199 (Sigma) supplemented with 5.7 mM cysteine, 1 mM ascorbic acid, 25 mM HEPES (pH 
6.9), 15 µg of DNA, and 30 µL of Superfect (Qiagen). After 3 hours at 37 °C, trophozoites 
were transferred to TYI-S-33 medium overnight and selected for stable transfection with 10 
µg/mL hygromycin over 3 weeks. 
 
3.3.7 Chemotactic migration  
Trophozoite migration assays were performed essentially as described previously [29].  
Briefly, amoebae harvested in log growth phase were suspended in serum free TYI growth 
medium, and 50,000 cells loaded in the upper chamber of a Transwell migration chamber 
(Costar, 8 µm pore size). The lower chamber contained growth medium with or without 15% 
adult bovine serum. Transwell plates were incubated at 37°C for 2 hr under anaerobic 
conditions (GasPak EZ, BD Biosciences).  
 
3.3.8 Host cell attachment 
Attachment of E. histolytica trophozoites to epithelial monolayers was assessed as previously 
described [30]. Chinese hamster ovary (CHO) cells were grown to confluency in 24-well 
plates, washed, and fixed in 4% paraformaldehyde for 30 minutes. Trophozoites (3 x 105) 
were added to the fixed monolayers in medium 199 supplemented with 5.7 mM cysteine, 1 
mM ascorbic acid, and 25 mM HEPES (pH 6.9). After incubation at 37°C for 30 minutes, 
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each well was washed gently two times with warm PBS to remove unattached trophozoites. 
Monolayer-attached trophozoites were quantified by counting with an inverted microscope. 
Each experiment was performed in quadruplicate and statistical significance determined by 
Student’s t-test. 
 
3.3.9 Cell killing 
Killing of mammalian cells (Jurkat) was assessed using the CytoTox-ONE membrane 
integrity assay (Promega). In 96-well plates, 5 x 105 Jurkat cells and/or 2.5 x 105 trophozoites 
were incubated at 37°C in 200 µL of medium 199 (Sigma) supplemented with 5.7 mM 
cysteine, 0.5% BSA, and 25 mM HEPES pH 6.8. After 2 hr, 50 µL of medium from each 
well was incubated with Cytotox reagent and a colorimetric measure of extracellular lactate 
dehydrogenase activity was obtained after 10 min. Each experiment was performed in 
quadruplicate and statistical significance determined by Student’s t-test. 
 
3.3.10 Cysteine protease activity 
Secreted cysteine protease activity in amoebic lysates was assayed essentially as described 
previously [31]. 106 trophzoites were incubated at 37 °C for 3 hr in 500 µL PBS 
supplemented with 20 mM cysteine, 0.15 mM CaCl2, and 0.5 mM MgCl2, conditions known 
to sustain E. histolytica growth and allow cysteine protease secretion [32].  Following 
centrifugation, the cell-free conditioned medium was assayed for cysteine protease activity. 2 
mg of azo dye-impregnated collagen (Sigma) with conditioned medium in 500 µL of 
protease activation buffer (100 mM Tris pH 7.0 and 10 mM CaCl2) were incubated at 37°C 
for 18 hr, then terminated with 500 µL of 10% TCA. Samples were centrifuged to exclude 
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intact collagen fibers, and supernatants collected for absorbance reading at 540 nm. In 
parallel experiments, the inhibitor p-hydroxy-mercuribenzoic acid (PHMB) was included at 1 
mM to assess the fraction of specific cysteine protease activity. Residual protease activity 
(after PHMB treatment) was subtracted to determine total cysteine protease activity.  
  
3.3.11 S2 cell culture and spreading assay 
S2 cells were obtained from the Drosophila Genome Resource Center (Bloomington, IL), and 
cultivated as described previously [33]. S2 cells were maintained in SF900 SFM (Invitrogen, 
Carsbad, CA) and transfected with 2 µg total DNA using the Amaxa nucleofector system 
(Lonza, Basel, Switzerland). Expression of transfected constructs was induced with 35 µM 
CuSO4. Double stranded RNAs were produced using Promega (Madison, WI) Ribomax T7 
kit according to manufacturer instructions. S2 cells at 50-90% confluency in 6-well plates 
were treated every other day for 7 days with 7.5 µg/ml of dsRNA.  On day 5 of RNAi 
treatment, cells were transfected as above and then induced on day 6. Cells were resuspended 
and plated on poly-L-lysine (Sigma-Aldrich, St. Louis, MO) coated coverslips and allowed to 
spread for 1 hour. For quantifying numbers of cells with spreading, each condition was 
repeated at least three times and ≥100 cells were counted per experiment. 
  Double stranded RNAs were produced using Promega (Madison, WI) Ribomax T7 kit 
according to manufacturer instructions. Primers used for dsRNA synthesis are as follows and 
are all preceded by the T7 sequence (5’-TAATACGACTCACTATAGG-3’). Control-fwd: 
5’-TAAATTGTAAGCGTTAATATTTTG-3’ and Control-rev: 5’-
AATTCGATATCAAGCTTATCGAT-3’ to amplify a region from the pBluescript plasmid;  
Rho-fwd: 5’-GTAAAACTTGCCTTCTGATTGTCT-3’,  Rho-rev: 5’-
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ATCTGGTCTTCTTCCTCTTTTTGA-3’; Rac1/2-fwd: 5’-
CTGATCAGCTACACGACCAAT-3’, Rac1/2-rev: 5’-CGAGCACTCCAGATACTTGAC-
3’; mtl-fwd: 5’-ATGTCAACCGGAAGGCCCATAAAG-3’, mtl-rev: 5’-
TTACATTATTAAACACTTTCG-3’. 
 
3.3.12 Immunofluorescence microscopy  
S2 cells were fixed with 4% formaldehyde (EM Sciences, Gibbstown, NJ) in HL3 buffer (70 
mM NaCl; 5 mM KCl; 1.5 mM CaCl2-2H2O; 20 mM MgCl2-6H2O; 10 mM NaHCO3; 5 mM 
trehalose; 115 mM sucrose; 5 mM HEPES; pH to 7.2), and permeabilized with PBST (PBS + 
0.1% Triton X-100). Cells were blocked with 5% normal goat serum (Sigma-Aldrich, St. 
Louis, MO) in PBST and stained with primary antibodies diluted into blocking solution at 
1:500. Following washing, cells were incubated with secondary antibodies (1:1000 dilution 
blocking solution) and Alexa 488-phalloidin (1:100 dilution; Invitrogen).  After washing, the 
cells were mounted in fluorescence mounting medium (Dakocytomation, Glostrup, 
Denmark). Antibodies are as follows: mouse anti-myc (Developmental Studies Hybridoma 
Bank, Iowa City, Iowa), mouse anti-FLAG and rabbit anti-HA (Sigma-Aldrich), 
RhodamineX-goat anti-rabbit, Cy5-goat anti-mouse, and DyLight 549–goat anti-mouse 
(Jackson Immunoresearch, West Grove, PA). Images were acquired using a CoolSnap HQ 
CCD camera (Roper Scientific, Ottobrunn, Germany) on a Nikon Eclipse Ti inverted 
microscope driven by Nikon Elements software (Tokyo, Japan). 
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3.4 RESULTS 
3.4.1 EhGα1 engages an RGS-RhoGEF effector and GTPase accelerating protein 
 The E. histolytica genome encodes a single classical Gα subunit effector, an RGS 
domain-containing RhoGEF (GenBank XP_653063; named EhRGS-RhoGEF) with distant 
similarity to the RGS-RhoGEF effectors of mammalian Gα12/13 subunits (Fig. 3.1). 
Transcription of EhRGS-RhoGEF was seen to be up-regulated upon overexpression of 
EhGα1 in E. histolytica trophozoites, suggesting a functional link to heterotrimeric G-protein 
signaling (Table 3.1). EhRGS-RhoGEF was purified from E. coli (Fig. 3.2) and found to bind 
directly to EhGα1 selectively in its GDP·AlF4- (AMF) nucleotide state as measured by 
surface plasmon resonance (Fig. 3.3 A-D). Reciprocal immobilization experiments each 
indicated an ~5 µM EhGα1·AMF/EhRGS-RhoGEF dissociation constant (KD). EhRGS-
RhoGEF also interacted with the constitutively active, GTPase deficient EhGα1(Q189L) 
mutant in its GTP-bound form, although with ~20-fold lower affinity than for EhGα1·AMF 
(KD ≈ 110 µM) (Fig. 3.3B). The EhGα1(Q189L)·GTP/EhRGS-RhoGEF binding affinity 
could not be precisely determined by equilibrium binding analysis due to concentration 
limitations of our assay. The preference of EhRGS-RhoGEF for the AMF nucleotide state 
over the GTP-bound state of EhGα1 is consistent with a similar order-of-magnitude 
difference in p115 RhoGEF affinity for Gαi1/13·AMF compared to Gαi1/13·GTPγS [34]. To 
determine whether the interaction occurs through the RGS domain of EhRGS-RhoGEF, a 
conserved glutamate at the predicted Gα subunit-binding surface was mutated to lysine 
(E39K; Fig. 3.1). Despite proper global folding of the E39K mutant (Fig. 3.2B), it exhibited 
drastically reduced affinity for EhGα1·AMF (Fig. 3.3D). The isolated RGS domain of 
EhRGS-RhoGEF could not be produced from E. coli. However, RGS domain expressed in 
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HEK 293T cells was seen to specifically co-precipitate with purified EhGα1·AMF and 
EhGα1(Q189L)·GTP, but not EhGα1·GDP (Fig. 3.2C), suggesting that the RGS domain 
alone is sufficient to bind EhGα1. 
 The relatively high affinity of wild type EhRGS-RhoGEF for the hydrolysis transition 
state-mimetic (AMF) form of EhGα1 suggested that the RGS domain of EhRGS-RhoGEF 
may serve as a GTPase accelerating protein (GAP) for EhGα1. Interestingly, EhRGS-
RhoGEF lacks the N-terminal extension containing the IIG motif that is required for the GAP 
activity of p115 RhoGEF (Fig. 3.1) [3]. However, single turnover GTP hydrolysis assays 
demonstrated that wild type EhRGS-RhoGEF, but not the EhRGS-RhoGEF(E39K) mutant, 
accelerates the intrinsic GTP hydrolysis activity of EhGα1 in a concentration-dependent 
fashion (Fig. 3.3E). Mutation of the conserved Asn-83 in the EhRGS-RhoGEF RGS domain, 
predicted to contact and orient EhGα1 switch residues for efficient catalysis of GTP 
hydrolysis [5], also eliminated GAP activity (Fig. 3.3F) and dramatically reduced EhRGS-
RhoGEF/EhGα1 binding affinity (Fig. 3.3C). 
 
3.4.2 EhGα1 and EhRacC activate EhRGS-RhoGEF to promote Rho-dependent cell 
spreading 
 To determine the ability of EhRGS-RhoGEF to modulate Rho-dependent cellular 
processes and its potential regulation by EhGα1, we utilized Drosophila S2 cells that 
undergo a dramatic morphological transition with distinctive reorganization of actin 
structures when Rho family GTPases are activated by various stimuli [35]. For example, 
overexpression of a GTPase-deficient and constitutively active D.m. Rac1(G14V) lead to cell 
spreading in ~80% of S2 cells on a poly-lysine coated surface, as compared to ~20% of cells 
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expressing RFP (Figure 3.4A,B). Expression of constitutively active EhGα1(Q189L) and 
EhRGS-RhoGEF was not sufficient to significantly increase cell spreading. However, 
additional expression of constitutively active EhRacC(Q65L) lead to spreading, suggesting 
that GTP-bound EhGα1 and EhRacC are necessary to activate EhRGS-RhoGEF. 
Importantly, EhRacC(Q65L) alone (not shown) or in combination with EhGα1 (Figure 3.4) 
did not trigger S2 cell spreading, indicating its inability to productively engage the 
endogenous D.m. Rho GTPase signaling machinery independently of EhRGS-RhoGEF. Wild 
type EhGα1 did not activate EhRGS-RhoGEF, and the EhRGS-RhoGEF(E39K) mutation 
prevented an increase cell spreading (Fig. 3.4A,B). Thus, co-expression of EhRGS-RhoGEF 
with constitutively active EhRacC and interaction with constitutively active EhGα1 at the 
RGS domain are required for enhanced cell spreading. 
 The observed cell spreading phenotype strongly suggested that EhRGS-RhoGEF was 
signaling through endogenous Drosophila Rho family GTPases. To investigate the 
dependence of the observed phenotype on endogenous Rho family GTPases, we knocked 
down expression of D.m. Rac1/2 (both isoforms targeted), Rho, and mtl by RNA 
interference, as demonstrated previously in S2 cells [33]. Specific knock down of D.m. Rac 
GTPases abolished the cell spreading effect of EhRGS-RhoGEF, EhGα1(Q189L), and 
EhRacC(Q65L), suggesting that either or both D.m. Rac isoforms may serve as substrates for 
overexpressed EhRGS-RhoGEF (Figure 3.4A). 
 To test whether activated EhRacC directly engages EhRGS-RhoGEF, surface 
plasmon resonance was utilized. EhRGS-RhoGEF selectively bound EhRacC(Q65L)·GTP, to 
the exclusion of EhRacC·GDP or nucleotide-free EhRacC (Figure 3.4D). This pattern of 
nucleotide state selectivity was consistent with a Rho GTPase and effector-like interaction, 
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rather than a RhoGEF and substrate Rho GTPase relationship. Although the observed 
recombinant EhRacC(Q65L)/EhRGS-RhoGEF affinity was relatively low (KD ≈ 34 ± 9 µM), 
the cell-spreading experiments suggest that a productive interaction occurs in a cellular 
context. The interaction of EhRGS-RhoGEF with an active species of Rho family GTPase 
was reminiscent of the structurally elucidated interaction between human RhoA·GTPγS and a 
hydrophobic patch on the PH domain of PDZ-RhoGEF [36]. An analysis of the PDZ-
RhoGEF PH domain residues involved in activated RhoA binding (PDB id 3KZ1) revealed 
poor conservation with the corresponding PH domain residues of EhRGS-RhoGEF (19% 
identity, 25% similarity); thus, we do not predict that EhRacC·GTP binds EhRGS-RhoGEF 
in a similar fashion. However, a direct interaction does occur between activated EhRacC and 
EhRGS-RhoGEF, potentially explaining the required co-expression of EhRacC(Q65L), 
together with EhGα1(Q189L) and EhRGS-RhoGEF to enhance cell spreading (Figure 
3.4A,B). 
 
3.4.3 EhRGS-RhoGEF modulates pathogenic processes of E. histolytica trophozoites 
 We next investigated the role(s) of RGS-RhoGEF signaling in E. histolytica 
trophozoites by engineering the virulent HM-1:IMSS strain to stably overexpress wild type 
EhRGS-RhoGEF (Fig. 3.5). We focused on measuring the effect of EhRGS-RhoGEF 
overexpression on trophozoite chemotactic migration, host cell attachment, and cell killing, 
given the known dependence of these vital pathogenic processes on actin cytoskeletal 
dynamics, as well as Rho GTPases and Dbl family RhoGEFs [13, 15]. Trophozoites 
ectopically overexpressing EhRGS-RhoGEF killed host cells less efficiently than the parent 
strain, as indicated by a membrane integrity assay (Fig. 3.5A). A number of cytotoxic 
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proteins are involved in host cell killing, including membrane-perforating amoebapores and 
cysteine proteases [12]. Reduced secretion of active cysteine proteases, as measured by an 
azo-collagen assay (Fig. 3.5B), may account in part for the impaired cell killing of the 
EhRGS-RhoGEF-expressing trophzoite strain. Direct attachment of E. histolytica 
trophozoites to host epithelial cells, primarily through a galactose-inhibitable lectin [37], is 
also required for tissue destruction. Amoebae overexpressing EhRGS-RhoGEF showed 
reduced attachment to Chinese Hamster Ovary (CHO) cell monolayers compared to the 
parent strain (Fig. 3.5D). E. histolytica trophozoites are also highly motile, a feature that is 
dependent on a dynamic actin cytoskeleton regulated by Rho family GTPase signaling [15]. 
Transwell migration experiments indicated that overexpression of EhRGS-RhoGEF also 
decreases trophozoite chemotactic migration toward serum, but not random migration 
(Figure 3.5C), suggesting that interfering with the EhGα1/EhRGS-RhoGEF signaling axis 
modulates the E. histolytica migratory response to serum factors.  
 
3.4.4 A crystal structure of EhRGS-RhoGEF 
 While isolated domains from mammalian RGS-RhoGEFs have been structurally 
characterized [3], a high-resolution structure of an RGS domain together with a DH-PH 
domain tandem has not been elucidated to date. We obtained a crystal structure of a nearly 
full-length EhRGS-RhoGEF protein (lacking only two residues from each terminus) to 2.3 Å 
by single wavelength anomalous dispersion (SAD) (Table 3.2). The structural model exhibits 
an N-terminal, canonical nine-helix RGS domain, an oblong DH domain, and a C-terminal 
PH domain (Figs. 3.6A). The RGS domain interacts with the DH domain surface opposite 
from the PH domain and the putative Rho GTPase binding site (Fig. 3.6). The linker between 
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the RGS and DH domains wraps around the oblong helical bundle of the DH domain (Fig. 
3.6A), forming an additional helix (termed the ‘inhibitory helix’). 
 The RGS domain of EhRGS-RhoGEF is involved in multiple crystal contacts (Fig. 
3.7); specifically, the putative Gα-binding surfaces of neighboring EhRGS-RhoGEF 
molecules in the crystal lattice contact one another. Although crystal contacts may modestly 
affect the disposition of the RGS domain, the similarity of its conformation to mammalian 
RGS domains in both crystallographic and NMR studies (Fig. 3.8B) [38], and significant 
burial of hydrophobic surface area (~850 Å2) at the RGS-DH domain interface suggest that 
the crystal structure architecture accurately reflects that of EhRGS-RhoGEF in solution. 
 The PH domain exhibits a conserved overall fold despite weak sequence similarity 
(2.9 Å r.m.s.d. compared to 324 equivalent residues of the Dbs PH domain with only 51% 
sequence similarity) (Fig. 3.9A). An analysis of protein sequence motifs and comparison of 
the EhRGS-RhoGEF PH domain structure to other PH domains in complex with 
phospholipid head groups [39] revealed poor conservation of a potential phospholipid-
binding site on EhRGS-RhoGEF. Thus, we do not hypothesize that the EhRGS-RhoGEF PH 
domain directly associates with phospholipids. 
 The EhRGS-RhoGEF DH domain is most similar to that of Intersectin (Dali server Z-
score 19.4; PDB id 1KI1). Superposition of Intersectin/Cdc42 [40] and EhRGS-RhoGEF 
highlights a number of DH domain structural differences (Fig. 3.6B). The α6 helix of 
EhRGS-RhoGEF, which is the longest of the Intersectin DH domain, is disrupted by a loop, 
giving rise to two helices at ~90° relative orientations (termed α6a and α6b). The PH domain 
adopts a very different orientation relative to the DH domain in EhRGS-RhoGEF as 
compared to Intersectin (Fig. 3.6B). The PH domain of RGS-RhoGEF directly obstructs the 
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putative Rho binding site, similar to a number of mammalian RhoGEFs, e.g. Vav and Sos 
[41]. The DH and PH domains of EhRGS-RhoGEF share a substantial interface (~1200 Å2 
buried surface area) that occurs predominantly through hydrophobic interactions between the 
α7 helix of the PH domain and the α3d, α4, α5, and α6b helices of the DH domain (Figure 
3.9B). Particularly, the hydrophobic side chains of Phe-393 and Met-397 project into an 
approximately triangular concavity formed by helices α3d, α4, and α5 (Figure 3.9B). The 
nature of the DH/PH domain interface suggests that the structural relationship between the 
two domains observed in the crystal structure likely also exists in solution. However, 
additional contacts of each domain with the inhibitory helix may also be necessary to 
maintain the observed DH and PH domain relationship (Figure 3.10), and alternative 
conformations are also possible. 
 
3.4.5 The inhibitory helix coordinates occlusion of the Rho GTPase binding site 
 In the inactive state of EhRGS-RhoGEF, the inhibitory helix, the α6b helix of the DH 
domain, and the PH domain all obstruct the presumptive Rho GTPase interaction surface of 
the DH domain (Fig. 3.6), as predicted based on comparison with the Intersectin/Cdc42 
structure [40]. In fact, the entire RGS-DH domain linker inhibitory helix lies within the space 
occupied by the Rho GTPase substrate in numerous, well-conserved Dbl family GEF/Rho 
interactions [6]. The inhibitory helix interacts with both the DH and PH domains through a 
series of hydrophobic and polar interactions (Fig. 3.10, 3.11). The hydrophobic residues Leu-
164, Ile-167, Ile-168, and Trp-175 interface with a hydrophobic patch at the DH α6B 
helix/PH domain interface, consisting primarily of the hydrophobic portion of Lys-386, Leu-
387, Ile-406, and Ile-450 (Fig. 3.10, 3.11). Surrounding the hydrophobic patch are a number 
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of apparent polar and ionic interactions, including those between Lys-161 of the inhibitory 
helix and Glu-511 of the PH domain as well as Lys-172 and Asp-383 of the inhibitory and 
DH domain α6B helices, respectively. The inhibitory helix residues Lys-166 and Ile-170 also 
form limited contacts with a DH domain loop from a neighboring molecule in the crystal 
lattice (Figure 3.7C), but these contacts likely do not contribute to the observed main chain 
conformation. Notably, the RGS-DH linker containing the putative inhibitory helix is much 
shorter in EhRGS-RhoGEF (26 residues) than the corresponding linker in its mammalian 
homologs, with p115 RhoGEF possessing the next shortest linker at 164 residues (Fig. 3.1C). 
Thus, it is likely that this region exhibits different structural features and potentially performs 
different functions in mammalian RGS-RhoGEFs. 
 
3.4.6 Convergent evolution of the EhGα1/EhRGS-RhoGEF interface 
 The RGS/DH domain interface consists of a central hydrophobic region with 
peripheral hydrogen bond and ionic interactions (Fig. 3.8A, 3.11C). The residues 
corresponding to this domain interface are not highly conserved among mammalian RGS-
RhoGEFs, such as p115 RhoGEF (Fig. 3.1). This observation, together with a previous 
small-angle X-ray scattering (SAXS) analysis of the elongated p115 RhoGEF [8], suggests 
that the structural relationships among the EhRGS-RhoGEF domains differ from those of 
mammalian homologs. 
 The RGS domain of EhRGS-RhoGEF closely resembles the nine-helix bundle found 
in canonical RGS domains, such as RGS4 (Fig. 3.8B). This canonical RGS domain fold is 
distinct from the 12-helix rgRGS domains of mammalian RGS-RhoGEFs, such as p115 (Fig. 
3.8C) [3]. EhRGS-RhoGEF is unique in possessing a canonical nine-helix RGS domain, 
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suggesting that the RGS and DH-PH domain combination within E. histolytica may have 
arisen through an independent evolutionary mechanism. 
In addition to possessing a distinctive RGS domain fold, the mammalian RGS-
RhoGEFs engage Gα12/13 subunits through an effector-like interface, primarily utilizing 
switch 2 and the α3 helix on Gα, although the N-terminal extension of the rgRGS domain 
required for GAP activity also contacts the three switches and the all-helical domain (Fig. 
3.12B) [3]. In contrast, canonical nine-helix RGS domains primarily interface with Gα 
switches 1 and 2 (Fig. 3.12A) [38]; hence, the Gα subunit switch 1 Gly-to-Ser “RGS-
insensitivity” mutation selectively disrupts canonical RGS domain interactions but not 
Gα/rgRGS domain interactions [42, 43]. To test whether the EhRGS-RhoGEF RGS domain 
interfaces with EhGα1 in a canonical fashion, we generated the EhGα1(G168S) mutant. 
EhRGS-RhoGEF exhibited drastically lower affinity for EhGα1(G168S) than wildtype 
EhGα1, as measured by SPR, and was unable to affect the intrinsic GTPase rate of 
EhGα1(G168S) (Fig. 3.3B, G). These experiments suggest that the EhGα1/EhRGS-RhoGEF 
interface most likely resembles a canonical RGS/Gα interaction, providing further evidence 
for an independent evolutionary mechanism giving rise to a Gα/RGS-RhoGEF signaling axis 
in E. histolytica. 
 
3.5 DISCUSSION 
The E. histolytica Gα subunit is divergent in its amino acid sequence as compared to 
mammalian Gα subunits and, in particular, does not belong to the Gα12/13 subfamily that 
couples to mammalian RGS-RhoGEFs (Fig. 3.13). However, EhGα1 does engage the RGS 
domain of EhRGS-RhoGEF in a nucleotide state-dependent fashion, resulting in accelerated 
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GTP hydrolysis. A search of publicly available sequenced genomes identified the RGS and 
DH-PH tandem domain combination exclusively in metazoan species (e.g. C. elegans and D. 
melanogaster) with the only non-metazoan exception being the Entamoeba species. 
Resistance of EhGα1 to conventional Gα subfamily classification, the RGS4-like nine-helix 
RGS domain fold of the EhRGS-RhoGEF N-terminus, and the canonical nature of the 
EhGα1/EhRGS-RhoGEF interface, as evidenced by the EhGα1(G168S), EhRGS-
RhoGEF(N83A), and EhRGS-RhoGEF(E39K) mutants, all suggest an evolutionary origin 
independent of the Gα12/13/RGS-RhoGEF signaling axis present in mammals.  
 Mammalian RGS-RhoGEFs are thought to achieve full activation through integration 
of multiple signals including, but not limited to, interactions with Gα12/13. For instance, Gα12-
mediated stimulation of leukemia-associated RhoGEF requires tyrosine phosphorylation by 
Tec [44]. Consistent with this theme, EhRGS-RhoGEF requires co-expression, not only with 
constitutively active EhGα1, but also with constitutively active EhRacC, to achieve apparent 
activation as evidenced by S2 cell spreading. Little is currently known about EhRacC 
signaling in E. histolytica, although it is evidently a substrate for EhGEF2 in vitro [45]. 
EhRacC was seen to bind EhRGS-RhoGEF directly, exclusively in the GTP-bound 
conformation, suggesting that EhRGS-RhoGEF may serve as an EhRacC effector. Activated 
human RhoA GTPase has been demonstrated to bind the PH domain of PDZ-RhoGEF in an 
analogous fashion [36]. RhoA also serves as a substrate for PDZ-RhoGEF-mediated 
exchange, suggesting a possible mode of feedback regulation in mammals. However, there is 
currently no evidence that EhRacC is a substrate for EhRGS-RhoGEF; in fact, EDTA-
treated, nucleotide-free EhRacC did not bind appreciably to EhRGS-RhoGEF (Fig. 3.4D). 
However, the full-length isolated EhRGS-RhoGEF used in these experiments is expected to 
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have an obstructed Rho substrate-binding site, and activation by EhGα1·GTP, EhRacC·GTP, 
and/or other factors may be required to allow efficient substrate binding. Although the 
putative exchange factor activity of EhRGS-RhoGEF was not directly measureable, selective 
knockdown of endogenous D.m. Rac1/2 in S2 cells impaired the cell spreading triggered by 
co-expression of EhRGS-RhoGEF, EhGα1(Q/L), and EhRacC(Q/L), suggesting that 
Drosophila Rac may serve as a substrate for EhRGS-RhoGEF in a cellular context. However, 
the cell spreading experiments provide limited insight into the precise signaling mechanics. 
For instance, additional cellular factors may contribute to EhRGS-RhoGEF activation, and 
we cannot rule out the possibility that overexpressed E. histolytica signaling components 
promote cell spreading through other endogenous signaling pathways. 
 In isolation, EhRGS-RhoGEF appears to adopt an autoinhibited conformation, with 
direct obstruction of the presumptive Rho substrate-binding surface by a putative inhibitory 
helix and its DH and PH domain interactions. We hypothesize that binding of EhGα1·GTP 
and EhRacC·GTP to EhRGS-RhoGEF, possibly together with other cellular context factors 
such as membrane localization or post-translational modifications, may lead to a structural 
rearrangement of the putative inhibitory helix and the PH domain, allowing for substrate Rho 
GTPase binding and nucleotide exchange. The predicted mode of EhRGS-RhoGEF 
autoinhibition, as derived from the crystal structure, is comparable to that of mammalian 
PDZ-RhoGEF, seen in solution studies [9]. However, in the case of PDZ-RhoGEF, an acidic 
stretch of its rgRGS-DH domain linker interacts with a DH domain surface basic cluster, 
distinct from the inhibitory helix interface seen here in the crystal structure of EhRGS-
RhoGEF. The rgRGS-DH linker of p115 RhoGEF also apparently inhibits the GEF activity 
of its DH-PH domain tandem, although both SAXS analyses and crystallographic studies of 
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the DH-PH domains with short segments of the linker intact suggest a different linker 
disposition than that seen in EhRGS-RhoGEF [7]. The RGS-DH linker in EhRGS-RhoGEF 
is >100 residues shorter than those of mammalian homologs (Fig. 3.1C), further suggesting 
that this region does not have a conserved structure across species. 
 Endogenous EhRGS-RhoGEF likely represents a functional signaling link between 
heterotrimeric G-proteins and Rho family GTPases in E. histolytica. Indeed, Rho GTPases 
and other Dbl family RhoGEFs in E. histolytica are also known to regulate multiple 
processes important for pathogenesis such as actin reorganization during chemotaxis, surface 
receptor capping, cell killing, phagocytosis, and tissue destruction [13]. A surprisingly large 
family of Rho GTPases (>20 members) is apparently simultaneously expressed in the single-
celled parasite [14]. Further studies are needed to determine which Rho family members are 
activated by EhRGS-RhoGEF and what downstream signaling pathways are utilized.  
 Overexpression of EhRGS-RhoGEF resulted in reduced E. histolytica trophozoite 
chemotactic migration, attachment to and killing of host cells, and secretion of cysteine 
proteases. By each of these measures, the EhRGS-RhoGEF trophozoite strain phenocopies a 
strain overexpressing a dominant negative EhGα1 point mutant and exhibits an opposing 
trend to trophozoites overexpressing wild type EhGα1 [16], consistent with ectopically 
overexpressed EhRGS-RhoGEF serving to accelerate GTP hydrolysis on EhGα1 and thus 
inhibit its signaling. Given the amenability of heterotrimeric G-protein signaling to 
pharmacological manipulation [1], this pathway provides a promising drug target for the 
treatment of amoebic colitis.  
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Figure 3.1. Multiple sequence alignment of the EhRGS-RhoGEF RGS and DH-PH 
domains. Sequence alignments were conducted with T-Coffee (www.tcoffee.org) for the 
RGS domain (A) and the DH-PH domains (B) of EhRGS-RhoGEF. The RGS domain most 
closely resembles canonical RGS domains rather than the RGS-like domain of p115 
RhoGEF. Glu-39 and Asn-83, residues highly conserved among canonical RGS proteins, 
were mutated in EhRGS-RhoGEF and eliminated both binding to EhGα1 and acceleration of 
GTP hydrolysis (Fig. 3.3). A DALI search indicated that the EhRGS-RhoGEF DH domain 
most closely resembles Intersectin. (C) The linker joining the RGS and DH domains of 
EhRGS-RhoGEF is substantially shorter than that of mammalian homologs. 
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Figure 3.2. Circular dichroism (CD) of EhRGS-RhoGEF(E39K) and nucleotide-
dependent interaction of EhGα1 with the isolated RGS domain.  (A) EhGα1, EhRGS-
RhoGEF, and point mutants used in biochemical experiments were purified from E. coli by 
affinity chromatography and gel filtration.  (B) Mutation of a predicted surface residue on 
EhRGS-RhoGEF (Glu-39 to Lys) does not disrupt global protein folding, as measured by 
CD. (C) HA epitope-tagged RGS domain (a.a. 1-152) was expressed in HEK-293T cells and 
co-precipitated with His6-tagged EhGα1 on NTA resin. The EhRGS-RhoGEF RGS domain 
selectively co-precipitated with EhGα1·AMF and EhGα1(Q189L)·GTP, compared to 
EhGα1·GDP or NTA resin alone. Ponceau S staining indicated approximately equal loading 
of EhGα1 in each experiment. 
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Figure 3.3. EhRGS-RhoGEF is an EhGα1 effector that accelerates its GTP hydrolysis.  
(A-D) Either EhGα1 or EhRGS-RhoGEF was immobilized on a surface plasmon resonance 
chip, and the complementary protein flowed over at increasing concentrations. EhRGS-
RhoGEF bound EhGα1 selectively in the GDP·AlF4--bound state (AMF); interaction affinity 
was independent of immobilized species (KD = 5.2 ± 0.8 µM, panel B; 5.7 ± 1.6 µM, panel 
D). The GTPase-deficient mutant mutant EhGα1(Q189L) also interacted with EhRGS-
RhoGEF, but with lower affinity (KD ≈ 110 µM). Mutation of the conserved EhRGS-
RhoGEF Asn-83, predicted to orient EhGα1 residues for rapid GTP hydrolysis, the predicted 
EhGα1-binding surface charge reversal EhRGS-RhoGEF(E39K), and the switch 1 mutant 
EhGα1(G168S) all drastically reduced binding affinity. Sensorgrams and equilibrium 
binding curves are representative of three experiments. (E, F) The GTPase rate of EhGα1 
was accelerated by EhRGS-RhoGEF in a dose-dependent fashion (kobs = 0.20 ± 0.02 min-1 
for EhGα1 alone and 1.45 ± 0.13 min-1 upon addition of 25 µM EhRGS-RhoGEF). EhRGS-
RhoGEF(E39K) and EhRGS-RhoGEF(N83A) had no effect on the hydrolysis rate. (G) GTP 
hydrolysis rates for the “RGS-insensitivity” mutant EhGα1(G168S) alone or in the presence 
of a high concentration of EhRGS-RhoGEF were indistinguishable. Error bars represent 
standard error of the mean for duplicate reactions. Each single turnover hydrolysis 
experiment was independently repeated at least twice.  
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Figure 3.4. EhRGS-RhoGEF activation by constitutively active EhGα1 and EhRacC 
leads to Rac-dependent S2 cell spreading. (A-C) Rho family GTPase activation in D. 
melanogaster S2 cells leads to spreading on a poly-lysine coated surface [33]. Coexpression 
of EhRGS-RhoGEF with GTPase-deficient and constitutively active EhGα1(Q189L) was 
insufficient to effect cell spreading. However expression of the constitutively active 
EhRacC(Q65L), together with EhGα1(Q189L) and EhRGS-RhoGEF significantly enhanced 
cell spreading, while EhRacC(Q65L) alone or in combination with EhGα1 had no effect. To 
determine which D. melanogaster Rho family GTPases were necessary for cell spreading, 
and thus potential substrates for overexpressed EhRGS-RhoGEF, double-stranded RNAi was 
employed as described previously [35]. RNAi-mediated knockdown of D.m. Rac isoforms, 
but not Rho or mtl, prevented significant enhancement of cell spreading by coexpression of 
EhRGS-RhoGEF, EhRacC(Q65L), and EhGα1(Q189L). Error bars represent standard 
deviation for three independent experiments, and * indicates statistically significant 
difference (p < 0.05) by Student’s t-test. Example micrographs are shown in panel B and 
western blots confirming expression of all E. histolytica proteins and mutants are shown in 
panel C. (D) Recombinant, activated EhRacC(Q65L)·GTP was seen to directly bind EhRGS-
RhoGEF by surface plasmon resonance, while EhRacC·GDP and nucleotide-free EhRacC 
exhibited negligible binding up to 40 µM concentration.  
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Figure 3.5. EhRGS-RhoGEF expression inhibits host cell attachment and killing, 
cysteine protease secretion, and chemotactic migration by E. histolytica trophozoites. 
(A) Amoebae were stably transfected to overexpress EhRGS-RhoGEF (inset). Expression of 
EhRGS-RhoGEF reduced the ability of E. histolytica to kill Jurkat (human lymphocyte-
derived) cells compared to the HM-1:IMSS virulent parent strain, as determined by a 
membrane integrity assay. (B) Trophozoites expressing EhRGS-RhoGEF exhibited reduced 
cysteine protease secretion, a process necessary for host cell killing and extracellular matrix 
invasion. (C) Overexpression of RGS-RhoGEF reduced trophzoite chemotactic migration 
across a porous membrane toward serum-containing nutritive media, but had no measureable 
effect on random migration. (D) Trophozoites attach to CHO cell monolayers, primarily 
through a galactose-inhibitable lectin. Overexpression of EhRGS-RhoGEF reduced lectin-
dependent monolayer attachment. All trophozoite experiments were conducted in 
quadruplicate. * indicates a statistically significant difference by Student’s t-test (p < 0.05).  
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Figure 3.6. The structure of EhRGS-RhoGEF reveals inter-relationship between RGS 
and DH/PH domains. (A) The RGS domain (yellow) adopts a canonical 9-helix fold and 
interacts with the DH domain (green) opposite from the predicted Rho binding site. The 
linker between the RGS and DH domains wraps ~180° around the DH domain and contains a 
15-residue α helix (termed the ‘inhibitory helix’; red) that engages both the conserved PH 
domain fold (orange) and the C-terminal portion of the DH domain. (B) The inhibitory helix, 
DH, and PH domains are superimposed with the structure of Intersectin/Cdc42 (gray; PDB id 
1KI1). The conserved site of Rho GTPase interaction, illustrated by a surface rendering of 
Cdc42, is obstructed in the case of EhRGS-RhoGEF. The inhibitory helix lies entirely within 
the space corresponding to Cdc42. In addition, the long α6 helix is continuous in Intersectin 
and other RhoGEFs, but is segmented into two helices related by an ~90° angle in EhRGS-
RhoGEF. The α6b helix both interacts with the putative inhibitory helix and contributes to 
obstruction of the Rho binding site. The EhRGS-RhoGEF PH domain is also predicted to 
interfere with Rho binding in this inactive conformation.  
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Figure 3.7. Crystal contacts of the EhRGS-RhoGEF RGS domain and inhibitory helix. 
The RGS domain (yellow) of EhRGS-RhoGEF contacts symmetry-related molecules in the 
crystal lattice. (A) The putative EhGα1-binding surface of the RGS domain contacts the 
corresponding face of a neighboring RGS domain (gray). (B) Two other RGS domain 
surfaces interface with additional neighboring RGS domains (blue and brown). Although 
crystal contacts may modestly affect the disposition of the RGS domain, the similarity of its 
conformation to mammalian RGS domains (Fig. 3.8B) and significant burial of hydrophobic 
surface area (~850 Å2) at the RGS-DH domain interface (Fig. 3.8A) suggest that the crystal 
structure architecture accurately reflects that of EhRGS-RhoGEF in solution. (C) The 
inhibitory helix (red) forms limited contacts with the neighboring DH domain (gray) in the 
crystal lattice. The side chains of Ile-170 and Lys-166 make van der Waals contacts with the 
main chain of the neighboring DH domain. Although no side chains depicted in the model 
are within hydrogen bonding distance, two side chain pairs could potentially form polar 
contacts, namely Lys-173/Gln-219 and Lys-166/Glu-294. 
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Figure 3.8. The EhRGS-RhoGEF RGS domain adopts a canonical fold and interacts 
with the DH domain. (A) Residues participating in the RGS (yellow) and DH (green) 
domain interface in EhRGS-RhoGEF are shown in sticks. A central hydrophobic region is 
surrounded by polar and ionic side chain interactions. (B) The EhRGS-RhoGEF RGS domain 
adopts a 9-helical bundle fold very similar to canonical RGS domains, typified by RGS4 
(red; PDB id 1AGR). (C) In contrast, the mammalian RGS-RhoGEFs possess an RGS-like 
domain with 12 helices, as seen in p115 RGS-RhoGEF (PDB id 1IAP). Dotted lines indicate 
loops that could not be accurately modeled. 
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Figure 3.9. The EhRGS-RhoGEF PH domain contacts the DH domain. (A) Despite only 
51% sequence similarity to the Dbs RhoGEF (cyan; PDB id 1RJ2), the EhRGS-RhoGEF PH 
domain (orange) is structurally similar with a 2.9 Å Cα r.m.s.d. The β-sandwich fold is 
conserved with variation in the lengths and positioning of individual β-strands. EhRGS-
RhoGEF also lacks the C-terminal helical extension seen in Dbs. (B) The α7 helix of 
EhRGS-RhoGEF, together with the β4-β4 loop of the PH domain (orange) contact the DH 
domain (green) and buy ~1200 Å2 of surface area. The side chains of Phe-393 and Met-397 
project into an approximately triangular concavity formed by helices α3d, α4, and α5 on the 
DH domain. 
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Figure 3.10. The EhRGS-RhoGEF inhibitory helix engages both the DH and PH 
domains. (A,B) The EhRGS-RhoGEF DH and PH domains share an interface with the 
hydrophobic inhibitory helix residues Leu-164, Ile-167, Ile-168, Trp-175, and the aromatic 
ring of Tyr-160 (gray sticks). Hydrogen-bond interactions and peripheral ionic interactions, 
e.g. Lys-172·Asp-383 and Lys-161·Glu-511, also contribute to this interface. N and C 
indicate the N- and C-terminal ends of the inhibitory helix, respectively.  
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Figure 3.11. Electron density maps of the inhibitory helix and RGS/DH domain 
interface regions. (A) A 2Fo-Fc map was rendered using Pymol and contoured to σ = 2.5. 
The inhibitory helix of the RGS-DH linker (red) contacts both the DH (green) and PH 
(orange) domains, as shown in Figure 3.10. (B) A simulated annealing omit map was 
generated with a model excluding the RGS-DH linker, shown in red sticks, and contoured to 
σ = 3.0. The average B-factor for the inhibitory helix (a.a. 158-178) was 47.2 Å2, as 
compared to 32.5 Å2 for the entire molecule. (C) The RGS and DH domains also share a 
substantial interface. A 2Fo-Fc map was contoured to σ = 2.5. 
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Figure 3.12.  Evolutionary analysis of the EhGα1/EhRGS-RhoGEF signaling pathway. 
Canonical RGS domains, illustrated by RGS4 (PDB id 1AGR), and rgRGS domains of 
mammalian RGS-RhoGEFs, represented by that of p115 (PDB id 3AB3), exhibit distinct 
folds. (A) The EhRGS-RhoGEF RGS domain structure (yellow) closely resembles RGS4 
(red), suggesting a canonical Gα/RGS domain interaction as exhibited by the RGS4/Gαi1 
complex. Canonical RGS domains engage primarily switches 1 and 2, while rgRGS domains 
interact with the effector interface of Gα12/13 (orange) family members, primarily through 
switch 2 and the α3 helix, although the N-terminal extension required for GAP activity also 
contacts the three switch regions and the all-helical domain (B). The EhGα1(G168S), 
EhRGS-RhoGEF(E39K), and EhRGS-RhoGEF(N83A) mutations can distinguish between 
the two modes of binding by selectively disrupting the canonical RGS domain binding site. 
Divergence of EhGα1 sequence from known mammalian subfamilies, together with the 
canonical nine-helix RGS domain of EhRGS-RhoGEF and its mode of EhGα1 interaction, 
suggest that the EhGα1/RGS-RhoGEF signaling axis arose by an evolutionary mechanism 
distinct from and functionally convergent with that of the mammalian Gα12/13/RGS-RhoGEF 
axis.  
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Figure 3.13. EhGα1 diverges from the Gα12/13 subfamily despite sharing a function in 
binding an RGS-RhoGEF protein. An unrooted dendrogram was constructed from a 
multiple sequence alignment of Gα subunits from Homo sapiens (H.s.), Drosophila 
melanogaster (D.m.), and Caenorhabditis elegans (C.e.). Other Gα12/13 subunits known to 
engage RGS-RhoGEF effectors cluster together, while EhGα1 exhibits low sequence 
similarity to each mammalian Gα subfamily. 
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Table 3.1. Rho family GTPase signaling and actin-associated genes differentially 
transcribed in E. histolytica trophozoites expressing EhGα1 or the dominant negative 
EhGα1S37C. 
 
Gene name AmoebaDB accession no. 
fold change upon  
EhGa1 
expression  
(p value) 
fold change upon 
EhGa1S37C 
expression  
(p value) 
Rho family signaling    
EhRGS-RhoGEF EHI_010670 2.2 (0.001)  
hypothetical (Rho GTPase activating) EHI_050670 2.2 (< 0.001)  
RhoGAP domain protein EHI_098030 2.0 (< 0.001)  
RhoGAP domain protein EHI_045100  -2.1 (< 0.001) 
RhoGAP domain protein EHI_055340  -1.7 (< 0.001) 
RhoGAP domain protein EHI_182930  1.9 (0.011) 
Rho guanine nucleotide exchange factor EHI_062800  -2.2 (0.013) 
Rho guanine nucleotide exchange factor EHI_100140  1.9 (0.003) 
Rho guanine nucleotide exchange factor EHI_131540  2.0 (< 0.001) 
Rho family GTPase EHI_029020  1.3 (0.001) 
Rho family GTPase EHI_129750  2.3 (< 0.001) 
    
actin-associated proteins    
hypothetical (profilin/allergen family) EHI_199670 2.0 (0.007)  
actin binding protein, filamin-like EHI_094030 -2.0 (0.004)  
actin EHI_008780  2.1 (< 0.001) 
actobindin EHI_039020  1.9 (< 0.001) 
calponin-like actin binding domain EHI_068450  2.6 (< 0.001) 
vinculin/alpha-catenin family EHI_083620  3.2 (< 0.001) 
actinin-like EHI_164430  2.1 (< 0.001) 
actinin-like EHI_164440  2.3 (< 0.001) 
actin binding, cofilin/tropomyosin 
family 
EHI_186840  6.0 (< 0.001) 
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Table 3.2.  Data collection and refinement statistics  
for selenomethionine EhRGS-RhoGEF. 
 
 EhRGS-RhoGEF 
PDB accession code 4GOU 
  
Data collection  
Space group C2 
Cell dimensions    
    a, b, c (Å) 86.1, 46.3, 142.6 
    α, β, γ  (°) 90, 104.2, 90 
 Peak 
Wavelength (Å) 0.97954 
Resolution (Å) 43.0 - 2.30 (2.32 - 2.30)* 
No. unique reflections 46,832 
Rmerge (%) 8.9 (58.4)** 
I / sI 18.5 (2.0) 
Completeness (%) 98.8 (86.4) 
Redundancy 4.3 (2.5) 
Wilson B-factor (Å2) 25.6 
  
Refinement  
Resolution (Å) 43.0 - 2.30 (2.35 - 2.30) 
No. reflections 46,587 (2639) 
Rwork / Rfree (%) 18.2 / 23.6 (26.5 / 32.0) 
No. atoms 4357 
    Protein 4363 
    Ligand/ion 0 
    Water 216 
B-factors (Å2)  
    Protein 32.5 
    Ligand/ion - 
    Water 32.5 
R.m.s deviations  
    Bond lengths (Å) 0.008 
    Bond angles (°) 1.080 
*Values in parentheses are for highest-resolution shell.  
**All data were collected from a single crystal. 
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CHAPTER 4 
UNIQUE STRUCTURAL AND NUCLEOTIDE EXCHANGE FEATURES OF THE 
Rho1 GTPase OF Entamoeba histolytica1 
 
4.1 OVERVIEW 
The single-celled human parasite Entamoeba histolytica possesses a dynamic actin 
cytoskeleton vital for its intestinal and systemic pathogenicity. The E. histolytica genome 
encodes several Rho family GTPases known to regulate cytoskeletal dynamics. EhRho1, the 
first family member identified, was reported to be insensitive to the Rho GTPase-specific C. 
botulinum C3 exoenzyme, raising the possibility that it may be a mis-classified Ras family 
member. Here, we report the crystal structures of EhRho1 in both active and inactive states. 
EhRho1 is activated by a conserved switch mechanism, but diverges from mammalian Rho 
GTPases in lacking a signature Rho insert helix. EhRho1 engages a homolog of mDia, 
EhFormin1, suggesting a role in mediating serum-stimulated actin reorganization and 
microtubule formation during mitosis. EhRho1, but not a constitutively active mutant, 
interacts with a newly-identified EhRhoGDI in a prenylation-dependent manner. 
Furthermore, constitutively active EhRho1 induces actin stress fiber formation in mammalian 
fibroblasts, thereby identifying it as a functional Rho family GTPase. EhRho1 exhibits a fast 
rate of nucleotide exchange relative to mammalian Rho GTPases due to a distinctive switch 
1 Bosch, D.E., Wittchen, E.S., Qiu, C., Burridge, K., and Siderovski, D.P. (2011) Unique structural and 
nucleotide exchange features of the Rho1 GTPase of Entamoeba histolytica. J. Biol. Chem. 286(45):39236-46. 
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one isoleucine residue reminiscent of the constitutively active F28L mutation in human 
Cdc42 which, for the latter protein, is sufficient for cellular transformation. Non-conserved, 
nucleotide-interacting residues within EhRho1, revealed by the crystal structure models, were 
observed to contribute a moderating influence on fast spontaneous nucleotide exchange. 
Collectively, these observations indicate that EhRho1 is a bona fide member of the Rho 
GTPase family, albeit with unique structural and functional aspects compared to mammalian 
Rho GTPases. 
 
4.2 INTRODUCTION 
The parasite Entamoeba histolytica is the causative agent of amoebiasis in humans, 
responsible for an estimated 50 million infections and 100,000 deaths per year worldwide 
[1]. Spread primarily by contaminated drinking water in its encysted form, E. histolytica 
infection is endemic among poor populations of developing countries, although outbreaks 
and infection among travelers occur frequently in the United States [2]. The water-borne 
pathogen can attach and invade intestinal mucosa to cause amoebic colitis, and can also enter 
the blood stream, leading to systemic amoebiasis characterized by liver, lung, and brain 
abscesses [3]. E. histolytica trophozoites are highly motile and undergo complex, dynamic 
cytoskeletal rearrangements [4]. Indeed, the cytoskeletal dynamics of E. histolytica are vital 
for many of its pathogenic processes, including chemotaxis and invasion, adhesion to 
intestinal epithelia, phagocytosis, and host cell killing [5]. 
 Rho family GTPases are small guanine nucleotide binding proteins of the Ras small 
G-protein superfamily [6] that produce multiple effects in cells when activated. The most 
prominent and immediate effect of Rho activation is actin cytoskeletal reorganization [7]. 
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Rho GTPases are molecular switches, with an active GTP-bound state and an inactive GDP-
bound conformation. Conformational shifts in response to nucleotide exchange are 
dominated by two conserved switch regions which contribute to nucleotide state-selective 
engagement of multiple Rho-interacting proteins [8]. Switch 1 contains a highly conserved 
phenylalanine that forms aromatic interactions with the nucleotide guanine ring [9]. Rho 
GTPases are regulated by the actions of guanine nucleotide exchange factors (GEFs), 
GTPase activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs) 
[10]. RhoGDIs preferentially bind inactive, GDP-bound Rho GTPases and are critical for 
shuttling them between cellular membranes [11]. Among the many effectors of activated 
human Rho GTPases is mDia, a formin protein that produces actin filaments by initiating 
nucleation and polymerization [12]. 
 The genome of E. histolytica encodes a family of small G-proteins with high 
sequence similarity to mammalian Rho GTPases [13, 14]. In fact, a remarkably large Rho 
family of at least 19 members is simultaneously expressed in E. histolytica trophozoites 
(Figure 4.1). Although studies are limited, certain E. histolytica Rho family GTPases have 
been shown to regulate its actin cytoskeletal dynamics, which are in turn linked to pathogenic 
processes. Overexpression of a constitutively active point mutant of the GTPase EhRacA in 
E. histolytica leads to altered phagocytic activity and surface receptor capping - a 
phenomenon vital for evasion of the host immune response [15]. Overexpression of EhRacG 
alters membrane turnover, uroid formation, and surface receptor capping [16]. Not 
surprisingly, Rho-activating GEFs have also emerged as critical players in E. histolytica 
pathogenesis [17, 18]. Similarly, E. histolytica possesses homologs to key Rho GTPase 
effectors, such as p21-activated kinase (PAK) and Diaphanous-like formins [19, 20]. 
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Although none of the formin family members have been shown to interact with Rho GTPases 
from E. histolytica, three of them (EhFormin1-3) contain Rho GTPase binding domains 
(GBDs), suggesting that they serve as a link between Rho GTPase activation and actin 
polymerization. Interestingly, overexpression of EhFormin1 in E. histolytica trophozoites 
revealed its co-localization with actin assemblies promoted by serum factors, association 
with microtubules during mitosis, and aberration of cell division [20]. 
 As the first identified [13] and highly expressed Rho GTPase family member in E. 
histolytica (Figure 4.1), EhRho1 serves as an exemplary small G-protein signaling molecule 
from E. histolytica. Protein sequence and biochemical analyses have suggested divergent 
guanine nucleotide binding motifs and a resistance to inhibitory ADP-ribosylation by 
Clostridium botulinum C3 exoenzyme, a hallmark of mammalian Rho GTPases [21]. Thus, 
Godbold et al. have suggested that EhRho1 may be a Ras-like GTPase rather than a true 
functional ortholog of mammalian Rho GTPases [21]. In the current study, we have resolved 
this functional categorization of EhRho1 via structural models of EhRho1 in two nucleotide 
states, obtained by X-ray diffraction crystallography. EhRho1 possesses both Rho- and Ras-
like structural features. While possessing a conserved structural mode of activation with 
mammalian G-proteins, multiple divergent residues in the nucleotide-binding pocket were 
seen to contribute to a fast basal exchange rate relative to mammalian Rho GTPases. EhRho1 
binds to EhFormin1 and to a novel EhRhoGDI in a nucleotide-dependent fashion. Finally, 
expression of constitutively active EhRho1 in mammalian cells induces stress fiber 
formation, implicating EhRho1 in the regulation of actin cytoskeletal dynamics in 
Entamoeba histolytica. 
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4.3 EXPERIMENTAL PROCEDURES 
4.3.1 Bioinformatic analysis of the E. histolytica Rho GTPase family 
 To identify Rho GTPase genes in the sequenced genome of E. histolytica [22] the amino 
acid sequence of EhRho1 (GenBank accession no. XP_654488.2) was used as a template for 
a sequence similarity search in the NCBI database with the BLAST algorithm [23]. Resultant 
candidate Rho proteins and associated transcripts were located in the publicly available 
microarray data [24]. An average expression unit value was calculated for each transcript 
using replicate data for unperturbed E. histolytica HM1:IMSS trophozoites. Rho genes that 
showed <3 expression units (considered to be not expressed based on a frequency 
distribution of all transcripts (Figure 4.1)) and protein sequences that were >80% identical to 
another E. histolytica Rho GTPase were excluded from further analysis to avoid inclusion of 
closely related isoforms and potential microarray probe cross-reactivity. The remaining 19 
Rho GTPase protein sequences were aligned with ClustalW2 [25] and a dendrogram 
generated with NJPlot [26]. Relative expression levels were assigned to each Rho GTPase 
transcript based upon a frequency distribution of all genes included on the microarray 
platform versus relative expression unit values (Figure 4.1). 
 
4.3.2 Protein expression and purification 
Open reading frames of EhRho1 lacking the C-terminal CAAX prenylation motif and its 
preceding polybasic region (amino acids 1-191), EhRacg, EhRhogdi (UniProt identifier 
O76754), and the EhFormin1 GBD-FH3 domains (amino acids 69-445) were separately 
amplified from E. histolytica genomic DNA (obtained from Dr. William Petri Jr., University 
of Virginia, Charlottesville, VA) by polymerase chain reaction (PCR) using Phusion 
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polymerase (New England BioLabs, Ipswich, MA) and primers from Invitrogen (EhRho1 (aa 
1-191) : sense, 5’- ATGCTTGCATTTTCTGATATGAAC-3’; antisense 5’-
CTAATTTGAGAAGATACAATC-3’; EhRacg: sense, 5’-ATGAGACCAGTGAAACTT 
GTC-3’; antisense, 5’-CTATTTAGCAGCTTTAGCAAGAAC-3’; EhRhogdi: sense, 5’-
ATGTCAGCAGCAGACATTGTTAAAAAC-3’; antisense, 5’-TTAATCCCAATCCTT 
GGC-3’; EhFormin1: sense, 5’-ATGCCACCTGAAGAAGTTG-3’; antisense, 5’-
CTAAGTGACTTGAAGAGATATTTGC-3’. PCR amplicons were resolved on, and 
extracted from, a 1% (w/v) agarose gel using the Qiagen Gel Extraction Kit. All three 
amplicons were subcloned using ligation-independent cloning [27] into a Novagen (San 
Diego, CA) pET vector-based prokaryotic expression construct (“pET-His LIC-C” or “pET-
GST LIC-C”) to form N-terminal tobacco etch virus (TEV) protease-cleavable, 
hexahistidine- or GST-tagged fusions. Point mutations to EhRho1 and Hs RHOA were made 
using PCR and the overlap extension method [28]. Clones of human RHOA and mouse 
mDia1 were a kind gift from Dr. John Sondek (University of North Carolina, Chapel Hill, 
NC).  
 For expression of hexahistidine-tagged EhRho1, EhRacG, Hs RhoA, mDia1 (a.a. 69-
450), and EhFormin1 and GST-tagged RhoGDI, BL21(DE3) E. coli were grown to an 
OD600nm of 0.8 at 37°C, followed by induction with 500 µM isopropyl-β-D-
thiogalactopyranoside (IPTG) for 14-16 hours at 20°C. Bacterial cells were pelleted by 
centrifugation and resuspended in N1 buffer composed of 50 mM Tris pH 7.5, 250 mM 
NaCl, 10 mM imidazole, 1 mM DTT, 5% (v/v) glycerol, and for Rho GTPases, 5 mM MgCl2 
and 50 µM GDP. Bacteria were lysed at 10,000 kPa using pressure homogenization with an 
Emulsiflex (Avestin; Ottawa, Canada). Cellular lysates containing hexahistidine-tagged 
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proteins were cleared with centrifugation at 100,000 x g for 60 minutes at 4°C, and the 
resulting supernatant was applied to a nickel-nitrilotriacetic acid (NTA) resin FPLC column 
(FF HisTrap crude; GE Healthcare, Piscataway, NJ), washed with N1 plus 30 mM imidazole 
before elution in N1 buffer with 300 mM imidazole. Lysates containing GST-tagged proteins 
were applied to a glutathione resin (FF GSTrap; GE Heathcare), washed with N1 buffer 
lacking imidazole, and eluted with imidazole-free N1 supplemented with 10 mM reduced 
glutathione. For GST-RhoGDI, His6-EhFormin1, and His6-mDia1, eluted protein was pooled 
and resolved using a calibrated size exclusion column (HiLoad 16/60 Superdex 200, GE 
Healthcare) in S200 buffer (50 mM HEPES pH 8.0, 250 mM NaCl, 2.5% (v/v) glycerol, and 
1 mM DTT). For the Rho GTPases, protein was pooled and dialyzed into imidazole-free N1 
overnight at 4°C in the presence of His6-tobacco etch virus (TEV) protease to cleave the N-
terminal affinity tag. The dialysate was then passed over a second NTA column to remove 
TEV protease and uncleaved protein. For exchange assays, Rho GTPases were resolved by 
size exclusion in Rho S200 buffer (50 mM Tris pH 8.0, 200 mM NaCl, 10 mM MgCl2, and 
5% (v/v) glycerol). For crystallization, EhRho1 was loaded with either GDP or GTPγS by 
incubation in EDTA-containing exchange buffer (50 mM Tris pH 7.5, 250 mM NaCl, 5 mM 
DTT, 15 mM EDTA, and 10-fold molar excess of either GDP or GTPγS) at room 
temperature for 45 minutes, followed by addition of excess nucleotide-stabilizing magnesium 
ion (50 mM MgCl2). Nucleotide-loaded EhRho1 was then resolved by size exclusion 
chromatography in crystallization buffer (50 mM Tris pH 8.0, 250 mM NaCl, 1 mM MgCl2, 
5 mM DTT, and either 50 µM GDP or 5 µM GTPγS). All proteins were concentrated to 0.5 – 
2 mM and snap frozen in a dry ice/ethanol bath for storage at -80°C. Protein concentration 
was determined by A280nm measurements upon denaturation in 8 M guanidine hydrochloride, 
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based on predicted extinction coefficients for each protein 
(http://us.expasy.org/tools/protparam.html). 
 
4.3.3 Crystallization of EhRho1·GDP and EhRho1·GTPγS and structure determination 
 Crystals of EhRho1 (residues 1-191) bound to GDP were obtained by vapor diffusion from 
hanging drops at 18°C. EhRho1·GDP at 15 mg/mL in crystallization buffer was mixed 1:1 
with (and equilibrated against) crystallization solution containing 1.5 M ammonium sulfate 
and 100 mM Tris pH 8.0. Rhomboidal crystals grew to ~200 x 100 x 100 µm over 5 days, 
exhibiting the symmetry of space group P212121 (a = 50.3 Å, b = 54.5 Å, c = 132.3 Å, α = β 
= γ = 90°) and containing two monomers in the asymmetric unit. For data collection at 100K, 
crystals were serially transferred for ~1 minute into crystallization solution supplemented 
with 25% (v/v) glycerol in 5% increments and plunged into liquid nitrogen. A native data set 
was collected at the SER-CAT 22-ID beamline at the Advanced Photon Source (Argonne 
National Laboratory). Data were processed using the HKL-2000 program [29]. The crystal 
structure model of human RhoA·GDP (PDB accession 1FTN [9]) was modified by removal 
of water, magnesium, and nucleotide and by trimming of side chains not conserved in 
EhRho1 using Chainsaw [30]. The resulting model was used as a molecular replacement 
search model in the program Phaser [31]. Refinement was carried out using phenix.refine 
[32] interspersed with manual revisions of the model using the program Coot [33]. 
Refinement consisted of conjugate-gradient minimization and calculation of individual 
anisotropic displacement and translation/libration/screw (TLS) parameters [34]. The current 
model contains two EhRho1 monomers bound to GDP and magnesium; residues at the N- 
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and C-termini (1-14 for both chains and 187-194 for chain A) could not be located in the 
electron density.  
 Crystals of EhRho1 bound to GTPγS were obtained by vapor diffusion from hanging 
drops at 18°C. EhRho1·GTPγS at 14 mg/mL in crystallization buffer was mixed 1:1 with 
(and equilibrated against) crystallization solution containing 25% PEG 4000, 150 mM 
ammonium acetate, and 100 mM sodium acetate pH 4.6. Rod crystals grew to ~200 x 75 x 50 
mm over 3 days and exhibited the symmetry of spacegroup P1 (a = 36.4 Å, b = 39.5 Å, c = 
63.6 Å, α = 81.8°, β = 80.8°, γ = 65.4°) with two monomers in the asymmetric unit. For data 
collection at 100K, crystals were serially transferred for ~30 seconds into crystallization 
solution supplemented with 30% saturated sucrose in 10% increments and plunged into 
liquid nitrogen. A native data set was collected at the SER-CAT 22-BM beamline at the 
Advanced Photon Source (Argonne National Laboratory). Data processing and refinement 
were carried out similarly to EhRho1·GDP, above. However, a molecular replacement 
solution was obtained using the crystal structure model of human RhoA bound to GTPγS 
(PDB accession 1A2B [35]) modified to exclude water, magnesium, nucleotide, and non-
conserved side chain atoms. The current model contains two EhRho1 monomers bound to 
GTPγS and magnesium; residues at the N- and C-termini (1-20 and 192-194 for chain A and 
1-20 and 189-194 for chain B) could not be located in the electron density. Despite low 
diffraction data completeness in the high resolution shells for EhRho1·GTPγS, strong 
electron density arose for GTPγS and missing side chains upon molecular replacement 
solution and no systematic defects were identified in the electron density map (see Figure 
4.2). To ensure model accuracy, the diffraction data were processed in parallel with a 2.5 Å 
resolution cutoff, producing a model with no observed differences from the high-resolution 
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inclusive data. However, inclusion of the less complete, high resolution data (2.5 – 1.8 Å) 
substantially increased the electron density quality.  For data collection and refinement 
statistics, see Table 4.1. All structural images were rendered with PyMOL (Schrödinger LLC, 
Portland, OR) unless otherwise indicated. 
 
4.3.4 Surface plasmon resonance (SPR) binding assays 
SPR-based measurements of protein-protein interactions were performed on a Biacore 3000 
(GE Healthcare). Approximately 8000 resonance units (RUs) of purified His6-EhFormin1 
and 10,000 RUs of His6-mDia1 GBD-FH3 domain tandem were separately immobilized on a 
nickel-charged NTA biosensor chip (GE Healthcare) using covalent capture coupling as 
previously described [36]. An irrelevant hexahistidine protein (Hs Gαi1) was loaded on an 
independent surface as a negative control. SPR experiments were performed in running 
buffer containing 50 mM HEPES pH 7.4, 150 mM NaCl, 0.05% NP-40 alternative 
(Calbiochem), 50 µM EDTA, 1 mM MgCl2, and 5 µM of either GDP or GTPγS. Thirty µL 
injections of increasing concentrations of GDP- or GTPγS-loaded EhRho1, EhRacG, and Hs 
RhoA were separately performed at 10 µL/min with a 300 second dissociation phase (using 
the KINJECT command). The surface was regenerated between Rho GTPase injections by 
injection of running buffer supplemented with 30 mM EDTA. To correct for non-specific 
binding and changes in the refractive index upon injection of samples, the observed 
sensorgram for the flow cell containing the irrelevant protein Hs Gαi1 was subtracted from all 
curves using BIAevaluation software v3.0 (GE Healthcare). Equilibrium binding analyses 
were conducted as previously described [37] using GraphPad Prism v5.0 to determine 
binding affinities. 
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4.3.5 GST-EhRhoGDI affinity co-precipitation 
 The full-length EhRho1 gene was synthesized following codon optimization for expression 
in mammalian cells (GeneArt, Invitrogen).  EhRho1 and mutants were subcloned with an HA 
epitope tag into pcDNA 3.1 and transfected into HEK293T cells using Lipofectamine 2000 
(Invitrogen), 1 µg of DNA per 6-well dish.  Cells expressing wild-type or mutant EhRho1 
were lysed in buffer containing 20 mM Tris pH 7.5, 100 mM NaCl, 1 mM MgCl2. 1% (v/v) 
NP-40, 0.25% (v/v) deoxycholate, and protease inhibitors. Soluble fractions of the cell 
lysates were incubated with 15 µg of either recombinant GST-RhoGDI or GST alone and 
glutathione agarose (Sigma) at 4°C overnight with gentle agitation.  Bound proteins were 
separated by centrifugation, washed 3 times with lysis buffer, and eluted with denaturing 
SDS-PAGE loading buffer. Proteins/lysates were separated by SDS-PAGE, transferred to 
nitrocellulose membranes, and subjected to western blotting with anti-HA as described 
previously [38]. Subsequently, membrane-bound proteins were stained with Ponceau S (Bio-
Rad). 
 
4.3.6 Fluorescent guanine nucleotide exchange assays 
The fluorescence of BODIPY FL GDP (Invitrogen) was monitored in real-time using a 
cuvette-based LS 55 spectrometer (Perkin Elmer, Waltham, MA) under thermostat control. 
Excitation and emission wavelengths were 502 ± 2.5 nm and 511 ± 2.5 nm, respectively. 
Exchange buffer alone (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 2 mM DTT, 5% 
(v/v) glycerol, 0.008% NP-40 alternative, and 75 nM BODIPY FL GDP) was monitored at 
15°C until a stable signal was achieved. At time zero, 400 nM Rho GTPase was added to the 
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cuvette with mixing. The increase in relative fluorescence of BODIPY FL GDP upon 
incorporation into the Rho GTPase nucleotide-binding pocket was monitored at 30 second 
intervals for 100 minutes. Since saturation exchange was not reached due to the 
characteristically slow release of GDP from Rho GTPases in the absence of guanine 
nucleotide exchange factor (GEF), 30 mM EDTA was added to the cuvette at the end of each 
time course, inducing rapid exchange; the fluorescence intensity after equilibration with 
excess EDTA was thus defined as 100% exchange. Each curve was fitted with an exponential 
association function to yield a rate constant, kobs, using GraphPad Prism v5.0. 
 
4.3.7 Actin stress fiber quantification 
Rat-2 fibroblasts were transfected with HA-tagged constitutively active human 
RhoA(G14V), EhRho1(Q78L), or empty vector control (pcDNA3.1) and plated onto 
fibronectin-coated coverslips (15 µg/mL) overnight. Transfection efficiency was 80-90%. 
Cells were fixed in 3.7% paraformaldehyde, and permeablized with 0.02% (v/v) Triton X-
100.  F-actin structures were stained with Texas Red phalloidin (Molecular Probes) and 
exogenously expressed Rho GTPases were visualized using anti-HA immunofluorescence. 
To quantify stress fibers, HA-positive cells were scored by a blinded observer for the 
presence or absence of stress fibers, with the criteria being: organized, thickened, parallel 
actin bundles throughout the majority of the cytoplasm. Results are plotted as percent cells 
positive for stress fiber phenotype, scoring ~200 cells from many fields in duplicate 
experiments.  Statistical significance was determined by Student’s t-test. 
 
162 
 
4.4 RESULTS 
4.4.1 Comparison of human and E. histolytica Ras superfamily GTPases 
EhRho1 (GenBank accession no. XP_654488.2) is most similar to RhoA (Uniprot P61586) 
among the human Ras superfamily of GTPases. Sequence identity of only 47% between 
these two proteins likely reflects unique features gained or lost across a relatively large 
evolutionary distance. A multiple sequence alignment of Rho and Ras family GTPases from 
E. histolytica and humans (Figure 4.3) identified unique and conserved residues in EhRho1.  
EhRho1 displays a conserved cysteine at position 35, which has been implicated as an 
important site for reactive oxygen and nitrogen species-mediated activation of human Rho 
GTPases [39]. Switch 2 is remarkably conserved from Entamoeba to humans, but switch 1 
diverges across species. Notably, EhRho1 displays an isoleucine at position 45 in place of the 
otherwise highly conserved, nucleotide-contacting phenylalanine. Mutation of the analogous 
residue in human Rho GTPases results in ~100-fold faster nucleotide exchange than wildtype 
in the absence of a GEF, resulting in constitutive activity [40]. In fact, the corresponding 
mutation in Hs Cdc42, F28L, can induce cellular transformation in fibroblasts [41]. This 
unique residue has led others to postulate that EhRho1 is constitutively active [21]. Two 
other putative nucleotide-contacting residues in EhRho1 differ from the Rho/Ras consensus, 
namely, Ser-166 and Val-167. These sequence features of EhRho1 taken together have 
suggested a unique mechanism of nucleotide exchange and thus activation [21]. To 
investigate the structural determinants of EhRho1 activation, we obtained high-resolution 
structural models of EhRho1 in two nucleotide states by X-ray diffraction crystallography. 
 
163 
 
4.4.2 Structures of EhRho1 in the active and inactive states 
Since Rho GTPases possess a conserved C-terminal prenylation site, the CaaX box, and an 
adjacent polybasic region that are not typically well-ordered in a crystalline state, we 
crystallized a truncated form of EhRho1 (residues 1-191) bound to a divalent magnesium ion 
and either GDP or the non-hydrolyzable GTP analog, GTPγS. Both forms of EhRho1 
produced well-diffracting crystals, with diffraction data extending to 1.95 Å and 1.80 Å 
resolution, respectively. Structural statistics of both complexes are listed in Table 4.1. Phases 
were resolved by molecular replacement using the crystal structure models of human RhoA 
bound to GDP [9] and GTPγS [35], respectively (PDB id 1FTN and 1A2B). 
 EhRho1 exhibits the highly conserved G-domain fold characteristic of Ras 
superfamily GTPases [10], consisting of a 6-stranded β-sheet surrounded by 5 α-helices. The 
core fold of EhRho1 is similar to that of both human RhoA (PDB 1A2B) and H-Ras (PDB 
5P21), with total Cα r.m.s.d. values of 1.1 Å and 2.0 Å, respectively. Superposition of the 
two EhRho1 conformations (Figure 4.4A) and a plot of Cα r.m.s.d per-residue between the 
EhRho1 structures (Figure 4.4B) highlights switch regions 1 and 2 as the most mobile areas 
associated with activation. The switch 1 loop is drawn closer to the nucleotide in the GTPγS-
bound form than when bound to GDP, and the N-terminal portion of switch 2 rearranges 
upon binding GTPγS due to polar contacts with the γ-phosphoryl group.  
 The switch regions of both monomers in the EhRho1·GDP structural model form 
minimal crystal contacts with neighboring molecules.  Only Glu-80 on switch 2 of chain A 
forms a polar contact with a neighboring molecule.  Chain B switch residues Tyr-49, Thr-55, 
and Tyr-81 also form hydrogen bonds with residues of another asymmetric unit.  Despite 
these differing crystal contacts, both EhRho1·GDP monomers display switch conformations 
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distinct from those of EhRho1·GTPγS, indicating that the observed switch conformation shift 
is not likely due to crystal packing. 
 The crystal structures of EhRho1 also revealed the absence of a signature Rho insert 
helix in the β5-α4 loop, a key feature conserved among all other known Rho family GTPases 
(Figure 4.4C) [9, 42]. Instead, the β5-α4 loop lacks uniform secondary structure, as seen in 
Ras family GTPases [43]. The insert helix is not vital for the interaction of human Rho 
GTPases with the majority of interacting partners [44, 45]. However it is required for some 
effector interactions, such as Cdc42-mediated activation of phospholipase D1 [46] and 
activation of NADPH oxidase by Rac [47]. The absence of an insert helix, in combination 
with its insensitivity to the Rho-specific Clostridium botulinum C3 exotoxin [21], led us to 
ask whether EhRho1 was actually a mis-classified Ras family GTPase. Accordingly, we 
looked for interaction of EhRho1 with E. histolytica homologs of classical effectors. 
 
4.4.3 EhRho1 interacts with an mDia homolog, EhFormin1 
The E. histolytica genome encodes a family of eight Formins [20]. EhFormins 1-3 contain a 
Rho GTPase binding domain (GBD) in tandem with a formin homology 3 (FH3) domain, 
homologous to mammalian mDia and Drosophila melanogaster Diaphanous [12]. 
EhFormin1, also known as EhDia, is known to regulate actin polymerization and cell cycle 
progress in E. histolytica trophozoites [20]. We cloned and purified the GBD-FH3 tandem of 
EhFormin1 (Figure 4.3B) and used surface plasmon resonance (SPR) to quantify binding to 
EhRho1 in each nucleotide state. EhFormin1 was observed to selectively bind EhRho1 (KD = 
1.7 ± 0.1 µM), but not the related GTPase EhRacG (Figure 4.5). The interaction was 
dependent on the nucleotide state of EhRho1 (Figure 4.5B), characteristic of a 
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GTPase/effector interaction.  The affinity of EhRho1·GTPγS/EhFormin1 was an order of 
magnitude lower than that observed for Hs RhoA·GppNHp/mDia1 (KD = 104 ± 37 nM) 
under identical conditions (Figure 4.5C, D).  However, this low µM affinity 
EhRho1/EhFormin1 interaction is likely relevant in a cellular context, given the observed 
stringent nucleotide state selectivity and previous evidence for colocalization of both proteins 
in the E. histolytica uropod [48]. We conclude that EhRho1 engages similar effectors to 
mammalian Rho family GTPases. 
 
4.4.4 EhRho1 interacts with a newly-identified RhoGDI 
Rho guanine dissociation inhibitors (GDIs) maintain a pool of soluble, inactive Rho GTPases 
by extracting prenylated GTPases from cellular membranes [11]. The E. histolytica genome 
encodes a single gene with a conserved RhoGDI domain, which we refer to as EhRhoGDI 
(UniProt identifier O76754).  We cloned and purified EhRhoGDI as a GST fusion and used 
the recombinant protein to co-precipitate EhRho1 expressed in HEK293T cells (Figure 4.6).  
Mammalian RhoGDIs contain a geranylgeranyl-binding pocket and favor binding to the 
inactive, GDP-bound conformation of Rho GTPases [11]. To examine the nucleotide state 
selectivity and Rho prenylation dependency of the EhRho1/EhRhoGDI interaction, we 
compared co-precipitation of a GTPase-deficient, constitutively active EhRho1 mutant 
(Q78L) and EhRho1 lacking the putatively-prenylated CaaX motif cysteine (C212S) to that 
of wildtype EhRho1.  While wild type EhRho1 was seen to robustly interact with GST-
EhRhoGDI in cellular lysates, the complex was disrupted by either EhRho1 constitutive 
activity or mutation of the putative prenylation site (Figure 4.6B). Consistent with a 
requirement for prenylation of EhRho1 to engage EhRhoGDI, we also did not observe 
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binding between GST-EhRhoGDI and C-terminally truncated EhRho1 produced 
recombinantly from E. coli (not shown). 
 
4.4.5 EhRho1 stimulates stress fiber formation in mammalian cells 
One of the most prominent and immediate effects of human RhoA activation in fibroblasts is 
the formation of filamentous actin bundles known as stress fibers [7].  To determine the 
behavior of EhRho1 in a cellular context, we expressed GTPase deficient, constitutively 
active EhRho1(Q78L) or constitutively active human RhoA in Rat-2 cells and examined 
stress fiber formation with phalloidin staining. Both constitutively active EhRho1 and Hs 
RhoA expression significantly induced stress fiber formation compared to mock-transfected 
Rat-2 cells (Figure 4.7).  Thus, EhRho1 modulates cellular actin structures, likely through 
signaling pathways similar to human RhoA. These findings, together with EhRho1 
interaction with the canonical effectors EhFormin1 and EhRhoGDI, imply that EhRho1 
functions as true Rho family member, despite its Ras-like lack of an insert helix (Figure 4.4) 
and insensitivity to the Rho-specific C3 exoenzyme [21]. 
 
4.4.6 Unique nucleotide interactions in EhRho1 
A structure-based multiple sequence alignment of EhRho1 with mammalian Rho GTPases 
(Figure 4.3A) revealed a potentially activating Ile-45 in the position occupied by a conserved 
phenylalanine in all other Rho GTPases (Phe-28 in Cdc42). Additionally, the non-conserved 
Ser-166 and Val-167 of EhRho1 replace residues of Rho GTPases that contact the guanine 
ring of GDP/GTP [9], suggesting a unique mechanism of nucleotide binding and exchange. 
The electron density map of the EhRho1·GDP complex shows clearly defined backbone and 
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side chains surrounding the bound nucleotide (Figure 4.8A), affording a detailed analysis of 
nucleotide contacts.  
 The aromatic side chain of Phe-30 of Hs RhoA makes π-orbital interactions with the 
guanine ring of GDP (Figure 4.8B) [49], and similar contacts are seen in Hs Cdc42 and Hs 
Rac [49, 50]. Mutation of this phenylalanine to leucine in each Rho family GTPase results in 
markedly faster basal nucleotide exchange [40] (Figure 4.9) and increased disorder in switch 
1, presumably allowing an easier exit route for GDP [49]. In contrast, switch 1 of 
EhRho1·GDP is well defined in the crystal structure with continuous, strong electron density 
(Figure 4.8A), despite substitution of a non-aromatic hydrophobic side chain at position 45. 
The “top” face of the GDP guanine ring forms Van der Waals interactions with the 
hydrophobic portion of Lys-133 in an identical fashion to Hs RhoA (Figure 4.8). Also 
conserved is a hydrogen bond network between Asp-135 and the 2-amino and 6-keto groups 
of the guanine ring. However, the residue triad in positions 165-167, Ser-Ser-Val of EhRho1, 
differs from the conserved Ser-Ala-Lys/Leu of other Rho GTPases (Figure 4.3A). Since the 
switch 1 phenylalanine side chain (typically available to form aromatic contacts with the 
“bottom” face of the guanine ring) is replaced by Ile-45 in EhRho1, we hypothesized that 
other non-conserved residues (Ser-166 and Val-167) may compensate to control the rate of 
spontaneous nucleotide exchange. Ser-166 is clearly defined in the electron density and does 
not engage the nucleotide through its side chain. However, an alternate Ser-166 rotamer 
could easily bring the non-conserved hydroxyl group within hydrogen bonding distance of 
the 6-keto or N7 position of the guanine ring, thus restraining the nucleotide. Similarly, the 
bulky hydrophobic side chain of Val-167 may serve to engage the guanine ring opposite Lys-
133 to stabilize nucleotide binding. To address these hypotheses, we sequentially mutated 
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these EhRho1 residues to the corresponding Hs RhoA side chains and tested their effects on 
guanine nucleotide exchange. 
 
4.4.7 Non-conserved residues in EhRho1 contribute to a restrained nucleotide exchange 
rate 
The intrinsic rate of nucleotide exchange on G-proteins can be monitored in real time by 
tracking the increase in fluorescence of a dye-labeled nucleotide upon binding into the 
nucleotide pocket (reviewed in [51]). The resulting binding curves yield kinetic information 
about the nucleotide exchange reaction, with the rate-limiting step being release of tightly 
bound nucleotide. We first examined the basal exchange rates of EhRho1 and HsRhoA to 
determine whether EhRho1 is constitutively active, given its isoleucine at position 45. 
EhRho1 was found to exchange nucleotide more quickly than Hs RhoA (and other human 
Rho GTPases [40]), with an ~4-fold higher kobs (Figure 4.9A). However, EhRho1’s rate of 
exchange is not comparable to the constitutively activating F30L Hs RhoA mutant, which 
exhibits an ~20-fold faster exchange than wildtype Hs RhoA and saturation within a few 
minutes. We reasoned that EhRho1 must have additional mode(s) of nucleotide retention, 
potentially through the non-conserved residues Ser-166 and Val-167 (Figure 4.8A), as 
previously described. Substitution of both residues for the analogous Hs RhoA residues 
(S116A/V167K) increased the exchange rate an additional ~2-fold over wildtype EhRho1, 
implicating these two residues as important for maintaining a controlled exchange rate 
despite the presence of Ile-45 on switch 1 (Figure 4.8A). However, the EhRho1 
S166A/V167K mutant still exchanged only ~8-fold faster than wildtype Hs RhoA, implying 
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other controlling mechanisms in EhRho1 that are not present in the extremely fast-
exchanging Hs RhoA F30L mutant [40]. 
 Finally, we asked whether the additional methyl group of isoleucine-45 relative to 
leucine might contribute to the controlled nucleotide exchange of EhRho1 compared to Hs 
RhoA F30L.  Mutation of Ile-45 to leucine increased the rate of exchange ~2-fold, 
comparable to the RhoA-like S166A/V167K double mutation (Figure 4.9B). Interestingly, 
insertion of a phenylalanine at this position (the conserved residue among other Rho 
GTPases) drastically dampened the fast EhRho1 exchange rate; EhRho1 I45F exhibited 
exchange indistinguishable from wildtype Hs RhoA (Figure 4.9B). In conclusion, Ile-45 of 
EhRho1 is sufficient to confer ~4-fold faster exchange over other known Rho GTPases, 
without resulting in an uncontrolled, constitutively active G-protein as is seen in Phe->Leu 
mutations of human Rho GTPases. 
 
4.5 DISCUSSION 
The genome of the single-cell protist E. histolytica encodes a strikingly large family of 
expressed Rho GTPases (19 members in E. histolytica vs. 20 in humans) (Figure 4.1), given 
the relative simplicity of a unicellular parasite compared to the diverse array of cell and 
tissue types in mammals. Mammalian Rho GTPases are known to have a complex 
choreography of spatio-temporal regulation of multiple family members within a single cell 
during such processes as cell migration (e.g. [52]). Amoeboid motility is also complex, 
though poorly understood, and requires membrane detachment from cytoskeletal components 
(blebbing) and rapid subsequent restructuring of actin [53]. In addition to motility, E. 
histolytica is dependent on a dynamic actin cytoskeleton for multiple pathogenic processes 
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such as attachment, destruction, and phagocytosis of host cells, chemotaxis, and shedding of 
host antibodies from the cell membrane [4, 54]. To begin to understand the role E. 
histolytica’s Rho family GTPases in regulating these processes via nucleotide cycling, we 
have now provided structural snapshots of a representative family member, EhRho1, yielding 
insights to its mechanisms of nucleotide-dependent activation and effector engagement. Like 
its mammalian homologs, EhRho1 exhibits a conformational change upon exchanging its 
bound GDP for a nucleotide bearing a third phosphoryl group, dominated by mobile two 
switch regions. Since the highly mobile N-terminal portion of switch 2 is uniformly 
conserved with the related EhRacG (and others), we hypothesize that switch 1 plays a 
dominant role in dictating nucleotide state-specific binding to EhRho1 effectors, such as 
EhFormin1. Surprisingly, EhRho1 lacks a signature Rho insert helix, conserved among 
mammalian Rho GTPases, resulting in a secondary structure pattern more closely akin to H-
Ras. Although EhRho1 has highest sequence similarity to Hs RhoA, we and others [21] 
questioned whether it might be mis-classified as a Rho GTPase. 
 Our present observations of nucleotide-state selective binding to EhFormin1 and 
EhRhoGDI, together with stress fiber induction in mammalian fibroblasts, indicate correct 
labeling of EhRho1 as a bona fide Rho GTPase. One may speculate that EhRho1, in lacking 
the characteristic Rho insert helix yet binding to classical Rho GTPase effectors, resembles 
an ancestral small G-protein family, and thereby represents an early split of the Rho GTPase 
subfamily from the greater Ras superfamily [6].  
 EhFormin1 localizes with actin filaments in E. histolytica trophozoites upon exposure 
to serum factors (19) and is co-enriched with EhRho1 in the uropod, suggesting roles for the 
EhRho1/EhFormin1 complex in amoebic motility and/or surface receptor capping [48]. 
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EhFormin1 also co-localizes with microtubules during mitosis, and its overexpression leads 
to delays in cell cycle progression [20]. It will be interesting to determine whether EhRho1 
mediates actin and/or microtubule dynamics in response to extracellular cues in E. histolytica 
trophozoites. Like its mammalian counterparts [10], EhRho1 might also exert control over 
cell division, either through EhFormin1 regulation of microtubule structures, or through other 
mechanisms such as transcriptional regulation.  
 Another unique feature of EhRho1 is its relatively fast rate of spontaneous nucleotide 
exchange in the absence of an exchange factor (GEF). Future experiments will determine 
whether exchange on EhRho1 is modulated by EhRhoGDI. The moderately fast, spontaneous 
exchange is mediated by three non-conserved residues surrounding the guanine moiety 
binding site. The switch 1 residue Ile-45, reminiscent of the constitutively active Hs Cdc42 
F28L mutant [41], is sufficient to endow EhRho1 with an exchange rate intermediate 
between a Rho-like phenylalanine substitution and a rapid exchanging leucine substitution. In 
addition, Ser-166 and Val-167 on the β6-α5 loop contribute to nucleotide binding stability to 
a greater extent than the analogous Ala-161 and Lys-162 in Hs RhoA. Together, these data 
suggest that EhRho1 has evolved a relatively high rate of basal activity through the loss of a 
highly conserved switch one phenylalanine residue. However, uncontrolled exchange and 
constitutive activity are avoided, in part through compensatory nucleotide-interacting 
residues. Interestingly, neither the I45L mutation nor the S166A/V167K double mutation 
recapitulated the uncontrolled exchange seen in the Hs RhoA F30L mutation [41]. In the 
crystal structures of EhRho1, the nucleotide binding pocket is nearly identical to that of Hs 
RhoA except for the residues highlighted in this study. We hypothesize that EhRho1 protein 
dynamics in solution, rather than amino acid sequence, may contribute to a more moderate 
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nucleotide exchange. NMR studies of Cdc42 have identified increased switch 1 mobility 
upon introduction of the F28L mutation [55]. Since the switch 1 region of EhRho1 is well 
ordered in the crystal structures, its conformational restrictions may contribute to relative 
nucleotide binding stability. 
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Figure 4.1. Identification of 19 expressed Rho family GTPases in E. histolytica. (A) 
Nineteen predicted Rho family GTPase open-reading frames encoded within the genome of 
E. histolytica were aligned to produce a dendrogram. Translations of mRNAs whose 
expression was not detected by microarrays were excluded. (B) A frequency distribution of 
relative expression units, derived from available microarray data on E. histolytica 
HM1:IMSS trophozoites [24] was used to determine the relative transcription levels of each 
Rho GTPase gene. (C) Named genes previously reported in the literature and 11 additional 
transcribed Rho GTPases are listed with NCBI accession numbers and their relative 
expression levels. 
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Figure 4.2. Electron density map derived from EhRho1·GTPγS diffraction data. (A) 
Diffraction data completeness was plotted against the high resolution limit of each shell. Data 
completeness is near 100% at lower resolutions, with a sharp decrease at ~2.5 Å. Data from 
2.5 to 1.80 Å were included in the refinement because in each shell, I/σI was greater than 2.5 
and Rsym was less than 0.28. Inclusion of the high-resolution data improved the electron 
density map (B) shown for the bound GTPγS and surrounding EhRho1 stick model. The map 
was contoured to σ = 2.3. 
175 
 
 
 
Figure 4.3. Sequence similarity among Rho and Ras family GTPases from Entamoeba 
histolytica and humans. (A) A multiple sequence alignment highlights conserved switch 
regions and nucleotide-interacting residues (closed circles) derived from the crystal structures 
of EhRho1 reported here. The characteristic Rho insert helix region is indicated in gray, and 
arrowheads mark residues mutated in this study. (B) Purified Rho GTPases and the tandem 
Rho GTPase binding (GBD) and formin homology 3 (FH3) domains of EhFormin1 (residues 
69-445) were resolved by SDS-PAGE and stained with Coomassie blue. EhFormin1 GBD-
FH3 co-purified with a likely C-terminally truncated form (asterisk). 
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Figure 4.4. The structural models of EhRho1 in two nucleotide states reveal a conserved 
mechanism of nucleotide-dependent activation with Rho- and Ras-like characteristics. 
(A) Models of the crystal structures of EhRho1 bound to magnesium and GDP (red) or the 
non-hydrolyzable GTP analog GTPγS (green) are superimposed. See Table 4.1 for 
crystallographic data collection and refinement statistics. GTPγS is modeled as blue sticks, 
and magnesium as a yellow sphere. The well conserved switch regions, shown in light 
shades, account for the majority of nucleotide state-dependent conformational shifts. EhRho1 
is seen to lack the signature Rho insert helix found on all members of the mammalian Rho 
GTPase family, represented by human RhoA (B), with the insert in yellow (PDB accession 
1A2B). Instead, EhRho1 shares a non-helical β5-α4 loop with Ras GTPases, represented by 
human H-Ras (C) (PDB accession 5P21). 
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Figure 4.5. EhRho1 interacts with EhFormin1, a homolog of the human Rho effector 
mDia. (A) The GBD-FH3 tandem of EhFormin1, also referred to as EhDia, was observed to 
bind EhRho1·GTPγS selectively (to the exclusion of EhRacG·GTPγS), as determined by 
surface plasmon resonance. (B) Injection of increasing amounts of GTPase over immobilized 
EhFormin1 revealed specific binding to the activated form of EhRho1 with low micromolar 
affinity.  (C, D)  The homologous interaction between Hs RhoA and mouse mDia1 GBD-
FH3 tandem was also highly nucleotide state-selective, with high nanomolar affinity. 
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Figure 4.6. EhRho1 interaction with EhRhoGDI is favored by the inactive conformation 
and prenylation at the CaaX motif. (A) EhRhoGDI was cloned from the E. histolytica 
genome and purified as a GST fusion from E. coli.  Purified GST-EhRhoGDI was resolved 
by SDS-PAGE and stained with Coomassie blue. (B) HA epitope-taged EhRho1 expressed in 
HEK293T cells co-precipitated with GST-RhoGDI immobilized on glutathione agarose, but 
not GST alone, as indicated by immunoblotting with anti-HA antibody. The 
EhRho1/EhRhoGDI interaction was disrupted by mutation of the key glutamine for GTP 
hydrolysis (Q78L), rendering EhRho1 constitutively active.  In addition, mutation of the 
CaaX motif cysteine that is geranylgeranylated in mammalian Rho GTPases (C212S in 
EhRho1) abolished binding to EhRhoGDI. 
180 
 
 
 
Figure 4.7. EhRho1 induces stress fiber formation in mammalian fibroblasts. Rat-2 
fibroblasts were transfected with either pcDNA3.1 (vector control), HA epitope-tagged 
constitutively active (CA) human RhoA(G14V) or EhRho1(Q78L). Following 24 hours 
plating on fibronectin-coated coverslips, the cells were fixed and stained with phalloidin and 
anti-HA antibody. Cells were scored for the presence of actin stress fibers by a blinded 
observer.  (A) Fibroblasts expressing either constitutively active Hs RhoA or EhRho1 had a 
significantly greater percentage of cells with actin stress fibers compared to vector control.  
Error bars represent S.E.M. for duplicate experiments and * indicates p<0.01 compared to 
vector control. (B) Representative phalloidin staining (upper panels) and anti-HA antibody 
immunofluorescence (lower panels) images indicate more prominent stress fibers in 
constitutively active Hs RhoA- and EhRho1-expressing cells compared to vector control.  
The scale bar represents 50 µm. 
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Figure 4.8. Unique guanine nucleotide binding pocket residues of EhRho1. (A) A stereo 
view of the nucleotide binding pocket from EhRho1·GDP illustrates a divergent set of 
residues interacting with the guanine ring of GDP (green) when compared to the 
corresponding region of human RhoA (B) (PDB accession 1FTN). Position 45 on switch 1 is 
occupied by an isoleucine (Ile-45) in EhRho1, corresponding to Phe-30 in Hs RhoA; the 
latter residue makes π-orbital interactions with the guanine ring of GDP [55]. The conserved 
triad of Ser-160, Ala-161, and Lys-162 in Hs RhoA is replaced by Ser-165, Ser-166, and 
Val-157 in EhRho1. The electron density map was contoured to σ = 3.0. 
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Figure 4.9. Non-conserved nucleotide binding pocket residues moderate an otherwise 
fast rate of nucleotide exchange on EhRho1. (A) Real-time measurement of Rho GTPase 
binding to fluorescent BODIPY-GDP demonstrated a ~4-fold higher spontaneous nucleotide 
exchange rate on EhRho1 compared to Hs RhoA, representative of the Rho family GTPases 
in mammals. The Hs RhoA F30L mutant exchanged nucleotide at a ~20-fold higher rate than 
wild type Hs RhoA. Substitution of the non-conserved guanine ring-interacting residues Ser-
166 and Val-167 of EhRho1 for the corresponding amino acids from Hs RhoA (Ala and Lys) 
results in a 2-fold higher rate of exchange compared to wildtype EhRho1, implicating these 
residues as important for limiting basal nucleotide exchange in wildtype EhRho1. (B) Ile-45 
in EhRho1 corresponds to the highly conserved Phe-30 of Hs RhoA, of which mutation to 
leucine results in very rapid exchange and constitutive activity [40]. Interestingly, the Hs 
RhoA-like substitution on EhRho1, Ile-45 to phenylalanine, produces a slow exchange rate, 
indistinguishable from wildtype Hs RhoA. Mutation of Ile-45 to leucine produces a 2-fold 
increase in the rate of exchange. (C) The average exchange rate constants, kobs, derived from 
exponential curve fitting were plotted with S.E.M. error bars for quadruplicate experiments.  
Asterisks indicate statistically significant differences from EhRho1 wildtype (*, p < 0.05; **, 
p<0.01). 
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Table 4.1. Data collection and refinement statistics for EhRho1 
 EhRho1·GDP EhRho1·GTPγS 
PDB accession code 3REF 3REG 
   
Data Collection   
Space group P212121 P1 
Unit cell: a, b, c (Å) 50.3, 54.5, 132.3 36.5, 39.5, 63.6 
                α, β, γ (°) 90, 90, 90 81.8, 80.8, 65.4 
Resolution (Å) 30.0 – 1.95 (1.98 – 1.95)a 40.0 – 1.80 (1.82 – 1.80) 
Rsym 0.047 (0.187) 0.043 (0.278) 
I/sI 21.9 (2.7) 16.1 (2.8) 
Unique reflections 27,267 (633) 23,929 (435) 
Completeness (%) 99.6 (99.4) 81.6 (45.9) b 
Redundancy 2.5 (1.7) 2.0 (1.4) 
Wilson B-factor (Å2) 23.0 21.6 
   
Refinement   
Resolution (Å) 28.3 – 1.95 (2.01 - 1.95) 33.0 – 1.80 (1.87 – 1.80) 
No. of reflections (work/free) 27,160/1366 (2660/123) 23,884/1214 (1558/86) 
Cut-off (s) 0.12 0 
Rwork / Rfree (%) 15.7 / 19.7 (19.0 / 25.8) 17.2 / 22.2 (21.5 / 29.1) 
No. of atoms   
   Protein 2468 2658 
   GDP 56 64 
   Ions 17 2 
   Water 213 229 
B-factor (Å2)   
   Protein 33.8 31.4 
   GDP 20.4 25.4 
   Ions 60.3 29.2 
   Water 36.4 38.8 
R.m.s. deviations   
   Bond Lengths (Å) 0.009 0.009 
   Bond Angles (°) 1.26 1.20 
Ramachandran   
   Favored (%) 95.7 98.5 
   Generally Allowed (%) 4.3 1.5 
   Disallowed (%) 0 0 
Missing residues A: 1-14, 188-194 
B: 1-14 
A: 1-20, 192-194 
B: 1-20, 189-194 
aValues in parentheses represent the highest resolution shell 
Diffraction data were generated from single crystals of EhRho1 in each nucleotide state.  
bDespite 81.6% completeness of the EhRho1·GTPγS data set, the resulting electron density 
was of high quality without systematic deficits (see Figure 4.2). 
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CHAPTER 5 
Entamoeba histolytica Rho1 REGULATES ACTIN POLYMERIZATION  
THROUGH A DIVERGENT, DIAPHANOUS-RELATED FORMIN1 
 
5.1 OVERVIEW 
Entamoeba histolytica requires a dynamic actin cytoskeleton for intestinal and systemic 
pathogenicity. Diaphanous-related formins represent an important family of actin regulators 
that are activated by Rho GTPases. The E. histolytica genome encodes a large family of Rho 
GTPases and three diaphanous-related formins, of which EhFormin1 is known to regulate 
mitosis and cytokinesis in trophozoites. We demonstrate that EhFormin1 modulates actin 
polymerization through its formin homology 2 (FH2) domain. Despite a highly divergent 
diaphanous autoinhibitory domain, EhFormin1 is autoinhibited by an N- and C-terminal 
intramolecular interaction, but activated upon binding of EhRho1 to the N-terminal domain 
tandem. A crystal structure of the EhRho1·GTPγS/EhFormin1 complex illustrates an 
EhFormin1 conformation that diverges from mammalian mDia1 and lacks a secondary 
interaction with a Rho insert helix. The structural model also highlights residues required for 
specific recognition of the EhRho1 GTPase and suggests that the molecular mechanisms of 
EhFormin1 autoinhibition and activation differ from mammalian homologs. 
 
1 Bosch, D.E., Yang, B., and Siderovski, D.P. (2012) Entamoeba histolytica Rho1 regulates actin 
polymerization through a divergent, diaphanous-related formin. Biochemistry. 51(44):8791-801. 
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5.2 INTRODUCTION 
Entamoeba histolytica is the causative agent of amoebic colitis and systemic amoebiasis [1]. 
Infection by the parasite is spread endemically among poor populations of developing 
countries, although outbreaks among travelers and susceptible populations occur in the 
United States [1]. Water-borne E. histolytica cysts cycle to the trophozoite form in the human 
host, in some cases leading to destruction of the intestinal mucosa (amoebic colitis). If 
untreated, trophozoites may enter the blood stream, leading to systemic amoebiasis 
characterized by liver, lung, and brain abscesses [2]. Many cellular processes critical to E. 
histolytica pathogenesis, such as chemotaxis, adherence to intestinal epithelium, cell killing, 
phagocytosis, and penetration of the mucosa are dependent on a highly dynamic actin 
cytoskeleton [3-5]. E. histolytica expresses a relatively large number of Rho family small 
GTPases [6, 7], conserved signaling molecules that are vital to coordination of actin 
cytoskeletal rearrangements [8].  Rho GTPases undergo a conformational change dominated 
by switch regions upon exchange of GTP for GDP, allowing engagement of specific 
downstream effectors [9]. Overexpression of constitutively active versions of the Rho family 
GTPases EhRacA or EhRacG in E. histolytica trophozoites impairs pathogenic processes 
such as phagocytosis and surface receptor capping [10, 11]. However, signaling mechanisms 
by which the actin cytoskeleton of E. histolytica is regulated have not been elucidated in 
molecular detail. 
 Formins constitute a major class of proteins that directly regulate actin filament 
formation and thus cellular morphology, adhesion, and motility [12]. Formins promote 
nucleation and polymerization of unbranched actin filaments [13]. The highly conserved 
formin homology 2 domain (FH2) forms a head-to-tail dimer that binds to the barbed ends of 
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actin filaments, catalyzing assembly through a processive capping mechanism [12, 14, 15]. 
The FH2 domain is commonly preceded by an unstructured, proline-rich formin homology 1 
domain (FH1) that engages profilin/actin complexes, thus recruiting G-actin monomers for 
incorporation into a growing filament [12]. Members of the Diaphanous-related formin 
(DRF) subfamily also possess an N-terminal Rho GTPase binding domain (GBD) and a 
formin homology 3 domain (FH3) that, in turn, is composed of an Armadillo repeat-
containing Diaphanous inhibitory domain (DID) and a dimerization domain [13]. C-terminal 
to the FH2 domain of DRFs is a Diaphanous autoinhibitory domain (DAD) that forms 
intramolecular interactions with the DID, maintaining the formin in an inactive state, as best 
characterized structurally for the DRF mDia1 [16, 17]. This autoinhibited conformation is 
released upon binding of specific Rho family GTPases to the GBD-FH3 domain tandem, 
likely due to active DAD displacement from its DID binding site by Rho-induced contingent 
folding of the GBD and by the Rho GTPase itself [18, 19]. Although mDia1 primarily 
engages one of its activating GTPases, RhoC, through the switch regions, the last Armadillo 
repeat of the DID also weakly contacts the signature Rho insert helix of RhoC [20]. Mutation 
of residues at this secondary interface leads to reduced RhoC/mDia1 affinity, but it is unclear 
whether the interaction is important for formin activation per se [14]. 
 E. histolytica possesses a family of eight formins, among which EhFormin1-3 are 
Diaphanous-related [21]. EhFormin1 and -2 are expressed in trophozoites and associated 
with pseudopodia, pinocytic and phagocytic vesicles, and F-actin in response to serum. Both 
formins are also co-localized with the microtubular assembly during mitosis [21]. 
Overexpression of EhFormin1 increases the number of binucleated cells and nuclear DNA 
content, suggesting roles for EhFormin1 in mitosis and cytokinesis [21]. A recent proteomic 
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characterization of E. histolytica cysts indicated that EhFormin1 is expressed during both the 
encysted and trophozoite life cycle stages [22]. We recently showed [7] that the GBD-FH3 
domain tandem of EhFormin1 binds EhRho1 in a nucleotide state-dependent fashion, which 
is typical of Rho GTPase/effector interactions. Furthermore, expression of constitutively 
active EhRho1 in fibroblasts induced stress fiber formation [7], suggesting that EhRho1 
might regulate actin filament formation in E. histolytica trophozoites through EhFormin1 or 
other effectors. Crystal structures of EhRho1 in different nucleotide states highlighted a lack 
of the signature Rho insert helix [7], suggesting that the EhRho1/EhFormin1 interaction 
might differ from that of RhoC/mDia1 [20]. 
 In the current study, we demonstrate that EhFormin1 regulates actin polymerization 
through its FH2 domain. Despite considerable sequence divergence of the DAD motif and 
the DID motif surface expected to bind the DAD, EhFormin1 is autoinhibited by interaction 
between its N- and C-terminal domains. As in the case of mDia1, highly selective binding of 
EhRho1 to the GBD-FH3 tandem is sufficient to activate EhFormin1. Finally, a crystal 
structure of the EhRho1·GTPγS/EhFormin1 complex reveals a primary interface between 
EhRho1 and the EhFormin1 GBD with similarities to that of RhoC/mDia1. However, the 
absence of a Rho insert helix within EhRho1 and a large conformational difference in the 
DID of EhFormin1 compared to mDia1 illustrate the lack of a secondary EhRho1/EhFormin1 
binding site, in contrast with mammalian homologs. 
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5.3 EXPERIMENTAL PROCEDURES 
5.3.1 Protein purification 
EhRho1, EhRacC, EhRacD, and EhRacD were cloned from E. histolytica genomic DNA by 
PCR amplification as hexahistidine-tagged open-reading frame fusions, expressed in 
BL21(DE3) E. coli, purified by nickel affinity and gel filtration chromatography, and loaded 
with GTPγS as described previously for EhRho1 [7].  EhFormin1 (UniProt C4M622) was 
cloned from genomic DNA, and fragments were PCR amplified and subcloned with a 
tobacco etch virus (TEV) protease-cleavable hexahistidine tag using ligation independent 
cloning [23]. Mutagenesis was performed using the two PCR method [24].  All EhFormin1 
fragments were expressed in B834 E. coli induced with 500 µM isopropyl-β-D-
thiogalactopyranoside (IPTG) for 14-16 hours at 20°C. For crystallization of the GBD-FH3 
domain tandem, a selenium-containing derivative was produced by induction in minimal 
media containing selenomethioine (Molecular Dimensions, Apopka, FL). Bacterial cells were 
pelleted by centrifugation and resuspended in N1 buffer composed of 50 mM Tris pH 7.5, 
250 mM NaCl, 10 mM imidazole, 1 mM DTT, and 5% (v/v) glycerol. Bacteria were lysed 
using pressure homogenization with an Emulsiflex (Avestin; Ottawa, Canada). Cellular 
lysates were cleared with centrifugation at 100,000 x g for 60 minutes at 4°C, and the 
resulting supernatant was applied to a nickel-nitrilotriacetic acid (NTA) resin FPLC column 
(FF HisTrap crude; GE Healthcare, Piscataway, NJ), washed with N1 buffer plus 20 mM 
imidazole before elution in N1 buffer with 300 mM imidazole. EhFormin1 GBD-FH3 
tandem selenomethioine protein was pooled and dialyzed overnight in imidazole-free N1 
buffer with His6-TEV protease to cleave the N-terminal affinity tag. The dialysate was then 
passed over a second NTA column to remove TEV protease and uncleaved protein. All 
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EhFormin1 fragments were resolved using a calibrated size exclusion column (HiLoad 16/60 
Superdex 200, GE Healthcare) in S200 buffer (50 mM HEPES pH 8.0, 150 mM NaCl, and 5 
mM DTT). All proteins were concentrated to 0.5 - 2 mM and snap frozen in a dry ice/ethanol 
bath for storage at -80°C.  
 Actin for in vitro polymerization assays was purified from rabbit skeletal muscle 
acetone powder as described previously [25], and further purified with gel filtration 
chromatography. The actin was polymerized and conjugated with pyrene as described 
previously [26]. Following a final gel filtration step, the pyrene-actin was stored at 2 mg/mL 
and 4°C in G buffer (2 mM Tris pH 8.0, 0.2 mM CaCl2, 0.5 mM ATP, and 5 mM DTT). 
Protein concentration was determined by A280nm measurements upon denaturation in 8 M 
guanidine hydrochloride, using predicted extinction coefficients for each protein 
(http://us.expasy.org/tools/protparam.html). 
 
5.3.2 Actin co-sedimentation 
Rabbit skeletal muscle actin for co-sedimentation assays was purchased from Cytoskeleton, 
Inc. (Denver, CO). EhFormin1 FH2 domain and F-actin co-sedimentation assays were 
conducted as previously described for talin [27]. Briefly, actin was diluted to 0.4 mg/mL in 
buffer containing 5 mM Tris pH 8.0, 0.2 mM CaCl2, 0.2 mM ATP, and 0.5 mM DTT and 
polymerized by addition of 50 mM KCl and 2 mM MgCl2, followed by incubation at room 
temperature for 1 hr. EhFormin1 fragments were incubated alone or with a 2:1 molar excess 
of polymerized actin in binding buffer (10 mM Tris pH 7.0, 1 mM ATP, 0.2 mM DTT, 1 mM 
EGTA, 0.1 mM CaCl2, and 2 mM MgCl2) for 1 hour at room temperature. Samples were 
centrifuged at 100,000 x g and 20°C for 15 minutes. Proteins in the supernatant and pellet 
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fractions of each experiment were resolved by SDS-PAGE and stained with Coomassie 
Brilliant Blue. 
 
5.3.3 Actin polymerization in vitro 
Monomeric pyrene-actin (~20% pyrene labeled, ~80% unlabeled) was diluted to 40 µM in 
buffer containing 25 µM Tris pH 7.4 and 5 mM DTT. 25 µL of diluted pyrene-actin (10 µM 
final concentration) and various amounts of EhFormin1 fragments and/or EhRho1 were 
brought to a volume of 95 µL in S200 buffer (50 mM HEPES pH 8.0, 150 mM NaCl, and 5 
mM DTT). Buffer conditions were held constant in all comparison experiments, since ionic 
strength and pH are known to influence actin polymerization kinetics [28]. Fluorescence of 
the pyrene moiety was monitored throughout the experiment at 30-second intervals using a 
FluoroLog modular spectrofluorometer (Horiba, Ann Arbor, MI) with excitation and 
emission wavelengths of 365 nm and 407 nm, respectively. Following establishment of a 
stable baseline fluorescence (~5 minutes), polymerization was initiated by addition of 5 µL 
polymerization buffer (1 mM Tris pH 7.4, 500 mM KCl, 20 mM MgCl2, 2 mM ATP, and 5 
mM DTT).  Polymerization was allowed to proceed for at least 1 hour.  The relative rate of 
polymerization was estimated by measuring the slope (fluorescence units/second) of the actin 
polymerization curve at 50% of the maximal fluorescent signal, as previously described [28].  
All slope measurements were averaged across at least 3 replicate experiments and statistical 
significance determined by Student’s t-test. 
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5.3.4 Surface plasmon resonance  
SPR-based measurements of protein-protein interactions were performed on the Biacore 
3000 of UNC’s Center for Structural Biology (GE Healthcare), as described previously [7].  
Approximately 10,000 resonance units (RUs) of purified His6-EhFormin1 GBD-FH3 tandem 
and 5,000 RUs of His6-EhFormin1 fusion were separately immobilized on a nickel-NTA 
biosensor chip (GE Healthcare) using covalent capture coupling as previously described [29]. 
An empty surface served as a negative control. Experiments were performed in running 
buffer containing 50 mM HEPES pH 7.4, 150 mM NaCl, 0.05% NP-40 alternative 
(Calbiochem), 50 µM EDTA, and 1 mM MgCl2.  For assessment of kinetic binding 
properties, 3 injections of 5 µM EhRho1·GTPγS were performed at 10 µL/min with a 300 
second dissociation phase. kobs was obtained by fitting the average of three injections with a 
single phase exponential association function using GraphPad Prism v5.0. Similarly, koff was 
obtained by fitting the average data immediately following the injections with a single phase 
exponential dissociation function.  Since kobs is dependent on the concentration of analyte, kon 
was derived by kon = (kobs - koff) / (analyte concentration). An affinity constant was derived 
from the kinetic data by KD = koff / kon. For equilibrium binding analyses, multiple injections 
were performed with increasing concentrations of GTPγS-loaded EhRho1, EhRacC, 
EhRacD, and EhRacG, and an affinity constant derived as described previously [7]. 
 
5.3.5 Crystallization and structure determination 
A complex of EhRho1·GTPγS and the selenomethionine derivative of the EhFormin1 GBD-
FH3 tandem (a.a. 69-418) was assembled by mixing the two proteins at a 1:1 molar ratio to a 
total concentration of 15 mg/mL in crystallization buffer (50 mM Tris pH 8.0, 250 mM NaCl, 
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2.5% (v/v) glycerol, 5 mM DTT, 50 µM GTPγS, and 1 mM MgCl2) and incubation for 30 
minutes at room temperature. Crystals of EhRho1·GTPγS / EhFormin1 were obtained by 
vapor diffusion from hanging drops at 18°C. The protein solution was mixed 1:1 with and 
equilibrated against crystallization solution containing 18% PEG 3350, 100 mM Tris pH 8.5, 
and 200 mM MgCl2. Clusters of six hexagonal rod crystals grew to ~200 x 100 x 100 µm 
over 3 days, but diffraction was limited to >3 Å resolution. Crystal clusters were used to 
microseed similar crystallization experiments using the method described previously [30]. 
Microseeded experiments yielded single hexagonal rod crystals (~300 x 150 x 150 µm) over 
5 days, exhibiting the symmetry of space group P61 (a = b = 138.6 Å, c = 57.8 Å, α = β = 
90°, γ = 120°) and containing one EhRho1/EhFormin1 dimer in the asymmetric unit. For data 
collection at 100K, crystals were serially transferred for ~1 minute into crystallization 
solution supplemented with 30% (v/v) glycerol in 10% increments and plunged into liquid 
nitrogen. Single wavelength (0.9795 Å) anomalous diffraction data were collected at the 
GM/CA-CAT 23-ID-B beamline at the Advanced Photon Source (Argonne National 
Laboratory). Data were processed using the HKL-2000 program [31]. Heavy atom searching, 
experimental phasing, and automated model building were performed with Phenix AutoSol 
[32]. Heavy atom searching identified 13 of 13 possible sites, and refinement yielded an 
estimated Bayes correlation coefficient of 51 to 2.6 Å resolution. After density modification, 
the estimated Bayes correlation coefficient increased to 58. ~75% of the model was 
constructed automatically, and the remaining portion was built manually throughout the 
refinement. The current model (Table 5.1) contains a single EhRho1/EhFormin1 dimer with 
EhRho1 bound to GTPγS and magnesium. Refinement was carried out against peak 
anomalous data with phenix.refine [32], keeping Bijvoet pairs separate, interspersed with 
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manual model revisions using the program Coot [33]. Refinement consisted of conjugate-
gradient minimization and calculation of individual atomic displacement and 
translation/libration/screw (TLS) parameters [34]. Residues 1-20 and 185-186 of EhRho1 
and residues 69-72 and 378-418 of EhFormin1 could not be located in the electron density. 
The model exhibits excellent geometry as determined by MolProbity [35]. A Ramachandran 
analysis of protein residue backbone angles identified 93% favored, 7% allowed, and 0% 
disallowed. Coordinates and structure factors are deposited in the RCSB Protein Data Bank 
(id 4DVG). 
 
5.4 RESULTS 
5.4.1 E. histolytica Formin1 modulates actin filament formation 
The Diaphanous-related formins catalyze actin polymerization through the FH2 domain [12]. 
To examine the potential interaction of EhFormin1 with actin, two FH2 domain-containing 
fragments of this protein were generated and expressed from E. coli:  FH2-DAD (a.a. 731-
1182) and FH2 (731-1127) (see Figure 5.1). To determine whether the EhFormin1 FH2 
domain interacts with actin, co-sedimentation assays were performed [27] using rabbit 
skeletal muscle-derived filamentous actin. The EhFormin1 fragments FH2-DAD and FH2 
were highly soluble alone, but both co-sedimented with polymerized actin (Figure 5.2A), 
suggesting a direct actin/FH2 domain interaction independent of the putative DAD motif. 
Mutation of a conserved surface lysine (K964, Figure 5.3) required for actin binding by other 
formin FH2 domains [36] abolished actin co-sedimentation, suggesting a conserved mode of 
FH2 domain/actin interaction (Figure 5.2A). To determine whether the EhFormin1/actin 
interaction altered actin polymerization kinetics, in vitro polymerization assays were 
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performed with pyrene fluorophore-labeled actin (~20% labeled). The FH2 and FH2-DAD 
fragments each decelerated actin polymerization in a concentration-dependent fashion 
(Figure 5.2B, C), as observed by the slope of the actin polymerization curve [28]. Some 
isolated FH2 domains, such as that of Cdc12 in fission yeast, slow overall actin 
polymerization in vitro despite a positive effect on actin filament formation in a cellular 
context [37]. Like Cdc12, the FH2 domain of EhFormin1 may cap actin filament barbed ends 
and require an FH1 domain-associated profilin to accelerate polymerization [38]. However, 
no FH1 domain-containing EhFormin1 fragments could be obtained as a soluble recombinant 
protein from E. coli, precluding a direct test of this hypothesis. Relatively high 
concentrations of all EhFormin1 fragments were required to significantly alter actin 
polymerization kinetics, likely reflecting a low affinity EhFormin1/actin interaction. 
Alignment of the EhFormin1 FH2 domain sequence with Diaphanous-related formins from 
other species [36] (28% identity and 48% similarity to yeast Bni1) indicates only moderate 
conservation of residues known to participate in the actin interaction (Figure 5.3). Similarly, 
the E. histolytica actin sequence differs significantly from rabbit skeletal muscle actin at 
FH2-domain interaction sites (not shown), suggesting that high EhFormin1 fragment 
concentrations may be required to overcome cross-species sequence and/or structural 
divergence. 
 
5.4.2 EhFormin1 is autoinhibited by N- and C-terminal interactions 
Other Diaphanous-related formins are maintained in an inactive conformation by interactions 
between the Diaphanous autoinhibitory domain (DAD motif) and a surface of the Armadillo 
repeat portion of the FH3 domain, also called the Diaphanous inhibitory domain (DID) [16, 
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17]. Inspection of the C-terminus of EhFormin1 revealed considerable sequence divergence 
from the core DAD motif conserved among other known formins (MDxLLExL) (Figure 
5.4C).  Accordingly, we wondered whether the DID/DAD autoinhibitory interaction would 
be conserved in the case of EhFormin1. Surprisingly, the EhFormin1 FH2-DAD long 
fragment was seen to interact with the N-terminal GBD-FH3 domain tandem, as determined 
by surface plasmon resonance (Figure 5.4A). This intramolecular interaction required the 
divergent putative DAD motif, since the FH2 domain alone did not bind the GBD-FH3 
domain tandem (Figure 5.4A,B). To determine the effects of the GBD-FH3 domain 
interaction on FH2 domain-catalyzed actin filament formation, in vitro polymerization assays 
were conducted in the presence or absence of a molar excess of GBD-FH3 tandem protein.  
Addition of the GBD-FH3 tandem selectively affected the DAD motif-containing construct, 
returning the rate of actin polymerization in its presence to one indistinguishable from actin 
alone (Figure 5.4D).  These results suggest that the C-terminus of EhFormin1 forms a DAD 
motif-dependent interaction with the N-terminal GBD-FH3 domain region that prevents the 
modulation of actin polymerization rate by the FH2 domain. 
 
5.4.3 Interaction of the EhFormin1 GBD-FH3 domain tandem with EhRho1 reverses 
autoinhibition of the FH2 domain 
In previous work [7], we demonstrated that EhRho1 binds the GBD-FH3 domain tandem of 
EhFormin1 (a.a. 69-445) selectively in its GTPγS-bound, activated conformation. Since some 
minor degradation of that particular GBD-FH3 fragment was reported during expression and 
purification (e.g., see Fig. 1B of [7]), we generated multiple alternative constructs containing 
the GBD-FH3 region, finding that amino acids 69-418 of EhFormin1 were highly stable as a 
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recombinant protein fragment. The residues removed from this smaller fragment (i.e., a.a. 
419-445) correspond to the dimerization domain of mDia1 [20]. The single-celled E. 
histolytica parasite expresses ~20 Rho family GTPases, raising the possibility of highly 
specific interactions between Rho GTPases and their signaling effectors. The EhFormin1 
GBD-FH3 domain tandem (a.a. 69-418) was observed to interact selectively with EhRho1 to 
the exclusion of three other Rho GTPases tested (Figure 5.5A). 
 Given apparent endoproteolytic sensitivity of its unstructured, proline-rich FH1 
domain, recombinant full length (and thus autoinhibited) EhFormin1 could not be produced 
and purified. To circumvent this problem, we produced a construct (hereafter referred to as 
“EhFormin1 fusion”) consisting of the N-terminal GBD-FH3 domain tandem and the C-
terminal FH2-DAD fragment, connected by a 40-residue linker to simulate the presumably 
flexible FH1 domain (see Figure 5.1). While either the EhFormin1 fusion or EhRho1·GTPγS 
alone had no measurable effect on in vitro actin polymerization, the EhFormin1 
fusion/EhRho1·GTPγS complex was observed to inhibit actin filament formation (Figure 
5.5B) to a similar degree as the corresponding FH2-DAD construct (Figure 5.2C).  This 
finding suggests that EhRho1 selectively engages the N-terminus of EhFormin1, freeing the 
C-terminal FH2 domain to regulate actin filament formation. Using SPR, EhRho1·GTPγS 
was shown to bind this EhFormin1 fusion protein with ~3 µM affinity (Figure 5.6). 
 
5.4.4 Structural features of the EhRho1/EhFormin1 complex 
The sequence of the GBD-FH3 domain tandem within EhFormin1 is highly divergent 
compared to other known Diaphanous-related formins, with mDia1 being the closest 
mammalian homolog (Figure 5.7).  EhRho1 also differs significantly from mammalian Rho 
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GTPases and other E. histolytica Rho GTPases (Figure 5.7), particularly given its lack of a 
signature Rho insert helix [7].  We sought a crystal structure of EhRho1 bound to EhFormin1 
to allow structure-based comparison with the mammalian RhoC/mDia1 complex and to 
elucidate the determinants of a highly selective Rho/effector interaction. Well-diffracting 
crystals of EhRho·GTPγS/EhFormin1 GBD-FH3 domain tandem were obtained with aid of 
microseeding (see Experimental Procedures).  Molecular replacement attempts with 
structural models of either EhRho1 (PDB id 3REF) or the mDia GBD-FH3 tandem (PDB id 
3EG5) did not produce electron density maps suitable for accurate modeling, likely given the 
divergent conformation of the GBD-FH3 domain tandem. A selenomethioine derivative of 
the EhFormin1 GBD-FH3 fragment was therefore generated and crystallographic phases 
determined by single-wavelength anomalous dispersion (SAD). For data collection and 
refinement statistics, see Table 5.1. 
 The overall structure of the EhRho1·GTPγS/EhFormin1 complex resembles that of 
human RhoC·GppNHp/mDia1 [20] except that the EhFormin1 fragment used for 
crystallography (a.a. 69-418) lacks the dimerization domain, and thus lacks the dimeric 
quaternary structure seen for mDia1 (Figure 5.8).  The Armadillo repeats of the DID domain 
in EhFormin1 are rotated ~40° away from EhRho1 relative to the conformation seen in the 
mammalian homolog (Figure 5.9). EhRho1 engages the EhFormin1 GBD and the N-terminal 
portion of the DID Armadillo repeats through its two mobile switch regions and its α3 helix, 
as also seen in mammalian homologs (Figure 5.8). However, the GTPase binding domain of 
EhFormin1 differs from that of mDia by a shortened second helix and an elongated α3 helix 
with clearly defined and continuous electron density. As a result of a shortened α2 helix, the 
GBD of EhFormin1 remains farther away (~4 Å) from the putative DAD-binding site within 
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the DID (Figure 5.10) which may indicate a slightly different mechanism of Rho-induced 
activation, since the contingently folded GBD of mDia1 is thought to contribute to DAD 
displacement by directly obstructing the DAD-binding site of the DID [18]. EhFormin1 also 
has an elongated α12-α13 loop relative to mDia1 (Figure 5.8). This loop is near the DAD-
binding site of the DID in mDia1 [18]; together with the highly divergent nature of the 
putative DAD motif within EhFormin1 (Figure 5.4), the presence of this elongated loop 
suggests that a unique mode of DAD-mediated autoinhibition may exist in the case of 
EhFormin1.  
 The conformation of EhRho1 in the complex is nearly identical with that we have 
previously reported [7] of free EhRho1·GTPγS (Cα r.m.s.d. 0.4 Å, PDB id 3REG), and is 
also similar to RhoC in the homologous RhoC·GppNHp/mDia1 complex (Cα r.m.s.d. 1.5 Å, 
PDB id 1Z2C) (Figures 5.9, 5.11). The Rho insert helix of RhoC approaches the C-terminal 
end of the mDia1 DID (Figures 5.8B, 6), leading to the hypothesis that a secondary binding 
site (beyond the switch region/GBD interaction) may be important for mDia1 activation [14, 
20].  In contrast, the lack of this insert helix within EhRho1 and the relative rotation of the 
EhFormin1 DID indicate that such a secondary interaction is absent in the E. histolytica 
orthologues (Figures 5.8A, 6). An EhRho1 molecule from the adjacent asymmetric unit is 
interposed between the non-uniformly structured β5-α4 loop of EhRho1 and the last 
Armadillo repeat of the EhFormin1 DID, raising the possibility that crystal contacts could be 
responsible for the rotation of the DID domain away from EhRho1 relative to the 
RhoC/mDia1 complex.  However, this is unlikely given the large magnitude of rotation and 
the absence of significant contacts between the interposed EhRho1 and the DID domain; 
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crystal contacts exist only between EhRho1 molecules in adjacent asymmetric units (see 
Figure 5.12). 
 The EhRho1/EhFormin1 interface is dominated by hydrophobic interactions between 
the two switch regions of the GTPase and the GBD (Figure 5.13A).  The critical EhRho1 
residues at this interaction site, such as Phe54 of switch 1 and Leu84 of switch 2, are 
conserved across the related GTPases (Figure 5.7A), suggesting that these hydrophobic 
interactions, while important for binding, do not necessarily determine the observed 
specificity of EhFormin1 for EhRho1. The non-conserved Asp91 of EhRho1 is positioned to 
potentially form ionic contacts with EhFormin1 α2 helix residues Lys108 and Lys112 
(Figure 5.13A).  The EhRho1 α3 helix contacts the first two Armadillo repeats of the 
EhFormin1 DID domain, primarily through residues His120 and Tyr121 (Figure 5.13B). The 
imidazole ring of His120 is oriented for a hydrogen bond interaction with Glu151 of 
EhFormin1.  Interestingly His120 and Tyr121 are conserved in RacD, but not RacC or RacG 
(Figure 5.7A), suggesting that these two interface residues may be important for specificity. 
Indeed, mutation of EhRho1 His120 to Gln, the analogous residue in EhRacG, drastically 
reduced affinity for the EhFormin1 GBD-FH3 tandem as measured by SPR (Figure 5.13D). 
Finally, the EhRho1 switch 2 residue Arg83 is inserted into a groove between the GBD and 
the DID domain, a region of slightly negative charge as indicated by vacuum electrostatic 
calculations (Figure 5.13C). Arg83 is within hydrogen bonding distance to multiple exposed 
peptide backbone carbonyl groups in this region (Phe156 and Arg157; see Figure 5.14).  
Arg83 of EhRho1 corresponds to Arg68 of human RhoC, which engages its formin effector 
in a strikingly similar fashion (Figure 5.9B) and is required for high affinity interaction [18]. 
However, RhoC Arg68 forms hydrogen bonds with the side chain of mDia N217 while 
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EhRho1 Arg83 is exclusively within hydrogen-bonding distance of backbone carbonyl 
groups (Figure 5.9, 5.14). This arginine is also present in EhRacG, but not other Rho family 
GTPases (Figure 5.7A), implicating this particular residue as a likely determinant of 
specificity for the EhRho1/EhFormin1 interaction. Mutation of EhRho1 Arg83 to the 
corresponding Gln in EhRacC and EhRacD drastically reduced affinity for EhFormin1 (KD 
>100 µM compared to ~3 µM for wild type EhRho1; Figure 5.13D). 
 
5.5 DISCUSSION 
The isolated FH2 domain of EhFormin1 was observed to slow actin polymerization in vitro, 
a phenomenon also exhibited by the corresponding domain from fission yeast Cdc12 [37], 
suggesting a possibly similar actin barbed-end capping interaction. Other formin regions 
mediate interactions with proteins that can also influence its activation state as an agent of 
actin polymerization [39]. Perhaps the best studied is the interaction of actin-bound profilin 
with the proline-rich FH1 domain [40]. Profilins can increase the rate of actin filament 
elongation by formins, possibly by increasing the local concentration of actin monomers to 
be included in the growing filament [15]. In the case of fission yeast Cdc12, the FH1 domain 
and associated profilin are required, in combination with the FH2 domain, for acceleration of 
actin polymerization [38]. While in vitro actin polymerization assays with EhFormin1 
fragments provide important mechanistic insights into activity of the isolated protein, it is 
important to note that the full-length protein in a cellular context is likely also modulated by 
subcellular localization and interactions with multiple other proteins. A limitation of the 
pyrene actin polymerization assay used in this study is its inability to differentiate the effects 
of EhFormin1 on nucleation of new actin filaments versus accelerated elongation of existing 
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filaments. Nucleation and elongation are catalyzed with varying efficiency among formins 
[12], and further studies are thus necessary to elucidate fully the mechanisms by which 
EhFormin1 modulates actin polymerization. 
 DRFs are commonly autoinhibited by an intramolecular interaction between the N-
terminal DID domain and the C-terminal DAD domain, consisting of a core MDxLLExL 
motif followed by a polybasic region [19].  However, the C-terminus of EhFormin1 contains 
a highly divergent segment (MExAANxG) corresponding to the core DAD motif, suggesting 
a potentially unique mode of regulation. Despite poor conservation of the putative DID/DAD 
interface, the N- and C-terminal fragments of EhFormin1 were seen to bind one another in a 
DAD-dependent fashion, resulting in inhibition of FH2 domain-mediated modulation of actin 
polymerization. Furthermore, a fusion protein containing the N-terminal GBD-FH3 tandem 
and the C-terminal FH2-DAD tandem mimicked the presumably autoinhibited state of full-
length EhFormin1, having no measureable effect on actin polymerization kinetics; binding of 
activated EhRho1·GTPγS to the GBD-FH3 region reversed the apparent autoinhibition of the 
EhFormin1 fusion, suggesting that the EhRho1/EhFormin1 interaction is sufficient to free the 
FH2 domain for modulation of actin polymerization. 
 The crystal structure in this study provides only the second exemplary snapshot of an 
interaction between a Rho GTPase and formin effector. Thus a comparison of the E. 
histolytica and human Rho/formin complexes reveals consistent structural features that are 
conserved across species and likely of shared importance for Rho-mediated activation of 
formins, as well as differences that may reflect properties of individual proteins, such as 
formin specificity for particular Rho GTPases. Our structural model of the 
EhRho1/EhFormin1 complex reveals a similar interface to that of human RhoC/mDia1 
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despite a distant evolutionary relationship as evidenced by substantial sequence divergence. 
The GTPase binding domain of EhFormin1 is quite similar to that of mDia1, with a 
predominant hydrophobic patch engaging the switch regions of EhRho1 [20]. Arg83 of 
EhRho1 projects into a relatively negatively charged groove between the GBD and DID 
domains in a manner highly homologous to Arg68 of RhoC [20].  However, the EhRho1 
Arg83 residue forms hydrogen bonds exclusively with backbone carbonyl groups rather than 
asparagine side chains, as seen in the mammalian homolog [20]. The EhRho1 switch 2 
residue Arg83, together with the buried side chains of His120 and Tyr121 on the α3 helix of 
EhRho1, are important determinants of Rho GTPase specificity in binding EhFormin1. 
EhRacC and EhRacD lack the critical switch 2 arginine, while EhRacG lacks the histidine-
tyrosine tandem, and all three of these Rac subfamily GTPases are unable to bind 
EhFormin1. Furthermore, mutation of EhRho1 residues Arg83 to the corresponding 
EhRacC/D glutamine or His120 to the EhRacG-like glutamine each reduced the affinity of 
EhRho1 for EhFormin1 by >100-fold. Such strict specificity of Rho GTPase and effector 
interactions is likely of particular importance in E. histolytica where at least 19 Rho family 
GTPases are apparently expressed in a single cell [7]. 
 Several lines of evidence suggest that the mechanisms of EhFormin1 autoinhibition 
and its activation by EhRho1 may differ significantly from that of the well-studied mDia1 
homolog [16, 17]. There is poor EhFormin1 sequence conservation in the putative core DAD 
motif and DAD-binding surface on the DID, and EhFormin1 has a uniquely elongated α12-
α13 loop near the putative DID/DAD interaction site.  Furthermore, the GBD of EhFormin1 
has a shortened α2 helix that would not directly obstruct the DAD-binding surface on the 
DID as modeled for mDia1 (Figure 5.10) [18]. Finally, EhRho1 lacks a Rho insert helix and 
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does not approach the C-terminus of the DID domain, indicating that a secondary 
EhRho1/EhFormin1 interaction between these two regions does not exist, in contrast with 
RhoC/mDia1. 
 Previous studies of EhFormin1 in the context of E. histolytica trophozoites [21], 
together with our findings ([7] and this paper), suggest that an EhRho1/EhFormin1 signaling 
axis may be important for formation of complex actin structures within pseudopodia and 
phagocytic and pinocytic vesicles, particularly in response to extracellular cues such as 
serum factors. EhFormin1 also apparently exerts effects on trophozoite mitosis and 
cytokinesis [21]. Interestingly, both EhRho1 and EhFormin1 are enriched in E. histolytica 
uropods [41], suggesting that the GTPase/effector pair may also regulate actin 
polymerization at the trailing edge during trophozoite migration and/or surface receptor 
capping critical for immune response evasion [5]. Knowledge of the structural determinants 
defining the EhRho1/EhFormin1 interaction, and of its differences from mammalian 
GTPase/formin complexes (Fig. 5.13), should assist in understanding the contributions of this 
actin polymerization pathway to E. histolytica infectivity and invasiveness.  
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Figure 5.1. EhFormin1 domain structure and constructs used in this study. The domain 
structure of EhFormin1 is represented with residue numbers indicating domain borders. The 
EhFormin1 fusion consists of residues 69-418 and 731-1182 with an intermediate 40-residue 
synthetic linker designed to be soluble and flexible. 
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Figure 5.2. The FH2 domain of EhFormin1 modulates actin filament formation. A) 
Actin co-sedimentation assays demonstrate that the EhFormin1 FH2 domain fragment (a.a. 
731-1127) and the FH2-DAD combination (a.a. 731-1182) both associate with pre-formed 
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filamentous actin derived from rabbit skeletal muscle. Mutation of the conserved Lys964 that 
is critical for other formin FH2/actin interactions abolished co-sedimentation. S and P 
represent the soluble and pellet fractions following high-speed centrifugation, respectively. 
B) Indicated fragments of EhFormin1, each containing the FH2 domain, modulate actin 
polymerization in vitro, as measured by pyrene-actin polymerization assays. C) The 
EhFormin1 FH2 and FH2-DAD fragments are both seen to slow actin polymerization, as 
quantified by measuring the slope of each fluorescence curve at 50% complete 
polymerization. Error bars represent standard error for three or more replicate experiments. * 
indicates a statistically significant difference from actin only (p < 0.05). 
212 
 
 
 
Figure 5.3. Multiple sequence alignment of FH2 domains and DAD motifs. The FH2 
domain and putative DAD motif of EhFormin1 is aligned with other known autoinhibited 
Diaphanous-related formins. S.c. indicates Saccharomyces cerevisiae and D.m. indicates 
Drosophila melanogaster, while mDia isoforms are derived from Mus musculus. Black dots 
indicate residues that contact actin the crystal structure of the S.c. Bni1/actin complex [36] 
(PDB id 1Y64). 
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Figure 5.4. EhFormin1 is autoinhibited by N- and C-terminal domain interactions. A) 
The N-terminal GBD-FH3 domain tandem (a.a. 69-418) of EhFormin1 binds to the C-
terminal FH2-DAD tandem (a.a. 731-1182), but not the FH2 domain alone (a.a. 731-1127) as 
determined by surface plasmon resonance. B) Equilibrium binding analyses revealed a DAD 
motif-dependent low micromolar affinity interaction with the EhFormin1 GBD-FH3 
fragment. C) The DAD motif region, with a core motif (MDxLLExL) highly conserved 
among other known Diaphanous-related formins, is divergent in EhFormin1. S.c. indicates 
Saccharomyces cerevisiae and D.m. indicates Drosophila melanogaster, while mDia 
isoforms are derived from Mus musculus. D) In vitro actin polymerization assays indicate a 
DAD-motif dependent interaction between the N- and C-terminal fragments of EhFormin1 
that prevents modulation of actin polymerization. Addition of a molar excess of GBD-FH3 
domain tandem (100 µM) had no effect on the isolated FH2 domain from EhFormin1 or on 
actin alone. However, the GBD-FH3 tandem prevented deceleration of actin polymerization 
by the FH2-DAD fragment. Error bars represent standard error for at least 3 replicate 
experiments. * indicates a statistically significant difference (p < 0.05) and ‡ indicates an 
indistinguishable slope compared to actin only. 
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Figure 5.5. EhRho1 activates EhFormin1 through interaction with the GBD-FH3 
domain tandem. A) The GBD-FH3 domain tandem (a.a. 69-418) of EhFormin1, 
immobilized on a nickel-NTA biosensor surface, selectively engaged EhRho1·GTPγS to the 
exclusion of multiple other Rho family GTPases from E. histolytica, as measured by surface 
plasmon resonance. B) The EhFormin1 fusion protein (25 µM) is apparently autoinhibited, 
having no measured effect on actin polymerization kinetics in vitro. While EhRho1·GTPγS 
alone (100 µM) did not perturb actin polymerization, it was capable of activating the 
EhFormin1 fusion, resulting in deceleration of actin polymerization comparable to that of the 
FH2-DAD fragment alone (Figure 5.2B, C). Error bars represent standard error for at least 3 
replicate experiments. * indicates statistical significance (p < 0.05) compared to actin only. 
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Figure 5.6. EhRho1·GTPγS/EhFormin1 fusion binding parameters. A) As measured by 
SPR, EhRho1·GTPγS bound the engineered fusion of the GBD-FH3 and FH2-DAD 
fragments with low µM affinity. For details of the EhFormin1 fusion and other constructs 
used in this study, see Figure 5.1. B) Kinetic and equilibrium binding parameters for the 
EhRho1·GTPγS/EhFormin1 fusion protein interaction were derived from SPR experiments. 
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Figure 5.7. Sequence comparisons of Rho family GTPases and Diaphanous-related 
formins. A) The protein sequence of EhRho1 is aligned with three additional E. histolytica 
Rho GTPases that do not engage EhFormin1 (Figure 5.5A). Secondary structure from the 
EhRho1·GTPγS/EhFormin1 crystal structure (PDB id 4DVG; this paper) is diagrammed 
above the primary sequence. Black dots indicate residues of EhRho1·GTPγS within 1 Å of 
EhFormin1 in the complex. B) The protein sequence of EhFormin1 GBD-FH3 domain 
tandem is aligned with its closest mammalian homolog, mDia1. Secondary structure from the 
EhRho1·GTPγS/EhFormin1 crystal structure (PDB id 4DVG; this paper) is diagrammed 
217 
above the primary sequence. Black dots indicate residues in EhFormin1 within 1 Å of 
EhRho1·GTPγS in the complex. All alignments were performed with ClustalW2. 
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Figure 5.8. The crystal structure of EhRho1·GTPγS bound to the GBD-FH3 tandem of 
EhFormin1. A) EhRho1 (dark green) in its activated state bound to GTPγS (blue sticks) 
engages EhFormin1 primarily through its mobile switch regions (light green) and its α3 
helix. The GTPase binding domain (GBD) of EhFormin1 is shown in yellow and the 
Armadillo repeats of the DID domain in orange. Magnesium is shown as a yellow sphere. B) 
The homologous mammalian complex between RhoC·GppNHp (cyan) and mDia1 (wheat 
and red) is posed in a similar configuration [20] (PDB id 1Z2C). EhRho1 lacks a signature 
Rho insert helix (highlighted in orange on RhoC) and the EhFormin1 DID domain Armadillo 
repeats are rotated away from EhRho1 relative to this mammalian complex. The EhFormin1 
GBD-FH3 tandem construct used in this study also lacks the dimerization domain portion of 
the FH3 domain, as shown in the RhoC/mDia1 complex. 
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Figure 5.9. Structural comparison of EhRho1/EhFormin1 with mammalian 
RhoC/mDia1. A) The EhRho1·GTPγS/EhFormin1 complex is superimposed with 
RhoC·GppNHp/mDia1 (PDB id 1Z2C) using the Cα atoms of the respective Rho GTPases, 
and colored as in Figure 5.8. The Rho GTPase and GBD domains are similar across species, 
but the DID domain exhibits a different conformation, with an ~40° relative rotation of C-
terminal Armadillo repeats. B) The switch 2 arginines, Arg-83 in EhRho1 and Arg-68 in 
human RhoC, adopt nearly identical orientations, inserting between the GBD (yellow/wheat) 
and DID domain (orange/red). However, Arg-68 of RhoC forms hydrogen bonds with Asn-
217 of mDia1 as well as backbone carbonyl groups, while Arg-83 of EhRho1 exclusively 
contacts main chain carbonyl groups. 
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Figure 5.10. The GBD of EhFormin1 does not impinge on the putative DAD motif-
binding region of the DID, in contrast to the known structures of mDia1. The GBD-DID 
domain tandems derived from the structures of EhRho1·GTPγS/EhFormin1 (PDB id 4DVG) 
and RhoC·GppNHp/mDia1 (PDB id 1Z2C) were superimposed with the mDia1 DID/DAD 
motif complex (PDB id 2F31) based on their DID domains. EhFormin1 is shown in yellow 
and orange, and the GBD motif from mDia1 in the RhoC/mDia1 complex in wheat. The 
DAD motif of mDia1 (red spheres) is docked on the putative DAD-binding site of the 
EhFormin1 DID domain. As shown previously [19], the GBD domain of mDia1 overlaps 
with the DAD-binding site, suggesting that the GBD participates in ejecting the DAD motif 
upon Rho-mediated activation. The GBD of EhFormin1 displays a shorter α2 helix and does 
not clash with the docked DAD motif, suggesting that an alternative mechanism of activation 
is operative with the E. histolytica DRF homolog EhFormin1. 
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Figure 5.11. The conformation of EhRho1 in the EhRho1·GTPγS/EhFormin1 complex 
resembles that of free EhRho1·GTPγS and of human RhoC. A) EhRho1 from the 
EhRho1·GTPγS/EhFormin1 complex of this study (green) is superimposed with free 
EhRho1·GTPγS [7] (gray, PDB id 3REG); the Cα r.m.s.d. is 0.4 Å. B) EhRho1 from this 
study is superimposed with RhoC from the RhoC/mDia1 complex (purple, PDB id 1Z2C); 
the Cα r.m.s.d. is 1.5 Å. 
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Figure 5.12. Crystal contacts between EhRho1 molecules. A) The structure of the 
EhRho1·GTPγS/EhFormin1 complex is shown as in Figure 5.8, with an EhRho1 GTPase 
from the adjacent asymmetric unit modeled in red. The neighboring EhRho1 does not form 
significant contacts with the DID domain. B, C) Two areas of contact between EhRho1 
molecules in adjacent asymmetric units are shown in greater detail. Crystal contacts may 
influence the conformation of EhRho1 switch 1 (panel A) and/or the β5-α4 loop (panel B) in 
the complex. 
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Figure 5.13. Structural determinants of EhRho1/EhFormin1 binding specificity.  
A) The EhRho1·GTPγS/EhFormin1 interface is dominated by a hydrophobic surface burial 
involving the switch regions of EhRho1 (green) and the EhFormin1 GBD (yellow). Key 
hydrophobic residues are shown in sticks. EhRho1 Asp91 is also in position to form an ionic 
interaction with Lys108 or Lys112 on EhFormin1. B) The α3 helix of EhRho1 (green) also 
contributes to the binding interface, with His120 and Tyr121 inserted between the GBD α3 
helix (yellow) and the N-terminal portion of the DID domain (orange). The imidazole ring of 
His120 is oriented for hydrogen bonding with Glu151 of EhFormin1. C) EhRho1 switch 2 
residue Arg83 inserts into a groove between the GBD and DID domains of EhFormin1 
(shown as an electrostatic surface). The guanidinium group of Arg83 resides near an area of 
relative negative charge (red surface) and is within hydrogen bonding distance of multiple 
backbone carbonyl groups (see Figure 5.14). D) Wild type EhRho1 binds the EhFormin1 
GBD-FH3 tandem, as measured by surface plasmon resonance. Mutation of either Arg83 to 
the corresponding glutamine in EhRacC and EhRacD or His120 to an EhRacG-like 
glutamine resulted in a >100-fold affinity reduction. 
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Figure 5.14. A representative electron density map of the region surrounding EhRho1 
Arg83. A 2Fo-Fc electron density map was modeled using Coot [33]. Arg83 is within 
potential hydrogen bonding distance of the carbonyl groups from EhFormin1 Phe156 and 
Arg157. The electron density map was contoured to σ = 2.2. 
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Table 5.1.  Data collection and refinement statistics for 
the EhRho1·GTPγS/EhFormin1 complex.	  	  	   EhRho1·GTPγS/EhFormin1 
PDB accession code 4DVG 
 	  
Data collection 	  
Space group P61 
Cell dimensions   	  	  	  	  	  a, b, c	  (Å) 138.6, 138.6, 57.8 
    α, β, γ 	  (°)	   90, 90, 120 	   Peak 
Wavelength (Å) 0.97954 
Resolution (Å) 40.0 - 2.6 (2.63 – 2.60)* 
Rmerge (%) 8.5 (58.0)** 
I /	  σI	   15.2 (2.1) 
Wilson B-factor 65.0 
Completeness (%) 98.4 (86.0) 
Redundancy 9.6 (6.4) 
	    
Refinement  
Resolution (Å) 35.7 - 2.6 (2.7 – 2.6) 
No. reflections 19211 (2420) 
Cutoff criterion Fobs/σFobs > 0 
Rwork / Rfree	  (%)	   21.5 / 25.1 (33.4 / 37.2) 
No. atoms  
    Protein 3747 
    Ligand/ion 33 
    Water 4 
B-factors (Å2)  
    Protein 79.5 
    Ligand/ion 57.4 
    Water 36.1 
R.m.s deviations  
    Bond lengths (Å) 0.010 
    Bond angles (°) 1.233 
*Values in parentheses are for highest-resolution shell.  
**All data were collected from a single crystal. 
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CHAPTER 6 
STRUCTURAL DETERMINANTS OF UBIQUITIN CONJUGATION 
IN Entamoeba histolytica1 
 
6.1 OVERVIEW 
Ubiquitination is important for numerous cellular processes in most eukaryotic organisms, 
including cellular proliferation, development, and protein turnover by the proteasome. The 
intestinal parasite Entamoeba histolytica harbors an extensive ubiquitin-proteasome system. 
Proteasome inhibitors are known to impair parasite proliferation and encystation, suggesting 
the ubiquitin-proteasome pathway as a viable therapeutic target. However, no functional 
studies of the E. histolytica ubiquitination enzymes have yet emerged. Here, we have cloned 
and characterized multiple E. histolytica ubiquitination components, spanning ubiquitin and 
its activating (E1), conjugating (E2), and ligating (E3) enzymes. Crystal structures of 
EhUbiquitin reveal a clustering of unique residues on the α1 helix surface, including an 
eighth surface lysine not found in other organisms, that may allow for a unique polyubiquitin 
linkage in E. histolytica. EhUbiquitin is activated by and forms a thioester bond with EhUba1 
(E1) in vitro, in an ATP- and magnesium-dependent fashion. EhUba1 exhibits a greater 
maximal initial velocity of pyrophosphate:ATP exchange than its human homolog,  
 
1 Bosch, D.E. and Siderovski, D.P. (2012) Structural determinants of ubiquitin conjugation in Entamoeba 
histolytica. J. Biol. Chem. 288(4):2290-302. 
          231 
suggesting different kinetics of ubiquitin activation in E. histolytica. EhUba1 engages the E2 
enzyme EhUbc5 through its ubiquitin-fold domain to transfer the EhUbiquitin thioester. 
However, EhUbc5 has a >10-fold preference for EhUba1~Ub compared to unconjugated 
EhUba1. A crystal structure of EhUbc5 allowed prediction of a non-covalent “backside” 
interaction with EhUbiquitin and with E3 enzymes. EhUbc5 selectively engages EhRING1 
(E3) to the exclusion of two HECT family E3 ligases, and mutagenesis indicates a conserved 
mode of E2/RING-E3 interaction in E. histolytica. 
 
6.2 INTRODUCTION 
Post-translational modification by ubiquitin and ubiquitin-like modifiers (ULMs) plays 
critical roles in the cellular biology of many eukaryotes [1]. Isopeptide bond-mediated 
attachment of monoubiquitin or polyubiquitin chains to specific target proteins regulates 
processes as diverse as cell cycle progression, development, and the immune response [2]. 
Polyubiquitination also serves as a primary signal for protein turnover, targeting proteins for 
degradation by the 26S proteasome [3]. ULM attachments are catalyzed by conserved 
enzyme cascades, with ATP-dependent ULM activation catalyzed by E1, conjugation by E2, 
and targeting of specific protein substrates by E3 ligases [3]. Ubiquitin activating enzymes 
(E1s) in eukaryotes serve to adenylate ubiquitin, consuming ATP and releasing 
pyrophosphate (PPi). Subsequently, a thioester bond is formed between an E1 active site 
cysteine and the dual-glycine C-terminus of the activated ubiquitin, releasing AMP, and a 
second ubiquitin molecule is also adenylated [4]. The resulting E1~Ub thioester complex 
engages a ULM conjugating enzyme (E2), with major contributions to the E1/E2 interface 
arising from the E1 ubiquitin-fold domain (UFD) [5]. The thioester bond between the 
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ubiquitin C-terminus and the E1 enzyme is transferred to a conserved cysteine residue on the 
E2, resulting in a covalent E2~Ub adduct [6]. E3 ubiquitin-ligating enzymes can be classified 
into two major groups, containing either homology to the E6AP C-terminus (HECT) or really 
interesting new gene related (RING) domains [3]. HECT family E3 enzymes possess a 
catalytic cysteine that accepts the ubiquitin thioester from bound E2~Ub prior to ubiquitin 
isopeptide bond formation with a lysine acceptor [7]. In the case of RING E3 enzymes, 
ubiquitin is directly transferred to the target protein from E2~Ub; the RING E3 enzyme 
serves primarily as an adaptor pairing ubiquitin-charged E2 enzymes with specific E3-bound 
substrates [3]. However, RING interactions with E2~Ub also prime the E2 for efficient 
ubiquitin conjugation to acceptor lysines [8]. Ubiquitin monomers can be added directly to 
surface lysines on substrate proteins, or can instead be linked into polyubiquitin chains, 
utilizing any of the seven lysines on the surface of ubiquitin, although some polyubiquitin 
linkages are more frequently utilized than others [9]. 
 The single-celled intestinal parasite Entamoeba histolytica is the causative agent of 
amoebic colitis and systemic amoebiasis, with the latter characterized by cysts in liver, lungs, 
and brain [10]. Spread in an encysted form, E. histolytica infection is endemic in developing 
countries with poor barriers between sewage and drinking water [11]. Although E. histolytica 
has been the subject of research for more than 50 years, the relatively recent sequencing of its 
genome [12] affords the opportunity for further insight into cellular machinery that may be 
amenable to pharmacologic manipulation, such as the ubiquitin-proteasome pathway. The 
cloning and characterization of an E. histolytica ubiquitin gene (termed ehubiquitin) 
highlighted a surprising degree of sequence divergence from homologs in humans and lower 
organisms, given the remarkably high degree of conservation among other species [13]. 
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Despite its relatively dissimilar sequence, EhUbiquitin complements deletion of the 
polyubiquitin gene ubi4 in yeast, suggesting conserved functions in E. histolytica [14]. More 
recent bioinformatic analyses of the E. histolytica genome revealed an extensive family of 
putative ubiquitin activating, conjugating, and ligating enzymes, as well as parallel systems 
for other ubiquitin-like modifiers [15]. However, functional studies of this putative 
ubiquitination machinery have not yet emerged. Interestingly, treatment with proteasome 
inhibitors impairs growth of E. histolytica trophozoites and encystation in the related species 
E. invadens, suggesting that the ubiquitin-proteasome pathway may be a valuable therapeutic 
target [16]. Altered expression of ubiquitin-proteasomal genes has also been correlated with 
perturbations in virulence (e.g. [17]). Our own study of heterotrimeric G-protein signaling in 
E. histolytica demonstrated that markers of trophozoite virulence are enhanced or reduced 
upon overexpression of the Gα subunit, EhGα1, or a dominant negative EhGα1 mutant, 
respectively [18]. A transcriptome analysis by RNA-seq revealed differential expression of 
multiple ubiquitin-proteasome pathway-related genes upon expression of wild-type or mutant 
EhGα1, including the ehubiquitin gene itself (Table 6.1). In the present study, we sought to 
characterize, both structurally and biochemically, various components of the E. histolytica 
ubiquitination machinery, spanning ubiquitin and its interacting E1-E3 enzymes. We 
hypothesize that differences revealed between the E. histolytica components and well-studied 
mammalian homologs may elucidate potential means for specific targeting of ubiquitination 
within the parasitic amoeba. 
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6.3  EXPERIMENTAL PROCEDURES 
6.3.1 Cloning and protein purification 
Genomic DNA was isolated from the virulent HM-1:IMSS strain of Entamoeba histolytica 
using a DNeasy Blood and Tissue Kit (Qiagen). Open reading frames of ehubiquitin 
(AmoebaDB accession EHI_083410), ehuba1 (EHI_020270), ehubc5 (EHI_083560), 
ehring1 (EHI_020100), ehhect1 (EHI_011530), and ehhect2 (EHI_124600) were PCR 
amplified from genomic DNA and subcloned as hexahistidine fusions into a pET vector-
based ligation-independent cloning vector, pLIC-His, as described previously [19]. PCR 
primer sequences were: ehubiquitin, 5’-ATGCAAATATTTGTTAAGAC-3’ and 5’-
TTAATATCCTCCTCTTAATC-3’; ehuba1, 5’-
ATGACACAACAAATTGATGAAGCCGTATTG-3’ and 5’- TTAGAAATTCAAAAG 
AACATCTGGAAATTC-3’; ehubc5, 5’-ATGGCTATGCGTAGAATTCAAAAAG-3’ and 
5’-TTATGGTCGAGCATACATAC-3’; ehring1, 5’-ATGTCAAGAGAAGATTGTG-3’ and 
5’-TTAGTGATAAATAATTCGGTG-3’; ehhect1, 5’- ATGCGGAAACACCTCAAATA 
ACAAATAA-3’ and 5’- TTAAATTAAACCAAATCCATTTGTATT-3’; ehhect2,  
5’- ATGAGACCGGCTTGGAGACTTA-3’ and 5’-TTAAGAAAATGCAAATCCTGAT 
TTTGATG-3’. Fragments subcloned and purified as recombinant proteins included the 
ubiquitin-fold domain of EhUba1 (a.a. 882-984), EhRING1 a.a. 1-246, EhHECT1 HECT 
domain (a.a. 277-660), and EhHECT2 HECT domain (a.a. 370-750). Point mutations to 
EhUbc5 were made using PCR and the overlap extension method [20]. 
 Recombinant human Uba1, derived from insect cells, was purchased from Boston 
Biochem. Ubiquitin from bovine erythrocytes was purchased from Sigma. Since the 
sequences of bovine and human ubiquitin are identical, the protein is referred to as human 
          235 
ubiquitin throughout the study, for clarity. For each of the E. histolytica components, BL21 
E. coli were grown to an OD600nm of 0.8 at 37°C and expression induced with 500 µM 
isopropyl-β-D-thiogalactopyranoside (IPTG) for 14-16 hours at 20°C. Pelleted bacterial cells 
were resuspended in N1 buffer containing 30 mM HEPES pH 8.0, 250 mM NaCl, and 30 
mM imidazole and lysed by high-pressure homogenization with an Emulsiflex (Avestin; 
Ottawa, Canada). Cellular lysates were cleared by centrifugation at 100,000 x g for 1 hour at 
4°C, and the supernatant applied to a nickel-nitrilotriacetic acid (NTA) FPLC column (GE 
Healthcare), washed extensively with N1, and eluted in N1 buffer with 300 mM imidzaole. 
For proteins used in biochemical experiments, eluted protein was pooled and resolved using a 
size exclusion column (HiLoad 16/60 Superdex 200, GE Healthcare) in S200 buffer 
containing 50 mM HEPES pH 7.5 and 100 mM NaCl (5 mM ZnCl2 was included in the case 
of EhRING1 purification). For proteins used in crystallographic studies, protein eluted from 
the NTA column was pooled and dialyzed into imidazole-free N1 supplemented with 5 mM 
DTT overnight at 4°C in the presence of His6-tobacco etch virus (TEV) protease to cleave 
the N-terminal affinity tag. The dialysate was then passed over a second NTA column to 
remove TEV protease and uncleaved protein, followed by resolution by size exclusion in 
S200 buffer. All proteins except EhUba1 were concentrated to 0.25 - 2 mM and snap frozen 
in a dry ice/ethanol bath for storage at -80°C. EhUba1 was found to precipitate upon 
freeze/thaw, but could be stably maintained at 4°C for at least two weeks. Protein 
concentration was determined by A280nm measurements upon denaturation in 8 M guanidine 
hydrochloride, based on predicted extinction coefficients for each protein 
(http://us.expasy.org/tools/protparam.html). 
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6.3.2 Crystallization and structure determinations of EhUbiquitin and EhUbc5 
Crystals of EhUbiquitin were obtained by vapor diffusion from hanging drops at 18°C in two 
different crystal forms. EhUbiquitin crystal form #1 was obtained by mixing EhUbiquitin at 
17 mg/mL 1:1 with crystallization solution containing 25% (w/v) PEG 3350 and 100 mM 
citric acid pH 3.5. A single crystal grew to ~500 x 400 x 400 µm over 5 days, exhibiting the 
symmetry of space group P3221 (a = b = 49.8 Å, c = 63.8 Å, α = β = 90°, γ = 120°) and 
containing one monomer in the asymmetric unit. For the second crystal form, EhUbiquitin at 
13 mg/mL in S200 buffer was mixed 1:1 with (and equilibrated against) crystallization 
solution containing 22% (w/v) PEG 3350, 200 mM LiSO4, and 100 mM Bis-Tris pH 5.5. 
Crystals grew to ~200 x 100 x 100 µm over 3 days, exhibiting the symmetry of space group 
P212121 (a = 38.6 Å, b = 49.9 Å, c = 76.8 Å, α = β = γ = 90°) and containing two monomers 
in the asymmetric unit. For data collection at 100K, crystals were serially transferred for ~1 
minute into crystallization solution supplemented with 30% (v/v) glycerol in 10% increments 
and plunged into liquid nitrogen. Native data sets were collected at the GM/CA-CAT 23-ID-
B beamline at the Advanced Photon Source (Argonne National Laboratory). Data were 
processed using HKL2000 [21]. The crystal structure model of human ubiquitin (PDB ID 
1UBQ) was used as a molecular replacement search model using PHENIX AutoMR [22]. 
Refinement was carried out using phenix.refine [22], interspersed with manual revisions of 
the model using the program Coot [23]. Refinement consisted of conjugate-gradient 
minimization and calculation of individual anisotropic displacement and 
translation/libration/screw (TLS) parameters [24]. The current model of crystal form #1 
contains one EhUbiquitin monomer; residues 7-10 and 73-77 could not be located in the 
electron density. Ramachandran plot analysis indicated 100% favored residues. The current 
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model of crystal form #2 contains two EhUbiquitin monomers; residues 75-77 of chain A and 
74-77 of chain B could not be accurately modeled in the electron density. Ramachandran plot 
analysis indicated 98.6% favored, 1.4% allowed, and 0% disallowed residues. 
 Crystals of EhUbc5 were obtained by vapor diffusion from hanging drops at 18°C. 
EhUbc5 at 8 mg/mL in S200 buffer was mixed 1:1 with (and equilibrated against) 
crystallization solution containing 100 mM Tris pH 7.5, 14% (w/v) polyvinylpyrrolidone 
K15, and 500 µM CoCl2. Hexagonal crystals grew to ~400 x 300 x 200 µm over 5 days and 
exhibited the symmetry of spacegroup P212121 (a = 47.0 Å, b = 49.6 Å, c = 63.5 Å, α = β = γ 
=90°) with one monomer in the asymmetric unit. For data collection at 100K, crystals were 
transferred for ~1 minute into crystallization solution supplemented with 25% glycerol and 
plunged into liquid nitrogen. A native data set was collected at the SER-CAT 22-BM 
beamline at the Advanced Photon Source (Argonne National Laboratory). Data processing 
and refinement were carried out similarly to EhUbiquitin, as mentioned above. A molecular 
replacement solution was obtained using the crystal structure model of human UbcH5b (PDB 
ID 2ESK), modified to exclude water. The current model contains one EhUbc5 monomer 
with a cobalt ion coordinated by surface residues and by a monomer from the neighboring 
asymmetric unit. All EhUbc5 residues could be located in the electron density. 
Ramachandran plot analysis indicated 97.3% favored, 2.7% allowed, and 0% disallowed 
residues. 
 
6.3.3 In vitro ubiquitin transfer assay 
Ubiquitin transfer experiments were conducted essentially as previously described for 
NEDD8ylation [25], with adaptations to allow visualization of EhUba1~EhUb thioester 
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formation. Briefly, 1 µM EhUba1, 5 µM wild-type or mutant EhUbc5, and 15 µM 
EhUbiquitin were incubated 15 minutes at room temperature in ubiquitin transfer buffer 
containing 50 mM HEPES pH 7.5, 100 mM NaCl, 10 mM MgCl2, and 5 mM ATP. The 
reactions were halted by denaturation in 5X non-reducing SDS sample buffer, and 50 mM 
DTT was added to specified reactions for 10 minutes prior to protein separation by 
denaturing SDS-PAGE and staining with Coomassie blue.  
 
6.3.4 In vitro polyubiquitin chain formation assay 
Polyubiquitin chain formation experiments were conducted essentially as previously 
described [26]. 50 nM EhUba1, 1 µM EhUbc5, 8 µM N-terminal FLAG epitope-tagged 
EhUbiquitin, and 10 µM EhRING1 were incubated at 37 °C for 45 minutes in reaction buffer 
containing 50 mM HEPES pH 7.5, 100 mM NaCl, 10 mM MgCl2, and 5 mM ATP. Reactions 
were halted by denaturation in 5X reducing SDS sample buffer, and 50 mM DTT was added 
to all reactions 10 minutes prior to protein separation by SDS-PAGE. Proteins were 
transferred to a nitrocellulose membrane and probed with anti-FLAG (M2 monoclonal; 
Sigma). 
 
6.3.5 PPi:ATP radioisotope exchange assay 
Isotope exchange assays were conducted as previously described [4]. All assays were 
performed at 37°C and contained 6 nM E1 ubiquitin-activating enzyme, 1 µM ubiquitin 
protein, 100 µM AMP, 10 mM MgCl2, 100 µM non-radioactive pyrophosphate (PPi), and 
variable ATP concentrations. Reactions were initiated by addition of the E1 enzyme. 
Concentrations of EhUba1 and human Uba1 were determined by the Bradford method. 
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Incubation times were <15 minutes and within the linear portion of the progress curve (prior 
to approaching equilibrium). Incorporation of 32PPi into ATP was determined by adsorbing 
the ATP to activated charcoal. Reactions were quenched with 5% (w/v) trichloroacetic acid 
(TCA) containing 4 mM non-radioactive PPi, mixed with a 10% (w/v) slurry of charcoal in 
2% TCA, pelleted by centrifugation, and washed three times with 2% TCA. Charcoal-bound 
radioactivity was quantified by Cherenkov radiation. Background radiation from control 
reactions lacking E1 was subtracted, and no significant exchange was observed in the 
absence of E1, ubiquitin, or ATP. All assays were performed in duplicate, and error bars 
represent standard error from three independent experiments. Data were fit by linear 
regression using GraphPad Prism v5.0. Approximate Km and Vmax values were derived from 
a Lineweaver-Burk plot, where the y-intercept = 1/Vmax and the x-intercept = -1/Km. 
 
6.3.6 Surface plasmon resonance (SPR) assays 
SPR-based measurements of protein-protein interactions were performed on a Biacore 3000 
(GE Healthcare), essentially as described previously [19]. Briefly, purified His6-EhUbc5 and 
His6-EhUbc5(F62A) proteins were separately immobilized on an NTA biosensor chip using 
covalent capture coupling [27]. EhUbiquitin, EhUba1, or E3 ligase proteins were injected in 
30 µL volumes at increasing concentrations. For binding experiments with EhUba1~EhUb, 
20 µM EhUba1 and 50 µM EhUbiquitin were incubated 20 minutes at 30°C in buffer 
containing 50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM ATP, and 10 mM MgCl2 to allow 
for ubiquitin activation and thioester formation. EhUba1~EhUb was injected in 30 µL 
volumes using the KINJECT command with a 300 second dissociation time. Each 
EhUba1~EhUb injection was followed by a 10 µL injection of 50 mM DTT to detach 
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thioester-coupled EhUbiquitin from the EhUbc5 surface. Experiments were performed in 
running buffer containing 50 mM HEPES pH 7.4, 150 mM NaCl, 0.05% NP-40 alternative 
(Calbiochem), 50 µM EDTA, and 1 mM MgCl2. Background changes in refractive index 
upon injection of samples was subtracted from all curves using BIAevaluation software v3.0 
(GE Healthcare). Equilibrium binding analyses were conducted as previously described [28] 
using GraphPad Prism v5.0 to determine binding affinities. 
 
6.4 RESULTS 
6.4.1 Structural features of a divergent ubiquitin from Entamoeba histolytica 
To give spatial context to the variant residues within E. histolytica ubiquitin [13] and their 
effects, if any, on the overall structure, we crystallized EhUbiquitin and determined its 
structure in two crystal forms. Under the first set of conditions, a single crystal was obtained 
that yielded diffraction data extending to 1.35 Å resolution. Although the diffraction data 
were of otherwise high quality (Table 6.2), detector overload resulted in exclusion of a 
significant fraction of low-resolution data during processing. Incomplete low-resolution data 
was manifested as unusually high R-factors and average B-factors during refinement (Table 
6.2); however, the electron density was of good quality (Figure 6.1B), with clear electron 
density obtained for the divergent residues of EhUbiquitin upon phasing by molecular 
replacement with human ubiquitin (PDB ID 1UBQ). We also obtained EhUbiquitin crystals 
under a second condition, and a structure was determined using diffraction data to 2.15 Å 
(Table 6.2; Figure 6.1C). The data collection and refinement statistics corresponding to the 
second EhUbiquitin crystal form were near the mean of other deposited structures of similar 
resolution [22]. Although the structures derived from both diffraction data sets were 
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essentially identical, the second crystal form was utilized for further analyses due to the 
unusually high R-factors of crystal form #1. 
 The Cα trace of EhUbiquitin is highly similar to human ubiquitin (r.m.s.d. 0.78 Å; 
Figure 6.1A). This finding is consistent with the protein core residues being identical 
between the two homologs [13], with the exception of position 26, which exhibits a subtle 
variation of isoleucine in E. histolytica compared to the conserved valine in a broad diversity 
of other species (Figure 6.1D). Mapping the variant EhUbiquitin residues compared to its 
human homolog revealed clustering of divergent residues on a single surface, dominated by 
the α1 helix and including proximal portions of the β2-α1 and β3-β4 loops (Figure 6.1A). 
Notably, one of the residues unique to E. histolytica (Figure 6.1D) is an extra surface lysine 
(Lys-54). Since each surface lysine on mammalian ubiquitin can be utilized for polyubiquitin 
chain formation [9], it may be that E. histolytica possesses a unique K54 linkage 
polyubiquitination pattern. 
 To identify potential interactions that may involve the divergent EhUbiquitin surface, 
we superimposed the EhUbiquitin structure on a number of ubiquitin complex structures 
available in the RCSB database. Most of the surface of ubiquitin is utilized by one or more 
ubiquitin-binding proteins; however, the well-characterized interactions with E2 conjugating 
enzymes (e.g. UbcH5), HECT family E3 ligases, deubiquitinating enzymes (e.g. the SAGA 
complex) and ubiquitin-interacting motifs (e.g. RAP80) are not predicted to form significant 
interactions with the unique ubiquitin residues of E. histolytica (Figure 6.2A). Thus, at this 
time, we do not predict that the sequence variation seen in EhUbiquitin will significantly 
affect its interactions with similar ubiquitin-binding proteins encoded by the E. histolytica 
genome. The distinct EhUbiquitin surface may be utilized for other interactions unique to E. 
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histolytica. However, no specific function of the divergent EhUbiquitin surface can be 
ascribed at this time. 
 
6.4.2 EhUbiquitin is activated by the E1 enzyme EhUba1 
The E. histolytica genome encodes a single predicted ubiquitin-activating E1 enzyme, as well 
as predicted activating enzymes for Nedd8, SUMO, and other ubiquitin-like modifiers [15]. 
The putative ubiquitin-activating enzyme EhUba1 (AmoebaDB accession EHI_020270) was 
cloned from genomic DNA, expressed and purified from E. coli. EhUba1 possesses a 
predicted domain structure similar to S. cerevisiae Uba1 and other eukaryotic E1s (not 
shown). The sequence of EhUba1 was most similar to that of the slime mold D. discoideum, 
followed by S. cerevisiae, when compared to a broad spectrum of E1 enzyme sequences from 
different species (Figure 6.2C). To determine whether EhUba1 was capable of activating 
EhUbiquitin, we examined in vitro ubiquitin transfer with purified components.  EhUba1 was 
seen to form a typical thioester bond with EhUbiquitin that was sensitive to reduction by 
DTT (Figure 6.3A). Magnesium and ATP were required for ubiquitin activation and thioester 
bond formation, suggesting a conserved mechanism of ubiquitin activation in E. histolytica. 
A number of mammalian E2 enzymes, together with an E1, are capable of catalyzing 
formation of isopeptide-linked polyubiquitin chains [29]. In vitro polyubiquitination 
experiments revealed that EhUbc5, together with EhUba1 could efficiently promote 
formation of EhUbiquitin chains up to four molecules in length (Figure 6.3B). Polyubiquitin 
chain formation required E2 enzyme, as well as the EhUba1 cofactors of magnesium and 
ATP. 
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 We next sought to compare the activities of ubiquitin activating enzymes from E. 
histolytica and humans. To quantify the kinetics of enzyme-dependent incorporation of 
pyrophosphate (PPi) into ATP, an in vitro radioactive 32PPi:ATP isotope exchange assay was 
employed as described previously [4]. In the presence of 1 µM ubiquitin protein, 100 µM 
AMP, 10 mM MgCl2, and 100 µM non-radioactive PPi, the initial rate of PPi:ATP exchange 
catalyzed by human Uba1 was 132 picomoles/min (linear regression 95% confidence interval 
(C.I.) 88 - 176 picomoles/min) (Figure 6.3C), in good agreement with previous 
measurements under similar conditions [4]. EhUba1, in contrast, exhibited a significantly 
faster initial isotope exchange velocity of 460 picomoles/min (95% C.I. 428 - 493 
picomoles/min), under identical conditions. The ~3.5-fold greater velocity of exchange for 
EhUba1 compared to human Uba1 is intrinsic to the E1 enzyme, given that the respective 
exchange rates in the presence of either human or E. histolytica ubiquitin substrates were 
indistinguishable (Figure 6.3C). A superimposition of EhUbiquitin with the structural model 
of S.c. Uba1~Ub suggests that the divergent ubiquitin surface in E. histolytica is not utilized 
in the E1/ubiquitin interface (Figure 6.2B), consistent with similar kinetics of the E1 
enzymes in activating either the human or E. histolytica ubiquitin substrate. Residues that 
contact ATP in other E1 enzymes (e.g. [30]), such as the GxGxxGCE motif, are well-
conserved in EhUba1 (not shown). A Lineweaver-Burk plot was constructed based upon 
PPi:ATP exchange experiments with varying ATP concentrations, allowing estimation of Km 
and Vmax with respect to the ATP substrate for both human and E. histolytica E1 enzymes 
(Figure 6.3D). EhUba1 exhibited higher velocities of isotope exchange with Vmax = 459 
picomoles/min (95% C.I. 392 - 552 picomoles/min), compared to its human homolog with 
Vmax = 115 picomoles/min (95% C.I. 93 - 152 picomoles/min) under these conditions. 
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However, the Km values with respect to ATP were highly similar, being 45 µM and 50 µM, 
respectively (Figure 6.3D). 
 
6.4.3 EhUba1 engages the E2 enzyme EhUbc5 and transfers activated EhUbiquitin 
A number of predicted E2 ubiquitin-conjugating enzymes have been identified within the E. 
histolytica genome, although none has been functionally assessed [15]. We cloned a subset of 
candidate E2s from the E. histolytica genome and attempted to express and purify each of 
them from E. coli. One E2 protein (Amoeba DB accession EHI_083560; Figure 6.4A) with 
similarity to yeast Ubc4 and Ubc5 (termed EhUbc5) was highly expressed and thus selected 
for further study. Surface plasmon resonance was performed with immobilized EhUbc5, 
indicating a low affinity interaction with non-ubiquitin associated EhUba1 (Figure 6.4B). A 
KD value for the EhUba1/EhUbc5 interaction could not be precisely quantified by 
equilibrium binding analyses due to the protein concentration limitations of our assay, but 
was greater than 150 µM. The isolated ubiquitin-fold domain (UFD) of EhUba1 (a.a. 882-
984) exhibited a similar apparent affinity for EhUbc5, indicating its sufficiency for binding 
the E2 (Figure 6.4B). In similar SPR experiments, EhUba1 was first allowed to activate 
EhUbiquitin and form an EhUba1~Ub thioester complex (under conditions similar to Figure 
6.3A) prior to injection over an EhUbc5 surface. Following dissociation of EhUba1~Ub, 
persistent residual resonance was observed (Figure 6.4C), suggesting that some activated 
ubiquitin may be transferred covalently to the EhUbc5-laden surface. Indeed, the residual 
resonance due to apparent thioester-coupled EhUbiquitin could be rapidly eliminated by 
injection of the reducing agent DTT (Figure 6.4C). An equilibrium binding analysis 
suggested at least a 10-fold greater affinity of EhUbc5 for EhUba1~Ub than for unconjugated 
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EhUba1 (Figure 6.4D). Notably, the apparent affinity of EhUbc5 for EhUba1~EhUb (KD ≈  
12 µM) is likely underestimated by this approach, given that saturation could not be reached 
with each analyte injection (Figure 6.4C) and the reported EhUba1~EhUb concentrations 
(Figure 6.4D) assume that 100% of the EhUba1 enzyme injected was conjugated to ubiquitin. 
However, correction of either potential source of error would further lower the apparent 
EhUba1~Ub/EhUbc5 dissociation constant value, resulting in a >10-fold preference of 
EhUbc5 for EhUbiquitin-conjugated over unconjugated EhUba1. Transfer of the EhUbiquitin 
thioester from EhUba1 to EhUbc5 was also demonstrated by an in vitro assay (Figure 6.3A). 
Ubiquitin activation by EhUba1 and subsequent transfer to the E2 enzyme was found to be 
dependent on the presence of ATP and magnesium. The EhUbc5~EhUb thioester bond was 
also sensitive to the reducing agent DTT. 
 
6.4.4 Structural features of the E2 ubiquitin conjugating enzyme EhUbc5 and its non-
covalent interaction with EhUbiquitin 
To gain further insight into ubiquitin conjugation in E. histolytica, EhUbc5 was crystallized 
and its structure determined by molecular replacement with diffraction data extending to 1.6 
Å resolution (Table 6.2). Although EhUbc5 crystallized under a variety of conditions, the 
crystal form described here required a cobalt (II) salt. A cobalt ion could be identified in the 
electron density, contacting EhUbc5 molecules in adjacent asymmetric units (Figure 6.5C). 
The cobalt ion appears to be octahedrally coordinated with two histidine and one aspartate 
ligand from one EhUbc5 monomer, complemented by a glutamine from a symmetry-related 
EhUbc5 and by a water molecule. The overall structural model of EhUbc5 is remarkably 
similar to human UbcH5B (Cα r.m.s.d of 0.69 Å), given only 73% sequence identity and 
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83% similarity (Figures 6.4A and 6.5A). As seen in the case of EhUbiquitin, the majority of 
the EhUbc5 hydrophobic core is identical to human UbcH5B, while divergent residues 
predominantly reside on the protein surface (Figure 6.5A, B). The β4-α2 and α2-α3 loops 
are highly conserved among E2 enzymes, including EhUbc5 (Figure 6.4A), suggesting a 
likely conserved mode of interaction with covalently attached ubiquitin (Figure 6.6A). In 
particular, EhUbc5 Cys-85 likely forms a thioester bond with the C-terminus of activated 
EhUbiquitin (Figure 6.3A). E2 enzymes are also known to bind ubiquitin-like modifiers in a 
non-covalent, “backside” interaction thought to be important for assembly of polyubiquitin 
chains [31, 32]. To assess a potential non-covalent interaction between EhUbc5 and 
EhUbiquitin, we predicted E2 enzyme residues likely to be involved based on the known 
interaction between human UbcH5A and human ubiquitin (Figure 6.4A) [33]. The analogous 
residues in EhUbc5 were 62% identical and 87% similar, suggesting a potentially conserved 
non-covalent interaction with EhUbiquitin. In support of this hypothesis, EhUbiquitin was 
found to bind EhUbc5, as measured by SPR (Figure 6.6B, C). The apparent low affinity of 
the EhUbc5/EhUbiquitin interaction (KD = 410 ± 80 µM) is consistent with other 
monoubiquitin interactions, specifically homologous non-covalent interactions with other E2 
enzymes (KD values ~100-500 µM) [2, 31]. 
 
6.4.5 EhUbc5 engages a RING family E3 ubiquitin ligase 
We next sought to identify E3 ligases in E. histolytica that may partner with EhUbc5 to 
ubiquitinate specific substrate proteins. The E. histolytica genome encodes a large number of 
putative E3 enzymes including HECT, RING, PHD, and U-box domain-containing proteins 
[15]. A subset of candidate E3s were cloned from E. histolytica genomic DNA and expressed 
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in E. coli. Of this subset, one RING family E3 and two HECT domains could be purified to 
near homogeneity in quantities suitable for biochemical experiments. The RING family 
protein (AmoebaDB accession EHI_020100), here termed EhRING1, contains predicted 
RING and zinc finger motifs according to SMART [34], although significant sequence 
divergence results in relatively high domain prediction E-values (Figure 6.7B). We were 
unable to identify a clear homolog for EhRING1 in either humans or yeast. The first 246 
amino acids of EhRING1 were seen to bind EhUbc5 with a dissociation constant of 9.5 ± 0.5 
µM, as determined by SPR (Figure 6.7B, C). In contrast, the HECT domains of two putative 
E3 ligases, termed EhHECT1 (EHI_011530) and EhHECT2 (EHI_124600), did not bind 
immobilized EhUbc5 (Figure 6.7B, C). A superimposition of EhUbc5 on crystal structure 
models of E2 enzymes in complex with a cIAP2 RING domain [35] and the CHIP U-box 
domain [36] suggests a well-conserved EhUbc5 surface at the predicted RING family E3 
binding site (Figure 6.7A). To test whether EhUbc5 engages EhRING1 in a similar fashion, 
we mutated the conserved phenylalanine-62 to alanine, a residue predicted to contribute to 
RING binding. Indeed, EhUbc5(F62A) displayed a drastically reduced affinity for EhRING1 
(Figure 6.7). However, EhUbc5(F62A) maintained its ability to form a thioester bond with 
activated EhUbiquitin (Figure 6.3A) and to bind EhUba1~EhUb (Figure 6.4D), indicating 
proper folding of the point-mutated EhUbc5 protein. EhRING1 had only modest effects, if 
any, on EhUbc5-catalyzed polyubiquitin chain formation, as assessed qualitatively by in vitro 
assays (Figure 6.3B). 
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6.5 DISCUSSION 
Our experiments demonstrate the presence of a functional ubiquitin activation and 
conjugation pathway in E. histolytica. The substantial differences in the EhUbiquitin protein 
sequence compared to other species cluster on a single surface, constructed primarily of the 
α1 helix. Our analyses suggest that this particular surface is not central to the structurally-
elucidated ubiquitin interfaces with E1s, E2s, HECT and RING E3s, ubiquitin interacting 
motifs (UIMs), and deubiquitinating enzymes (DUBs) in other species. However, the high 
degree of conservation at this surface in a diverse set of other organisms suggests a likely 
role(s) in ubiquitin functions. EhUbiquitin may have evolved to lack these functions, 
allowing sequence drift on the α1 helix and surrounding surface. Alternatively, EhUbiquitin 
may have evolved an as yet undetermined alternative use for this surface. The function of the 
α1 helix region has not yet been established in E. histolytica; accordingly, its potential value 
as a therapeutic target is unclear. Of particular interest is the presence of an eighth surface 
lysine (Lys-54) unique to EhUbiquitin (arginine in all other organisms examined) and 
included in the divergent surface. Complex polyubiquitination patterns utilizing all seven 
surface lysines and the N-terminus of ubiquitin exist in other species, corresponding to an 
array of interaction modes and affinities for various ubiquitin binding domains [37]. Thus, it 
is likely that additional unique polyubiquitination patterns and interactions arise in E. 
histolytica, involving the additional exposed lysine. Further studies are necessary to 
determine the prevalence of Lys-54 polyubiquitination in E. histolytica and its potential 
functions. 
 EhUba1 appears to activate ubiquitin in a similar fashion to its homologs in other 
species. However, the observed significant difference in maximal velocity of PPi:ATP 
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exchange compared to human Uba1 suggests differences in ubiquitin activation kinetics. 
Additional work is needed to determine whether ubiquitin activation by this enzyme is 
necessary for parasitic virulence, and whether specific inhibition of EhUba1 is a viable 
therapeutic goal. Inhibitors of mammalian E1s have been used with some success, 
demonstrating the feasibility of this approach [38]. 
 EhUbc5 exhibited a striking selectivity for EhUba1~Ub compared to unconjugated 
EhUba1. Since the EhUba1 ubiquitin-fold domain (UFD) bound EhUbc5 with an affinity 
similar to that of unconjugated EhUba1, it appears that some portion of the EhUba1~Ub 
complex, in addition to the UFD, contributes to E2 binding following ubiquitin activation. 
An altered EhUba1 conformation, or perhaps the EhUbiquitin molecule itself, may provide a 
higher affinity surface for EhUbc5. This functionality may help EhUbc5 recognize ubiquitin-
bound E1 for efficient transfer and/or allow for rapid release of the E1/E2 complex once 
ubiquitin transfer has occurred. The non-covalent interaction of EhUbiquitin with EhUbc5 
suggests a likely conserved mechanism for conjugating polyubiquitin chains [31]. EhUbc5 
was also seen to engage a RING family E3 (EhRING1) through a conserved mode of 
interaction, to the exclusion of two HECT family E3s. This finding suggests a possible RING 
E3 specificity for EhUbc5; however, we cannot rule out the possibility that EhUbc5 interacts 
with other, untested HECT E3 ligases, like its yeast homologs [39]. It is unclear at this time 
which target proteins are ubiquitinated downstream of EhUbc5 and EhRING1. 
 The E. histolytica ubiquitin-proteasome pathway may provide therapeutic targets for 
potential treatment of amoebic colitis and amoebiasis. Of particular feasibility may be a 
proteasome inhibitor with selectivity for the E. histolytica protein target, given the previously 
demonstrated effects of proteasome inhibition on trophozoite proliferation and encystation 
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[16]. Alternatively, EhUba1-specific E1 inhibition may be expected to grossly perturb 
trophozoite function and viability, given the necessity of ubiquitin activation for multiple 
vital cellular processes in other eukaryotes [38]. 
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Figure 6.1. Sequence variations in EhUbiquitin cluster on a single surface. (A) The 
crystal structure of EhUbiquitin (gray) is superimposed with human ubiquitin (wheat; PDB 
ID 1UBQ), highlighting the similarities of their backbone structures. Sequence and structural 
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alignments were used to identify conservative (yellow) and non-similar (orange) amino acid 
differences between the E. histolytica and human homologs. The non-identical residues of 
EhUbiquitin cluster onto a single surface dominated by the first α-helix. EhUbiquitin 
possesses an additional surface lysine (Lys-54) that may allow for unique polyubiquitin 
linkage in E. histolytica. (B) Diffraction data for EhUbiquitin crystal form #1 extended to 
1.35 Å resolution. Despite low-resolution incompleteness, the 2Fo-Fc electron density map 
contoured to σ = 3.0 was of good quality. Red spheres represent ordered water molecules. 
(C) Diffraction data from the EhUbiquitin crystal form #2 were of high quality, given a lower 
resolution limit of 2.15 Å. The 2Fo-Fc electron density map is contoured to σ = 3.0. (D) The 
protein sequence of EhUbiquitin was aligned to ubiquitin molecules from other species.  
EhUbiquitin shows the highest degree of sequence divergence, with 7 non-identical residues 
compared to human ubiquitin. The predicted sequence of EhUbiquitin also includes a C-
terminal tyrosine that may be cleaved in E. histolytica trophozoites to expose a conserved C-
terminal Gly-Gly motif. D.m. indicates Drosophila melanogaster, S.c. is Saccharomyces 
cerevisiae, H.s. is Homo sapiens, D.d. is Dictyostelium discoideum, and M.m. is Mus 
musculus. 
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Figure 6.2. The divergent EhUbiquitin surface is not frequently utilized by structurally 
elucidated ubiquitin binding proteins. (A) The non-identical residues of EhUbiquitin 
cluster onto a single surface dominated by the first α-helix. This ubiquitin surface is not 
utilized by many of the best-studied and structurally characterized ubiquitin binding partners. 
EhUbiquitin (gray) was superimposed on structural models of ubiquitin-like modifier (ULM) 
homologs in complex with ULM-interacting proteins. Ubiquitin thioester formation with 
conjugating E2 enzymes and a HECT family E3 ligase are represented by UbcH5B (PDB ID 
3A33) [6] and the Nedd4 HECT domain (PDB ID 2XBB) [40], respectively. Ubiquitin 
interaction with de-ubiquitinating (DUB) enzymes is illustrated by the SAGA DUB complex 
(PDB ID 3MHS) [41]. A ubiquitin interacting motif (UIM) protein is also exemplified by 
RAP80 (PDB ID 3A1Q) [42]. (B) The domain structure of yeast Uba1 is drawn and colored 
as in [30]. The interaction of EhUbiquitin with E1 enzymes was modeled by superposition of 
EhUbiquitin with yeast Uba1~Ub (PDB ID 3CMM). The divergent residues of EhUbiquitin 
(colored yellow and orange as in Figure 6.1) are not predicted to alter interaction with E1 
enzymes. IAD indicates the inactive adenylation domain, FCCH is the first catalytic cysteine 
half-domain, 4HB is the four helix bundle domain, AAD is the active adenylation domain, 
SCCH is the second catalytic cysteine half-domain, and UFD is the ubiquitin-fold domain. 
(C) E1 enzyme sequence similarity and identity were compared across species. EhUba1 is 
most similar to that of the slime mold D. discoideum. 
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Figure 6.3. The ubiquitin activating enzyme EhUba1 catalyzes EhUbiquitin thioester 
formation and transfer to the E2 enzyme EhUbc5. (A) Recombinant EhUba1 derived 
from E. coli forms a thioester bond with EhUbiquitin in an ATP- and magnesium-dependent 
fashion, as illustrated by SDS-PAGE and Coomassie blue staining under non-reducing 
conditions. Activated EhUbiquitin is seen to be transferred to the ubiquitin conjugating 
enzyme EhUbc5. Each of the covalent interactions detected was sensitive to 50 mM DTT 
reducing agent. The loss-of-E3-binding mutant EhUbc5(F62A) did not significantly affect 
ubiquitin thioester formation. (B) EhUba1 and EhUbc5 were sufficient to catalyze 
polyubiquitin chain formation in the presence of ATP and magnesium, as detected by SDS-
PAGE and western blotting under reducing conditions. EhUba1 and EhUbc5 were seen to 
efficiently promote formation of chains up to four ubiquitin molecules under these 
conditions, and addition of EhRING1 had modest effects. (C) PPi:ATP radioisotope 
exchange was utilized to compare in vitro ubiquitin activation by EhUba1 and human Uba1 
in the presence of 6 nM E1 enzyme, 1 µM ubiquitin, 1 mM ATP, 100 µM AMP, and 100 µM 
non-radioactive PPi. Under these conditions EhUba1 exhibited a statistically significant ~3.5-
fold increase in isotope exchange rate compared to its human homolog (460 ± 33 (95% C.I.) 
versus 132 ± 46 (95% C.I.) picomoles/minute). The observed difference in ubiquitin 
activation kinetics is apparently intrinsic to the E1 enzyme, because isotope exchange rate 
was independent of the ubiquitin species utilized. These data represent average values of 
triplicate experiments with standard error of the mean. * indicates a statistically significant 
difference between EhUba1 and human Uba1 determined by Student’s t-test. (D) The 
dependency of human Uba1- and EhUba1-mediated isotope exchange on ATP was assessed 
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under identical conditions as panel C, excepting ATP concentration. A Lineweaver-Burk plot 
allowed estimation of Km and Vmax values describing E1 activity with respect to ATP. Under 
these conditions, the apparent Km and Vmax values were 45 µM and 459 picomoles/min (95% 
C.I. 392 - 552 picomoles/min) for the E. histolytica components and 50 µM and 115 
picomoles/min (95% C.I. 93 - 152 picomoles/min) for the human components, with respect 
to ATP. Each initial velocity measurement was conducted in duplicate, and the displayed 
results are representative of two independent experiments. 
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Figure 6.4. EhUba1 interacts directly with EhUbc5 through its ubiquitin-fold domain, 
and affinity is enhanced by the presence of activated EhUbiquitin. (A) The protein 
sequence of EhUbc5 was aligned to its closest homologs in yeast and humans, as well as 
human Ubc12. The secondary structure elements reflect the crystal structure of EhUbc5. 
Residues involved in interaction with E2 binding partners were derived from previously 
published structures (PDB IDs in parentheses). The majority of predicted interaction residues 
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are conserved in EhUbc5. (B) Surface plasmon resonance was utilized to measure direct 
binding of either unconjugated EhUba1 or its isolated ubiquitin-fold domain (UFD) to 
immobilized EhUbc5. EhUba1 binds EhUbc5 with low affinity in the absence of activated 
EhUbiquitin, and the UFD of EhUba1 is sufficient for binding. (C) EhUba1 was allowed to 
form covalent linkage with activated EhUbiquitin prior to injection over immobilized 
EhUbc5. Residual resonance following injection of EhUba1~EhUb was sensitive to the 
reducing agent DTT, likely indicating thioester transfer of EhUbiquitin to the immobilized 
EhUbc5. (D) The apparent affinity of EhUba1~EhUb for EhUbc5 was significantly higher 
than that of unconjugated EhUba1 (panel B). The apparent KD value of ~12 µM is likely 
overestimated because less than 100% of the injected EhUba1 is expect to be conjugated to 
EhUbiquitin (Figure 6.3) and equilibrium of binding could not be reached under these 
experimental conditions (panel C). The loss-of-E3-binding mutant EhUbc5(F62A) did not 
significantly affect affinity for EhUba1~EhUb. 
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Figure 6.5. The crystal structure of EhUbc5 is highly similar to human UbcH5B despite 
sequence divergence. (A) The crystal structure of EhUbc5 (gray) is superimposed on its 
closest human homolog, UbcH5B (wheat, PDB ID 2ESK) [43]. Sequence and structural 
alignment was used to identify conservative (yellow) and non-similar (orange) amino acid 
differences between the E. histolytica and human homologs. (B) A representative 2Fo-Fc 
electron density map of the EhUbc5 hydrophobic core, contoured to σ = 2.5, was rendered 
using PyMol. (C) Cobalt (cyan sphere) was required for crystallization and found 
incorporated in the crystal lattice at an interface between symmetry-related EhUbc5 
molecules. Cobalt ion (cyan sphere) is coordinated by two histidines and an aspartic acid 
from one EhUbc5 molecule (yellow), a glutamine from the adjacent EhUbc5 molecule 
(green), and a water molecule. Each of the six apparent coordinating groups is 2.1-2.2 Å 
from the cobalt ion. The 2Fo-Fc electron density map is contoured to σ = 3.5. 
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Figure 6.6. EhUbc5 engages EhUbiquitin through covalent thioester and non-covalent 
“backside” interactions. (A) The predicted interactions of EhUbc5 with thioester-
conjugated ubiquitin (blue) and non-covalent “backside” bound ubiquitin (purple) was 
modeled by superimposition of EhUbc5 with human UbcH5B~Ub (PDB ID 3A33) [6] and 
non-covalent UbcH5A/Ub (PDB ID 3PTF) [33]. The two predicted ubiquitin interfaces of 
EhUbc5 are relatively well-conserved, suggesting similar modes of interaction in E. 
histolytica. (B, C) EhUbc5 interacts non-covalently with EhUbiquitin, as determined by SPR. 
The low affinity of interaction is consistent with the analogous interaction between human 
E2 domains and human ubiquitin [2]. 
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Figure 6.7. EhUbc5 exhibits a conserved mode of interaction with a RING-family E3 
ligase. (A) The predicted interaction between EhUbc5 and RING family E3 ligases was 
modeled by superposition of EhUbc5 on the structural coordinates of the human 
UbcH5/CHIP U-box complex (PDB ID 2OXQ) [36] and the UbcH5/cIAP2 RING domain 
complex (PDB ID 3EB6) [35]. Phenylalanine 62 is highly conserved across species and 
contributes to the E2/RING E3 interface. (B) EhRING1 possesses an N-terminal predicted 
RING domain and zinc finger (ZnF) domain, as well as additional, weakly predicted RING 
and zinc finger domains. Domain prediction E-values were derived using SMART [34]. All 
biochemical experiments described in this study were conducted with EhRING1 residues 1-
246. (C, D) EhUbc5 bound a putative RING family E3 ubiquitin ligase from E. histolytica 
with low micromolar affinity, but not two HECT family E3 ligases, as measured by SPR. 
Mutation of Phe-62 drastically reduced the affinity of EhUbc5 for EhRING1, indicating a 
likely conserved mode of E2/E3 interaction in E. histolytica. 
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Table 6.1. Ubiquitin and proteasome system genes differentially transcribed in E. 
histolytica trophozoites expressing EhGα1 or the dominant negative EhGα1S37C. 
Gene name AmoebaDB accession no. 
fold change upon  
EhGα1 expression  
(p value) 
fold change upon 
EhGα1S37C expression  
(p value) 
ubiquitin system / proteasome    
hypothetical (RING finger domain) EHI_104520 1.9 (0.004)  
ubiquitin-activating enzyme EHI_004850 1.7 (0.013)  
zinc finger protein (RING-type) EHI_165120 1.8 (0.004)  
Ulp1 protease family, catalytic EHI_138530 2.2 (0.002)  
F-box domain containing protein EHI_103710 -1.9 (0.007)  
26S protease regulatory subunit EHI_185410 -1.8 (0.011)  
RING zinc finger protein EHI_023310  -2.1 (0.008) 
hypothetical (UBX domain) EHI_027910  -2.5 (< 0.001) 
proteasome subunit alpha type 3 EHI_098060  -2.0 (0.007) 
zinc finger protein (RING-type) EHI_130650  -1.9 (0.004) 
RING zinc finger protein EHI_161980  -2.1 (< 0.001) 
zinc finger, RING-type EHI_159840  -2.3 (< 0.001) 
proteasome subunit alpha type 2-A EHI_052140  1.7 (0.019) 
WWE domain EHI_069610  1.7 (< 0.001) 
ubiquitin EHI_083410  2.2 (< 0.001) 
zinc finger, RING-type EHI_110790  2.3 (< 0.001) 
ubiquitin conjugating enzyme E2 EHI_131530  2.0 (< 0.001) 
ubiquitin conjugating enzyme E2 EHI_135460  1.8 (0.009) 
26S protease regulatory subunit EHI_177320  1.9 (< 0.001) 
19S cap proteasome S2 subunit EHI_198010  3.6 (< 0.001) 
26S protease regulatory subunit EHI_053020  2.2 (0.020) 
          262 
Table 6.2.  Data collection and refinement statistics for EhUbiquitin and EhUbc5. 
 
 EhUbiquitin (#1) EhUbiquitin (#2) EhUbc5 
PDB access. code 4GU2 4GSW 4GPR 
    
Data collection    
Space group P3221 P212121 P212121 
Cell dimensions      
    a, b, c (Å) 49.80, 49.80, 63.83 38.61, 49.87, 76.82 46.97, 49.58, 63.46 
    α, β, γ  (°) 90.0, 90.0, 120.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
    
Wavelength (Å) 1.000 1.000 1.000 
Resolution (Å) 25.7 - 1.35 (1.36-1.35)* 40.0 - 2.15 (2.17-2.15)* 50.0 - 1.60 (1.62-1.60) 
No. unique reflect. 20493 (486) 8430 (210) 19998 (426) 
Rmerge (%) 4.3 (55.7)** 8.5 (27.9)** 4.4 (30.9) ** 
I / σI 100 (6.9) 32.8 (3.1) 45.6 (2.8) 
Completeness (%) 99.0 (100.0) 97.5 (96.8) 99.2 (87.3) 
Redundancy 19.2 (17.9) 3.5 (3.3) 8.2 (3.7) 
Wilson B-factor (Å2) 18.9 31.9 17.1 
    
Refinement    
Resolution (Å) 25.6 - 1.35 (1.42 - 1.35) 34.5 - 2.15 (2.28 - 2.15) 39.0 - 1.60 (1.64 -1.60) 
No. reflections 20454 (2718) 8379 (1154) 19950 (1148) 
Rwork / Rfree (%) 22.0 / 27.4 (22.8 / 31.3) 20.9 / 27.1 (26.6 / 35.0) 17.6 / 20.5 (20.6 / 26.0) 
No. atoms    
    Protein 1157 1171 1195 
    Ligand/ion - - 1 
    Water 66 44 179 
Avg. B-factors (Å2)    
    Protein 55.2 41.5 15.0 
    Ligand/ion - - 8.1 
    Water 58.5 41.9 27.2 
R.m.s deviations    
    Bond lengths (Å) 0.015 0.014 0.014 
    Bond angles (°) 1.642 1.493 1.504 
*Values in parentheses are for highest-resolution shell.  
**All data were collected from a single crystal. 
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CHAPTER 7 
CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS 
 
7.1 TARGETING HETEROTRIMERIC G PROTEIN SIGNALING 
Although effective therapies for invasive amoebiasis, such as nitroimidazoles, have been 
available for many years, infection with E. histolytica remains prevalent in many parts of the 
world, primarily due to poor sanitation conditions and lack of access to health care resources 
[1]. Furthermore, standard treatments (typically metronidazole followed by paromycin) are 
not effective in all cases of symptomatic infection, with drug-related toxicities such as 
allergic reactions, neuropathies, and additional gastrointestinal symptoms contributing to 
treatment intolerance [1, 2]. Drug resistance has not yet emerged as a major problem for E. 
histolytica therapeutics; however, other causative agents of communicable infectious diseases 
frequently evolve to survive common therapies, particularly where inappropriate drug usage 
and failures to complete treatment abound [3]. Thus, pursuit of alternative therapeutics for 
invasive amoebiasis is warranted (e.g. [4-6]). One of the most attractive parasite-specific 
targets is the heterotrimeric G protein signaling pathway described in chapters 2 and 3, given 
that approximately one third of all currently FDA-approved drugs modulate G protein 
signaling [7, 8]. In particular, agonists, inverse agonists, and antagonists frequently target 
seven-transmembrane GPCRs [7]. As such, identification of a GPCR/ligand pair in E. 
histolytica would be valuable as a means for perturbing G protein signaling, both as a tool for 
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investigating contributions to amoebic biology and pathogenesis, and as a potential target for 
therapeutic intervention. 
 
7.1.1 Identification of a GPCR and ligand in E. histolytica 
No functional GPCR encoded by the E. histolytica genome has yet been established, 
although various hormones (typical mammalian GPCR ligands) modulate its pathogenicity as 
well as encystation of the related species E. invadens (reviewed in chapter 1) [9-13]. A 
bioinformatic analysis of the E. histolytica genome identified numerous predicted seven-
transmembrane proteins (unpublished data). Among them was a single protein, termed 
Eh7TM1, that exhibited some sequence features held commonly among other known GPCRs 
as detected by 7TMRmine [14], as well as very limited sequence similarity to the cyclic 
AMP receptor cAR1 in Dictyostelium discoideum [15]. A codon-optimized Eh7TM1 gene 
was expressed in mammalian cells as a mCherry fusion protein and found to localize to the 
plasma membrane (Adam Kimple, unpublished data), consistent with GPCR-like behavior. 
The TANGO assay, based upon β-arrestin recruitment to activated GPCRs [16], was 
employed with mammalian cells stably expressing an Eh7TMR1 fusion protein in an attempt 
to identify a putative agonist for the candidate GPCR (Adam Kimple, unpublished data). 
Although no clear agonists were identified among thousands of screened compounds, 
expression of Eh7TM1 did cause a slightly elevated rise in apparent basal β-arrestin activity, 
suggesting that the membrane protein may adopt a recognizable conformation. Since the E. 
histolytica genome does not encode clear G protein coupled receptor kinases or β-arrestin 
homologs (unpublished data), Eh7TM1 may not assume a conformation upon ligand binding 
that is efficiently recognized by mammalian signaling machinery. Another approach utilizing 
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co-expression of Eh7TM1 and chimeric G proteins in yeast [17] likewise failed to identify 
clear ligands or establish Eh7TM1 unequivocally as a GPCR (Wes Kroeze, unpublished 
data). Putative E. histolytica GPCRs may not couple to yeast or mammalian G protein 
subunits, given the distinct sequence and structural features of EhGα1 (chapter 2) [18]. 
 Given the limitations of leveraging mammalian GPCR de-orphaning systems to 
identify an E. histolytica receptor, e.g. dependency on coupling to mammalian or yeast 
proteins, an approach utilizing axenic trophozoite cultures may be preferable. Entamoeba 
histolytica prefers anaerobic growth conditions [19], a limitation for cell-based, medium or 
high throughput screening approaches. However, others have utilized mineral oil layering to 
minimize the oxygen exposure of trophozoites in traditional culture plate-formatted assays 
[20]. A number of genes are differentially transcribed in E. histolytica upon overexpression 
of either EhGα1 or EhGα1S37C (chapter 2) [18]; accordingly, some may also be expected to 
undergo transcriptional changes upon trophozoite exposure to putative G protein-coupled 
receptor ligands. Promoters from differentially transcribed genes may be coupled with the 
open reading frames of firefly luciferase or other reporter enzymes, with preference given to 
those transcripts with large up- or down-regulation upon overexpression of EhGα1 or 
EhGα1S37C (chapter 2) [18]. Trophozoites stably transfected with the resulting transcriptional 
reporters may be monitored for altered luciferase activity upon exposure to candidate GPCR 
ligands in a relatively high throughput fashion. Limitations of this approach include the 
current lack of positive controls for G protein signaling activation or deactivation, and the 
likelihood that transcriptional regulation of individual genes may not be specific to 
heterotrimeric G protein signaling. Simultaneously screening compounds against multiple 
transcriptional reporter strains and pursuing only compounds that alter transcription of 
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multiple target genes may lessen the latter limitation. One may also potentially counter-
screen with trophozoites containing the transcriptional reporter and simultaneously 
overexpressing the dominant negative EhGα1S37C in an attempt to isolate G protein signaling-
dependent compounds. This transcriptional reporter approach would also not directly identify 
a specific E. histolytica GPCR, although further experiments such as compound-based 
affinity purification and radioligand binding with trophozoite membrane preparations may 
assist in receptor identification. 
 Although Eh7TM1 is the current best candidate GPCR by bioinformatic analysis 
(unpublished data), its roles in E. histolytica are currently unknown. Trophozoites could be 
engineered to overexpress, under tetracycline control, either an epitope-tagged wild type 
Eh7TM1 protein or a point mutant at the conserved “ionic lock” [21] of Eh7TM1, predicted 
to render the putative receptor constitutively active. Subsequent experiments could determine 
whether perturbed Eh7TM1 expression modulates processes related to EhGα1 signaling, 
such as trophozoite chemotactic migration, invasion, host cell killing, and cysteine protease 
secretion (chapters 2, 3) [18]. If the phenotypic effects of overexpressing Eh7TM1 were seen 
to parallel those of the EhGα1- or EhRGS-RhoGEF-overexpressing strains, there would be 
indirect, correlative evidence for Eh7TM1 being a GPCR. Limitations to this approach 
include its inability to demonstrate unequivocal GPCR (GEF) activity for Eh7TM1, the 
potential for mis-localization and non-physiological effects of Eh7TM1 overexpression, as 
well as the possibility that Eh7TM1 has little or no basal activity and that its overexpression 
may not significantly alter trophozoite behaviors in the absence of a stimulating ligand. 
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7.1.2 Investigating other heterotrimeric G protein signaling components 
As discussed in chapter 1, the E. histolytica genome encodes a potential second Gα subunit, 
here termed EhGα2 (AmoebaDB accession EHI_186910), consisting of a N-terminal 
predicted Gα-like fold lacking conserved nucleotide binding motifs and a C-terminal PP2C-
like phosphatase domain [22]. Full length EhGα2 and its isolated Gα-like domain (a.a. 1-
338) could each be purified as recombinant proteins. EhGα2, but not the isolated Gα-like 
domain bound immobilized recombinant EhRGS-RhoGEF in SPR experiments (Figure 7.1) 
with an apparent affinity of 2 µM, comparable to that of EhGα1·AMF/EhRGS-RhoGEF 
(chapter 3) [23]. The unexpected lack of Gα-like domain binding to EhRGS-RhoGEF at 
concentrations up to 100 µM (Figure 7.1) could potentially be explained by the recombinant 
protein fragment being improperly folded or otherwise non-functional, or by a true 
requirement of the phosphatase domain for high-affinity interaction. These possibilities could 
potentially be addressed by similar binding experiments with a recombinant phosphatase 
domain fragment (i.e. EhGα2 lacking the Gα-like domain). To determine whether the Gα-
like domain engages the RGS domain of EhRGS-RhoGEF in a manner akin to EhGα1 and 
like mammalian Gα/RGS interactions, the RGS domain point mutants E39K and N87A may 
be utilized (chapter 3) [23]. The Drosophila S2 cell spreading assay previously used to detect 
EhRGS-RhoGEF activation by both EhGα1 and EhRacC (chapter 3) [23] could also allow 
investigation of whether EhGα2 binding to EhRGS-RhoGEF can trigger downstream 
signaling in a cellular context. Interestingly, EhGα2/EhRGS-RhoGEF binding was 
insensitive to nucleotide state (Figure 7.1), suggesting together with absent nucleotide-
binding motifs that EhGα2 may not cycle nucleotide like other known Gα subunits. GTPγ35S 
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radionucleotide binding and single turnover GTPγ32P hydrolysis assays can be employed to 
determine the nucleotide cycling, if any, of recombinant EhGα2. Initial attempts at detecting 
general phosphatase activity by recombinant EhGα2 using a broad specificity Ser/Thr 
phosphatase substrate have been unsuccessful (unpublished data), but other phosphatase 
substrates may be tried. An interesting possibility is that EhGα2 both binds and de-
phosphorylates EhRGS-RhoGEF in trophozoites. Although no evidence currently exists for 
phosphorylation of EhRGS-RhoGEF in vivo, the E. histolytica strain overexpressing FLAG-
EhRGS-RhoGEF [23] could be utilized to assess posttranslational modifications, for instance 
by anti-FLAG immunoprecipitation of EhRGS-RhoGEF in the presence of phosphatase 
inhibitors, and either phospho-antibody immunoblotting or mass spectrometry experiments. 
If EhRGS-RhoGEF is phosphorylated in vivo, the putative phosphatase activity of 
recombinant EhGα2 could potentially be assessed in trophozoite cell lysates or in EhRGS-
RhoGEF enriched immunoprecipitates. 
 Potential signaling by EhGβγ, independent of EhGα1 and EhRGS-RhoGEF, also 
remains to be explored. Gβγ subunit signaling typically accompanies Gα signaling, or can be 
solely responsible for downstream effects, as seen in A. thaliana sugar sensing [24]. 
Candidate EhGβγ effectors encoded by the E. histolytica genome include two phosducin-like 
proteins and multiple phosphoinositide 3-kinases. Although EhGβγ could not be 
recombinantly produced in E. coli or insect cells (unpublished data), the dimer can be 
expressed in mammalian cells (chapter 2) [18]. Thus, potential interactions with co-expressed 
candidate effector proteins could be assessed with co-immunopreciptation experiments. A 
more unbiased approach to identifying EhGβγ binding partners could be accomplished with 
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yeast two hybrid assays utilizing EhGβ1 as bait, or yeast three hybrid using EhGβ1 and 
EhGγ1/2 as baits.  
 
7.2 RHO FAMILY GTPase SIGNALING SPECIFICITY 
 
7.2.1 Structure and function of the EhRacC/EhPAK4 complex 
Three of seven encoded p21-activated kinases have been characterized in E. histolytica, as 
detailed in chapter 1, with overexpression studies suggesting roles for EhPAK1 and EhPAK2 
in migration, surface receptor capping, and phagocytosis [25-27]. PAKs are Ser/Thr kinases 
that contain N-terminal regulatory regions that include a p21 binding domain (PBD) and a C-
terminal kinase domain [28]; some PAK isoforms in lower organisms also possess a PH 
domain [29]. The regulatory regions of mammalian type I PAKs (PAK1-3) contain an 
autoinhibitory switch domain, and Rac and Cdc42 activate autoinhibited PAK dimers [30, 
31]. In contrast, the type II PAKs (PAK4-6) exhibit a higher basal kinase activity that is 
weakly modulated through different mechanisms upon Rho family GTPase binding in vitro; 
cellular localization alterations induced by activated Rho GTPase binding are also thought to 
impact function [30]. The mammalian PAK isoforms are important players in the 
pathogenesis of multiple diseases, including specific cancers [32, 33], and have thus been the 
target of small molecule inhibitor development efforts. For instance, the compound IPA-3 
(Figure 7.2A) was found to selectivity inhibit Cdc42-mediated PAK1 activation in vitro [33]. 
Despite the reactive and reduction-sensitive nature of IPA-3, as suggested by its internal 
disulfide bond (Figure 7.2A), the compound was found to inhibit PAK1 activation in 
mammalian cells at mid-micromolar concentrations, apparently through covalent 
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modification of the regulatory region including the PBD [33, 34]. Application of IPA-3 to E. 
histolytica trophozoites resulted in dose-dependent inhibition of chemotactic migration 
toward serum-containing media (IC50 ~22 µM; Figure 7.2B), consistent with its potential 
impairment of known PAK functions in amoebic motility [27, 35]. However, compound 
toxicity may contribute to the observed reduction in migration, as a 4-hour exposure to high 
concentrations of IPA-3 induced trophozoite death (LD50 ~200 µM), as detected by a 
membrane integrity assay (Figure 7.2C). An inactive structural isomer of IPA-3, PIR3.5 [33] 
can be employed in parallel experiments to further assess the potential non-specific and/or 
toxic effects of IPA-3 on E. histolytica trophozoites. Interpretation of these results are also 
limited by the current lack of a validated IPA-3 target in E. histolytica, an issue of particular 
concern given the reactive nature of IPA-3 (likely a covalent cysteine-modifier) [34]. The 
hypothesized binding of IPA-3 to E. histolytica PAK isoforms could be examined, for 
instance, with multiple recombinant PAK proteins and radioactive IPA-3, as described 
previously for mammalian PAK1 [34]. 
 Together with three described diaphanous related formins and the GBD-containing 
actin binding protein EhNCABP166 (chapter 1), the seven PAK homologs in E. histolytica 
constitute the putative Rho family GTPase effectors with annotated Rho-specific binding 
motifs [36]. EhRacA has been observed to bind the regulatory region of EhPAK2 [35], and a 
crystal structure and biochemical analysis of the EhRho1/EhFormin1 GBD-FH3 domain 
tandem revealed some determinants of Rho family signaling specificity (chapter 5) [37]. 
However, the degree of signaling specificity or redundancy among the >20 E. histolytica Rho 
GTPases and their putative effectors, as well as their effector activation mechanisms remain 
largely unknown at this time. 
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 The isolated p21-binding domains from two uncharacterized E. histolytica PAK 
homologs, here termed EhPAK4 (AmoebaDB access. EHI_152540) and EhPAK5 
(EHI_043140) were seen to bind purified, activated EhRacC with a high degree of specificity 
and nucleotide state selectivity, as assessed by SPR experiments (Figure 7.3). The affinities 
of the GTPase deficient EhRacC(Q/L)·GTP for EhPAK4 and EhPAK5 were ~170 nM and 
~1.9 µM, respectively. To further elucidate the determinants for the specific 
EhRacC·GTP/EhPAK4 PBD interaction, a stable complex was assembled and crystallized, 
and a structure determined to 2.85 Å resolution. A preliminary structural model of the 
complex (additional diffraction experiments and refinement are in progress) exhibits 
structural similarity to mammalian Rho family GTPase and PBD complexes, (e.g. 
Rac3/PAK4, PDB access. 2OV2; Figure 7.4). The overall structure of EhRacC(Q/L)·GTP is 
highly similar to other activated Rho family GTPases. The central β-sheet of the EhRacC G 
domain fold [38] is extended by a β-hairpin in the EhPAK4 PBD, a theme conserved among 
other Rho/PAK PBD complexes as well as Cdc42/WASP PBD [39]. However, the β-strands 
of the β-hairpin in the EhPAK4 PBD align slightly differently than mammalian Rho/PBDs of 
known structure, and the single EhPAK4 PBD α-helix is uniquely rotated ~90° relative to its 
homologs (Figure 7.4). Additional EhPAK4 contacts occur in the EhRacC switch regions 
(Figure 7.4), likely contributing to the nucleotide-state specificity observed in binding 
experiments (Figure 7.3). A detailed analysis of the protein/protein interface in this crystal 
structure will likely identify EhPAK4 and EhRacC residues important for binding, generating 
hypotheses that can be tested by mutagenesis and additional binding experiments. 
Furthermore, comparison of the EhPAK4-contacting regions of EhRacC with other E. 
histolytica Rho family GTPases may reveal variant residues responsible for specific 
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Rho/effector interactions. For instance, mutation of EhRacC residues to the corresponding 
EhRho1, EhRacD, or EhRacG residues would be expected to diminish binding to EhPAK4 
and/or EhPAK5 (Figure 7.3). Conversely, it may be possible to introduce RacC-like residues 
into other Rho family GTPases and produce a gain-of-function binding to EhPAK4 and/or 
EhPAK5. Also of interest may be determining whether EhRacC binding activates EhPAK4 
or EhPAK5 kinase activity. This may potentially be accomplished by quantifying EhPAK4/5 
kinase activity in vitro with ATPγ32P-dependent phosphorylation of myelin basic protein by 
recombinant PAK (e.g. [33]), or in mammalian cells with overexpressed EhPAK4/5 
potentially phosphorylating itself or a typical PAK substrate, such as myosin light chain 
kinase or LIM kinase [28]. 
 
7.2.2 Characterization of FYVE domain-containing RhoGEFs 
A family of eleven Dbl-related RhoGEFs, termed EhFP1-11, that also contain phospholipid-
binding FYVE domains have been described in E. histolytica, as discussed in chapter 1 [40]. 
The FYVE domain of one such RhoGEF (EhFP4) was shown to mediate recruitment of the 
RhoGEF to trophozoite phagocytic cups and phagosomes through phospholipid binding, and 
when overexpressed in isolation, to impair phagocytosis [40]. Recombinant EhFP4 interacted 
with four E. histolytica Rho GTPases in pull-down assays, although nucleotide selectivity 
was not assessed and GEF activity could not be demonstrated in that report [40]. Thus, it was 
unknown whether the DH-PH tandems of these functionally important proteins serve as 
RhoGEFs and whether there is functional interplay between the FYVE and DH-PH domains. 
A number of FYVE domain-containing RhoGEFs were differentially regulated upon 
overexpression of either EhGα1 or EhGα1S37C in E. histolytica trophozoites (chapter 2) [18], 
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suggesting a possible additional indirect link between heterotrimeric and Rho family G 
protein signaling. Among these transcriptionally regulated RhoGEFs, the DH-PH domain 
tandem from EhFP5 (AmoebaDB access. EHI_131540; a.a. 3-337) could be highly purified 
as recombinant protein (unpublished data). Although the EhFP5 DH-PH tandem did not 
accelerate fluorescent nucleotide exchange on a number of E. histolytica Rho GTPases tested 
(EhRho1, EhRacC, EhRacD, and EhRacG; unpublished data), it did promote nucleotide 
exchange on human RhoA (Figure 7.5). GEF activity has only been demonstrated at a single, 
relatively high concentration (10 µM EhFP5 DH-PH) thus far, but a GEF concentration-
response curve generated with similar experiments would establish the potency of EhFP5 as 
an exchange factor for the non-physiological substrate human RhoA. Although an E. 
histolytica Rho substrate has not yet been identified, other recombinant family members can 
be assessed with this assay to determine the EhFP5/Rho GTPase specificity. A 
complementary approach would be to assess binding affinities (e.g. with SPR) for the EhFP5 
DH-PH tandem toward E. histolytica Rho family members, as well as human RhoA, with the 
expectation that the GEF will have highest affinity for Rho GTPases in their nucleotide-free 
states [41]. Although human RhoA is a non-physiological substrate for EhFP5, this cross-
species coupling allows utilization of mammalian cell-based assays for exploring the 
potential interplay between domains within EhFP5. For instance, full length EhFP5, the 
isolated DH-PH tandem, or the isolated FYVE domain may be exogenously expressed in 
mammalian cells, and human Rho signaling activation assessed by stress fiber formation or 
serum response element (SRE) transcriptional reporter induction [42]. The EhFP5 DH-PH 
tandem is hypothesized to activate human RhoA in cells, based on its in vitro GEF activity 
(Figure 7.5), while the isolated FYVE domain likely does not. The FYVE domain in the full 
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length EhFP5 may potentially modulate the GEF activity of the DH-PH tandem, perhaps in a 
membrane phospholipid-dependent fashion. 
 
7.3 DE-UBIQUITINATING ENZYMES IN E. histolytica PATHOGENESIS 
In addition to functional ubiquitin conjugation enzymes (chapter 6), the E. histolytica 
genome encodes a ~20-member family of de-ubiquitinating enzymes (DUBs) (unpublished 
data). DUBs are cysteine proteases that cleave isopeptide-linked ubiquitin molecules, 
allowing for reversibility of protein ubiquitination and recycling of ubiquitin monomers [43]. 
Development of specific DUB-inhibiting small molecules is ongoing, particularly for 
applications in the treatment of various cancers where inhibition of DUBs can induce 
selective cell death [44]. Since ubiquitination and de-ubiquitination are important for 
numerous critical cellular processes across species [45], DUB inhibition in E. histolytica may 
be expected to grossly impair or kill trophozoites. Three commercially available DUB 
inhibitors with reported broad specificity, PR-619, G5, and WP1130 [44], were selected and 
examined for effects on trophozoite proliferation. Two-day exposure to WP1130 and G5 
impaired trophozoite proliferation in a typical concentration-dependent fashion (Hill slope 
~1), with IC50 values of ~10 µM and ~25 µM, respectively (Figure 7.6B). PR-619 only 
impaired trophozoite proliferation at high micromolar concentrations, and exhibited an 
atypical concentration-response pattern (Hill slope ≠ 1), suggesting non-specific toxicity 
(Figure 7.6B). The observed effects of DUB inhibitors on E. histolytica proliferation could be 
due to either increased cell death or impaired cell division. Trophozoite cell death in response 
to DUB inhibitor application was investigated with a membrane integrity assay. At time 
points up to four hours, WP1130 and G5 did not induce marked amoebic cell death, while 
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PR-619 exhibited a dose-dependent cytotoxicity (Figure 7.6C, D). Although the toxicity of 
PR-619 could potentially be due to its on-target inhibition of DUB enzymes, the atypical 
concentration-response pattern with respect to proliferation and the dual azido groups in the 
PR-619 chemical structure suggest promiscuous reactivity (Figure 7.6A, B). WP1130 and G5 
did not significantly induce cell death at times up to 4 hours; however, either compound 
might cause trophozoite death at later time points. Alternatively, these two compounds may 
exert their effects on proliferation by impairing amoebic cell division, a hypothesis that could 
be tested by cell division rate measurements, such as the degree of BrdU incorporation into 
newly synthesized DNA or dilution of a cytoplasmic fluorescent marker (CFSE). Also 
currently unknown are the molecular targets of WP1130 and G5. Ubiquitin derivatives that 
act as covalently-modifying “suicide substrates” for active DUBs have been leveraged, 
together with mass spectrometry, to yield profiles of DUB activity in cells on a proteomic 
scale [46]. The putative E. histolytica DUB targets of WP1130 and G5 could be suggested by 
profiling active DUBs in trophozoite lysates following treatment with either DUB inhibitors 
or DMSO, as done for mammalian cells in [47]. 
 A single de-ubiquitinating enzyme from E. histolytica, here termed EhDUB1 was 
isolated for biochemical characterization and comparison to mammalian DUBs. Recombinant 
EhDUB1 hydrolyzed a human ubiquitin dye conjugate (ubiquitin-rhodamine) commonly 
used as a generic DUB substrate [48], a reaction impaired by pretreatment of EhDUB1 with 
the “suicide substrate” inhibitor ubiquitin-aldehyde [49] (Figure 7.7A-C). A Michaelis-
Menten kinetic analysis of EhDUB1 activity revealed a Km of ~500 nM with respect to the 
ubiquitin-rhodamine substrate and a Vmax of ~3 s-1. Some DUBs preferentially hydrolyze 
specific polyubiquitin linkages [50]. An internally quenched fluorescence (IQF) assay, with 
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Lys-48 or -63 linked di-ubiquitin substrates, demonstrated that EhDUB1 can cleave either 
linkage with apparently similar efficiencies (Figure 7.7D). WP1130, G5, and PR-619 did not 
inhibit EhDUB1 activity in similar in vitro experiments at concentrations up to 100 µM 
(unpublished data), suggesting that this specific enzyme is not a DUB inhibitor target 
contributing to impaired trophozoite proliferation. However, these experiments do establish a 
similarity of biochemical function among E. histolytica and mammalian DUBs and provide a 
viable method by which other DUBs may be profiled for small molecule inhibition. 
 Collectively, the work presented in this dissertation have elucidated structural and 
biochemical aspects of G protein signaling and ubiquitination in E. histolytica, as well as 
some of their relationships to the pathogenesis of invasive amoebiasis. However, much 
remains to be explored, and further efforts will likely add to our understanding of trophozoite 
biology and pathogenicity, as well as suggest potential targets for anti-amoebiasis drug 
development. 
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Figure 7.1. EhGα2 engages EhRGS-RhoGEF in a nucleotide state-independent fashion. 
(A) Full length EhGα2, but not the isolated Gα-like domain (a.a. 1-338), bound immobilized 
EhRGS-RhoGEF as measured by SPR. (B) The affinity of EhGα2 for EhRGS-RhoGEF was 
similar to that of EhGα1 (chapter 2), but binding was independent of nucleotide state (AMF 
indicates GDP·AlF4-). 
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Figure 7.2. The mammalian PAK inhibitor IPA-3 impairs E. histolytica chemotactic 
migration. (A) The chemical structure of IPA-3 includes a disulfide bond, likely implicated 
in covalent modification of PAK regulatory regions. (B) Exposure of trophozoites to IPA-3 
or DMSO as a negative control for 2 hours resulted in a concentration-dependent impairment 
of chemotactic migration toward serum-containing TYI medium, as measured by a Transwell 
assay. (C) IPA-3 is cytotoxic to trophozoites (4-hr incubation) at high concentrations, as 
indicated by a membrane integrity assay. 
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Figure 7.3. The EhPAK4 and EhPAK5 PBDs selectively bind activated EhRacC. The 
isolated p21-binding domains of two previously uncharacterized PAK isoforms were 
immobilized and found to bind the GTPase-deficient mutant EhRacC(Q/L)·GTP, to the 
exclusion of three other Rho family GTPases, as measured by SPR. Both PAKs exhibited 
high nucleotide state selectivity and affinity for activated EhRacC, suggestive of a 
Rho/effector relationship. 
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Figure 7.4. The crystal structure of EhRacC·GTP/EhPAK4 PBD reveals similarity to 
mammalian Rho/PBD complexes. The crystal structure of EhRacC(Q/L)·GTP/EhPAK4 
PBD was modeled using data extending to 2.85 Å resolution. Refinement is incomplete, but 
current Rwork and Rfree values are 19.3% and 27%, respectively. The E. histolytica complex is 
superimposed with the semi-transparent crystal structure of human Rac3/PAK4 PBD (PDB 
access. 2OV2). The signature β-harpin of the PBD is conserved, although the β-strands are 
aligned slightly differently. The C-terminal α-helix is rotated ~90° in the E. histolytica 
complex compared to other PBDs of known structure. 
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Figure 7.5. The DH-PH tandem of EhFP5 stimulates nucleotide exchange on human 
RhoA. Although EhFP5 GEF activity was not detected using multiple E. histolytica Rho 
GTPase substrates (unpublished data), nucleotide exchange on human RhoA was accelerated 
by 10 µM EhFP5 DH-PH, as measured by a fluorescent bodipy-GDP exchange assay. 
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Figure 7.6. De-ubiquitinating enzyme inhibitors impair trophozoite proliferation. (A) 
Three broad-specificity DUB inhibitors were profiled for effects on E. histolytica 
proliferation and cell death. PR-619 contains two azido groups, suggestive of promiscuous 
covalent reactivity. (B) All three DUB inhibitors altered trophozoite proliferation following 2 
days of exposure, although PR-619 was only effective at 50-100 µM and exhibited an 
atypical concentration-response curve. G5 and WP1130 exhibited IC50 values of 9.7 ± 3.0 
µM and 26 ± 16 µM, respectively. A dotted line indicates initial seeding of cultures with 25 x 
104 amoebae. (C, D) PR-619, but not G5 or WP1130, was cytotoxic to trophozoites as 
measured by a membrane integrity assay. Under these conditions PR-619 exhibited an LD50 
of ~10 µM. 
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Figure 7.6. EhDUB1 hydrolyzes ubiquitin isopeptide bonds. (A) Recombinant purified 
EhDUB1 hydrolyzes a dye conjugated human ubiquitin substrate, and is inhibited by the 
“suicide substrate” ubiquitin-aldehyde. (B) A Michaelis-Menten kinetic analysis of EhDUB1 
revealed a Km value of ~500 nM with respect to the ubiquitin-rhodamine substrate. (C) An 
Eadie-Hofstee plot of the kinetic data gave consistent estimates of Km and Vmax. (D) 
EhDUB1 hydrolyzed K-48 and K-63 linked di-ubiquitin substrates with similar efficiency, as 
measured by an internally quenched fluorescence (IQF) assay. 
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